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 PROLOGUE
General outline of the thesis
‘when you talk, you are only repeating what 
you already know; but if you listen, you may 
learn something new’
Dalai Lama
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PRologUE
Sarcoidosis is an intriguingly complex immunological disorder. It is characterized by 
the formation of non-necrotizing granulomas that are most commonly found in the 
mediastinal lymph nodes (MLN) and lungs of patients (1). Sarcoid granulomas also often 
affect the eyes and the skin, and in rare cases the heart, liver, central nervous system or 
bones (1). 
A granuloma is a conglomerate of immune cells, and is formed in response to chronic 
antigenic stimulation (2). Granuloma formation likely occurs in order to optimize interac-
tions between antigen presenting cells (APC) and adaptive immune cells, such as T cells. 
Typically, a fibrotic rim encapsulates the granuloma, aiding in preventing dissemination 
of the (infectious) antigen. A granuloma can arise in response to infectious agents such 
as mycobacteria and fungi, but also inorganic agents, such as silica and beryllium, can 
induce granuloma formation (2). Although several antigens have been proposed to be 
part of sarcoidosis etiology, not one antigen has yet been identified that can explain all 
cases of the disease (3, 4). Therefore, sarcoidosis is considered a multisystem granuloma-
tous disorder of unknown cause (1). 
The disease affects people all over the world, but the incidence/prevalence rates and 
natural course of the disease vary greatly (1, 5, 6), probably as a consequence of diverse 
local environmental triggers interacting with the genetic background of the affected 
population (7, 8). For example, the incidence rate of sarcoidosis is approximately three 
times higher in Afro-Americans than Caucasians (1, 6). Furthermore, the incidence in 
Japan is lower, however in this population the heart is more often affected, leading to 
higher mortality (1). 
Intriguingly, granulomas tend to resolve spontaneously in the majority of patients, 
but in approximately 30% of the patients, granulomas persist, which can lead to chronic, 
sometimes progressive disease with need for treatment (1, 9). Some features at disease 
presentation have been identified that can help gain perspective on disease prognosis 
(10). For example, Afro-American women with pulmonary sarcoidosis have a higher 
chance of developing chronic disease (11). Clinical presentation with the Löfgren triad, 
that is lung bihilar lymphadenopathy on the lungs alongside uveitis and erythema 
nodosum or ankle arthritis, is typically associated with a good prognosis and occurs 
more often in Caucasians (12). Interestingly, Löfgren patients that have a specific human 
leucocyte antigen (HLA) genotype, i.e. HLA-DR*03, are most likely to undergo resolution 
(12). 
Although a lot of progress has been made in Löfgren patients (which is likely a distinct 
disease entity than sarcoidosis (13)), it still remains largely unknown what environmen-
tal, genetic and/or immunological factors determine the disease course of non-Löfgren 
sarcoidosis patients. Thus, no variables have yet been identified that are routinely used 
in clinical practice to help predict disease course of sarcoidosis patients.
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Gaps in knowledge on sarcoidosis disease etiology and determinants of disease 
course have thus far impeded rational decisions on ‘Who, When and How’ to treat. The 
mainstay of sarcoidosis therapy remains immunosuppressive, using relatively high doses 
of systemic prednisone. However, although often effective, corticosteroid treatment can 
be accompanied by severe side effects and knowledge on optimal dosing strategies 
balancing effects and side effects, is lacking (14). Detailed insight in the immunological 
response occurring in pulmonary sarcoidosis patients can help find determinants of 
disease etiology and disease course, which can yield new therapeutic targets. Therefore, 
the first aim of this thesis is to further unravel the immune-related pathogenesis of pul-
monary sarcoidosis (Part 1). The second aim of this thesis is to gain insight into current 
prednisone treatment, in order to optimize treatment strategies to reduce side-effects 
and increase quality of life of pulmonary sarcoidosis patients (Part 2). 
general outline of the thesis
Part 1: Unraveling the pathogenesis of pulmonary sarcoidosis
Several clinical features and lines of evidence in sarcoidosis support a key role for CD4+ T 
cells in sarcoidosis, making them attractive candidates to help unravel the pathogenesis 
of this disease. First, the hallmark of sarcoidosis is the non-necrotizing granuloma that 
consists of a core of epithelioid- and multinucleated-giant cells, that is encircled by 
specifically CD4+ T cells (1). Second, a cardinal feature of sarcoidosis clinical presenta-
tion is CD4+ T-cell alveolitis (15). Third, lung CD4+ T cells in sarcoidosis were found to 
be of limited clonal origin, suggesting that they are responsive to the putative antigen 
(16). Fourth, genes that have repeatedly been associated with sarcoidosis susceptibility 
and phenotype encode HLA class II antigens, which are well known to play a key role 
in CD4+ T-cell activation (17). And lastly, other genes that have been associated with 
sarcoidosis code for proteins involved in T-cell activation, differentiation, proliferation 
and survival, including butyrophilin-like protein (BTNL)-2, NOTCH 4 and ANXA11 (17). 
Therefore, in-depth characterization of CD4+ T cells in sarcoidosis will help shed light on 
the etiology of the disease, since these cells are very likely to respond to the putative 
antigen presented by HLA class II antigens on APCs. 
In Chapter 1 current knowledge on phenotypical and functional properties of sarcoid-
osis APCs and CD4+ T cells is reviewed. A model is proposed for granuloma formation in 
sarcoidosis combining careful clinical observations with current literature that describes 
immunological findings in sarcoidosis blood, lungs and lymph nodes. 
Sarcoidosis is characterized by an exaggerated T helper (Th)1/Th17 response upon 
exposure to one or several antigens in genetically susceptible individuals (see Chapter 
1). However, mechanisms leading to this exaggerated immune response remain largely 
obscure. Key players in a disease are often identified by mouse models that lack or over-
express a specific protein or cell type of interest. Development of a universally accepted 
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mouse model for sarcoidosis has proven difficult, hampering research efforts employing 
this strategy. Interestingly, in Chapter 2 we describe how emerging clinical observations 
in human cancer treatment shed new light on key players in sarcoidosis pathogenesis. 
Since treatment with anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) agents in human 
cancers can induce sarcoidosis or sarcoid-like disease, we questioned whether CTLA4 
expression is affected in pulmonary sarcoidosis patients. 
Results described in Chapter 2 suggest a key role for specifically regulatory T cells 
(Tregs) and Th17 cells in pulmonary sarcoidosis. Although both Tregs and Th17 cells 
have been investigated in sarcoidosis, findings remain conflicting or inconclusive, re-
spectively. 
Failure of immune regulation by Tregs has long been suggested to contribute to 
ongoing inflammatory responses in pulmonary sarcoidosis (18). However, factors con-
tributing to this phenomenon remain largely unknown and conflicting data is published 
regarding their proportions in various affected organs (see Chapter 1). In Chapter 3 we 
aimed to get grip on the role of Tregs in sarcoidosis and systematically investigate the 
role of Tregs in pulmonary sarcoidosis by analyzing proportions, phenotype, survival 
and apoptotic susceptibility. 
While Th17 cells were previously found to be increased in patient lungs, sarcoidosis 
was largely thought to be a Th1 mediated disease, because the total proportions of 
interleukin (IL)-17-producing cells remained very low. However, Chapter 2 demonstrates 
a key role for Th17 cells in pulmonary sarcoidosis and concomitantly it became clear in 
the T-cell field that stringent classification of T cells based on cytokine production may 
not be correct. Certain T-cell subsets, such as Th17 cells, are found to be more prone to 
plasticity and can adopt cytokine production capabilities of other T-cell subsets (19). 
We previously identified increased proportions of IL-17A/interferon (IFN)-γ-double-
producing memory Th cells in a small sarcoidosis patient cohort (20) and therefore 
hypothesized that the role of Th17 cells in pulmonary sarcoidosis may be greater than 
anticipated. T helper 17 cells perhaps play an important role in the disease pathogenesis 
by mimicking Th1 cytokine (IFN-γ) production. Indeed, so called Th17.1 cells are known 
for this ability in other disease states (21). In Chapter 4 we aimed to identify the origin 
of IFN-γ-producing cells in pulmonary sarcoidosis.
Primary Th cell activation and subset differentiation occurs in lung draining MLN. 
Above mentioned IFN-γ-producing Th17.1 cells can derive from Th17 cells under influ-
ence of a specific cytokine milieu (22, 23). Therefore, we hypothesized that in pulmonary 
sarcoidosis Th17 cells are primarily induced in the MLN and that the granulomatous 
environment in the lungs induces plasticity towards Th17.1 cells. In Chapter 5 we chal-
lenged this hypothesis and aimed to gain more insight in the induction of Th17.1 cells in 
sarcoidosis by looking into proportions and phenotypic characteristics of CCR6+ Th17-
lineage cells in sarcoidosis and control MLN, and sarcoidosis lungs. 
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Finally, in Chapter 6 recent insights in sarcoidosis T-cell immunology are reviewed. 
Based on new findings in Tregs, Th17.1 cells and checkpoint inhibitors a comprehensive 
model is proposed that integrates all observations that highlight a key role for both 
Tregs and Th17-lineage cells in the pathogenesis of pulmonary sarcoidosis. 
Part 2: Optimization of prednisone treatment in pulmonary sarcoidosis
Prednisone is the main stay of treatment in pulmonary sarcoidosis because it quickly 
relieves symptoms and controls inflammation (1, 4, 9, 24). A meta-analyses of random-
ized controlled trials however concluded that limited evidence was found that (early) 
prednisone therapy in pulmonary sarcoidosis alters disease progression in the long term 
(24). Thus, although prednisone remains the first choice regimen for treatment of pul-
monary sarcoidosis (1, 24-26), therapy is only indicated in certain cases, such as during 
development of a dangerous health situation or when there is a significant decrease in 
the patient’s quality of life (27). Unfortunately, the optimal dose and duration of pred-
nisone treatment remains uncertain, thus current guidelines include a broad range (1, 
25), which could result in low dose-treated patients versus high dose-treated patients, 
depending on the physician’s practice, which might lead to unmet therapeutic goals or 
unnecessary side effects. 
Identifying the optimal treatment strategy that preserves organ function and relieves 
symptoms, but simultaneously minimizes side-effects, may increase quality of life of 
newly-treated pulmonary sarcoidosis patients. Therefore, in order to gain insight in what 
dosing strategy has the best balance between effect and side-effects, in Chapter 7 we 
aimed to describe forced vital capacity (FVC) (effect) and weight (side-effect) changes 
during different prednisone doses used in daily practice for treatment naïve pulmonary 
sarcoidosis patients.
Available evidence and results presented in Chapter 7 suggest that early dose taper-
ing is very likely to reduce side-effects in prednisone therapy for pulmonary sarcoidosis, 
while retaining effect. It has previously been suggested that prednisone effect on FVC 
occurs quickly within one month (28, 29). However, a prospective study monitoring 
individual lung function changes on a daily basis in newly-treated sarcoidosis patients 
to identify effect optimum, and also including clinical symptoms, is lacking. Therefore, in 
Chapter 8 results are presented of a prospective, observational study, evaluating early 
FVC and symptom changes during prednisone treatment and tapering in newly-treated 
sarcoidosis patients, using daily home spirometry. 
Finally, findings of Part 1 and Part 2 of the thesis are integrated into a general discus-
sion (Epilogue) of the thesis, highlighting results of this thesis that could be of specific 
interest for clinical practice, providing an overview of outstanding questions and sug-
gestions for future research. 
General outline of the thesis
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 CHAPTER 1
Granuloma Formation in Pulmonary Sarcoidosis
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Don Draper
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Chapter 1
aBSTRaCT
Sarcoidosis is a granulomatous disorder of unknown cause, affecting multiple organs, 
but mainly the lungs. The exact order of immunological events remains obscure. Re-
viewing current literature, combined with careful clinical observations, we propose a 
model for granuloma formation in pulmonary sarcoidosis. A tight collaboration between 
macrophages, dendritic cells and lymphocyte subsets, initiates the first steps towards 
granuloma formation, orchestrated by cytokines and chemokines. In a substantial part 
of pulmonary sarcoidosis patients, granuloma formation becomes an on-going process, 
leading to debilitating disease and sometimes death. The immunological response, 
determining granuloma sustainment is not well understood. An impaired immunosup-
pressive function of regulatory T cells has been suggested to contribute to the exag-
gerated response. Interestingly, therapeutical agents commonly used in sarcoidosis, 
such as glucocorticosteroids and anti-TNF agents, interfere with granuloma integrity 
and restore the immune homeostasis in autoimmune disorders. Increasing insight into 
their mechanisms of action may contribute to the search for new therapeutical targets 
in pulmonary sarcoidosis. 
Granuloma formation in pulmonary sarcoidosis
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InTRoDUCTIon
Sarcoidosis is a granulomatous disorder of unknown cause, affecting multiple organs, 
but mainly the lungs. In 10-30% of the cases, sarcoidosis becomes chronic and progres-
sive leading to debilitating disease and sometimes death (1). Its etiology is intriguing, 
since a part of its definition (i.e. unknown cause) makes it uniquely different from 
granulomatous disorders arising from exposure to a known chronically persisting an-
tigen, such as tuberculosis, visceral leishmaniasis and chronic beryllium disease (2, 3). 
Nevertheless, several observations support an antigen-induced disease etiology. First, 
epidemiological research identified environmental and occupational risk factors, such 
as exposure to musty odors and insecticides (4). Second, infectious agents, including 
Propionibacterium acnes (P.acnes) and Mycobacterium tuberculosis (Mtb), have been 
implicated, since genomes of these species are detected within sarcoid granulomas (5). 
A role for mycobacterial peptides is further supported by the presence of T lymphocytes 
that are highly responsive towards 6-kDa early secreted antigenic protein (ESAT-6) or 
catalase peroxidase (KatG) in the bronchoalveolar lavage fluid (BALF) of sarcoidosis pa-
tients (6-8). Third, a limited clonality of CD4+ T cells, expressing the AV2S3 T cell receptor, 
was demonstrated within the lungs of HLA-DRB1*03 positive sarcoidosis patients, which 
is consistent with an antigenic response (9-12). Finally, evidence for an antigen-induced 
disease lies within the granulomatous reaction that is virtually indistinguishable from 
sarcoid granulomas and occurs in individuals with sarcoidosis upon subcutaneous 
injection of homogenates from allogeneic sarcoid spleen or lymph nodes (LN), i.e., the 
Kveim-Siltzbach test (13, 14). 
genetic risk factors in sarcoidosis 
People all over the world suffer from sarcoidosis (15). Familial clustering (16), increased 
concordance in monozygotic twins (17) and variations in susceptibility and disease 
presentation among different ethnic groups (18), suggest the importance of genetic, 
next to environmental risk factors in the etiology. 
Genome-wide association studies (GWAS) identified polymorphisms within genes 
coding for proteins involved in T-cell activation, differentiation, proliferation and sur-
vival, including NOTCH 4 and ANXA11 (19, 20). Additionally, GWAS and case-control 
studies identified important genetic risk factors within the antigen presentation locus at 
6p21.3, which contains genes encoding proteins involved in both antigen presentation 
and T-cell regulation, including human leucocyte antigen (HLA) and butyrophilin-like 
protein (BTNL)-2, respectively (20-23). 
Specific HLA class II antigens are associated with certain sarcoidosis disease pheno-
types. For example, the HLA-DRB1*03 and DQB1*0201 alleles have been associated with 
an acute disease onset, Löfgren syndrome and resolving disease, whereas in contrast 
HLA-DRB1*15 and DQB1*0601 are associated with chronic sarcoidosis (24-27). It is 
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conceivable that both resolving and persistent sarcoidosis arise due to a unique combi-
nation of a specific genetic background and exposure to one or several environmental 
triggers (28). This unique combination might lead to persistent stimulation of the im-
mune system, contributing to granuloma formation and sustainment.
In this article we review the current knowledge on the role of the immune activation 
in pulmonary sarcoidosis and propose a hypothesis on the origin of granuloma forma-
tion. Secondly, we aim to discuss granuloma integrity, highlighting areas for research 
into new therapeutical targets. 
gRanUloma foRmaTIon
A well-developed sarcoid granuloma consists of a tightly formed conglomerate of 
epithelioid- and multinucleated giant cells (MGCs) encircled by lymphocytes, especially 
CD4+ T helper (Th) cells, but also rare CD8+ T cells and B cells (1). Both granuloma forma-
tion and integrity depend on the availability and supply of these different cells (29). The 
chronological order of immunological events and the exact role of these cells during the 
sarcoid granulomatous response remain obscure, due to the lack of an animal model 
for sarcoidosis. Nevertheless, careful clinical observations and in-depth research on 
functional properties of different cells involved provide essential information to unravel 
the cellular and molecular mechanisms of granuloma formation. 
Clinical signs
Cardinal features of pulmonary sarcoidosis are mediastinal lymphadenopathy, paren-
chymal and airway granulomas, giving rise to upper lobe nodules in a perilymphatic or 
bronchovascular distribution and signs of a CD4+ T-cell alveolitis. An interstitial pneu-
monitis, found on open lung biopsy, is classically thought to represent a very early stage 
of granuloma formation (30). Spontaneous remission and reactivation of sarcoidosis 
makes it difficult to ascertain the exact sequence of these cardinal features, however 
several findings strongly suggest a certain order in the majority of patients, which may 
add to the hypothesis on granuloma formation as described below.
Although it is well known that patients do not go through all disease stages as de-
scribed by Scadding (from I to IV) sequentially, arguably pulmonary sarcoidosis starts in 
the draining LN. As stage I (bihilar lymphadenopathy) is most often asymptomatic, it is 
conceivable that it precedes pulmonary involvement, seen in stage II and III. Addition-
ally, progression of stage I to II disease is well-known, while development of stage I after 
stage III is uncommon. Finally, a recent trial found an increased diagnostic sensitivity 
of LN-derived fine needle aspirates, compared with transbronchial lung biopsies (31). 
These data suggest that the first granulomas are formed within the mediastinal LN, only 
later followed by granuloma formation within the lungs.
Granuloma formation in pulmonary sarcoidosis
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Consequently, LN-specific immune reactions are important in early sarcoid granuloma 
formation, such as antigen presentation by dendritic cells (DCs). DCs are the only cells 
capable to pick up antigens and migrate to the LN where they present antigens to naïve 
T cells. Hereby they initiate highly specific clonal T cell differentiation and prolifera-
tion (32). Alternatively, LN-resident DCs may encounter antigenic particles, which we 
propose are submicroscopic and may therefore have passively migrated through the 
afferent lymph. The activated and differentiated Th cells migrate towards the site of 
inflammation, orchestrated by chemokines. 
Macrophages contribute to early recognition of the putative sarcoid antigen in the 
lungs, thereby attracting mononuclear cells, including monocytes and LN-activated 
lymphocytes. The ensuing influx of cells leads to an interstitial pneumonitis, character-
ized by a mixed mononuclear cell infiltrate in the alveolar wall and CD4+ T-cell alveolitis 
(30). 
At the site of antigen encounter, antigen-presenting cells (APCs) induce persistent 
stimulation of the immune response, mediated by HLA-related proteins, leading to 
continuous recruitment and local expansion of lymphocytes and eventually granuloma 
formation. The central localization of macrophages within the final epithelioid aggregate 
supports an important role in antigen presentation at the site of granuloma formation. 
Alternatively, DCs may play a critical role in antigen presentation within the granuloma. 
Their capacity for antigen sampling within the lymph fluid makes them likely candidates 
to contribute to the induction of the perilymphatic localized granulomas (33, 34). 
In the following paragraphs we describe the current knowledge on the role of mac-
rophages, DCs and lymphocytes in sarcoid granuloma formation in more detail, also 
summarized in Figure 1. 
macrophages
Upon activation, macrophages release nuclear factor (NF)-κB-dependent pro-inflam-
matory cytokines, such as interleukin (IL)-1 and tumor necrosis factor-α (TNF-α) (35). In 
sarcoidosis, BALF cells and monocytes highly express toll-like receptor (TLR)-2 (36, 37) 
and produce increased amounts of TNF-α, IL-1β and IL-6 compared with controls, when 
stimulated with TLR-2 ligands, including ESAT-6 and KatG (7, 36-38). A role for TLR-2 
in immune activation and granuloma formation in sarcoidosis is further supported by 
genetic and mouse studies (38, 39). Lately, continuous TLR-2 ligation by macrophage-
derived serum amyloid A has been suggested to contribute to persistent stimulation of 
the immune response in sarcoidosis (37). 
Intrinsically, unstimulated sarcoid-derived alveolar macrophages (AMs) produce in-
creased amounts of IL-1 and TNF-α (40-43) and are highly activated (44, 45). The amounts 
of spontaneously produced TNF-α by BALF cells in vitro correlate with the presence of 
aggregates of AMs in the tissue (46, 47). Only AMs from patients with active and progres-
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sive disease produce increased amounts of TNF-α (48-51). These data highlight the role 
of TNF-α in granuloma formation and integrity, also supported by mouse studies (52-54). 
Important mechanisms of action of TNF-α include macrophage activation, promotion 
of cellular migration towards the site of infl ammation and leucocyte adhesion (52, 55, 
56). In a mycobacterial-driven mouse model, TNF-α is responsible for the early produc-
tion of chemokines that attract mononuclear cells to the site of infl ammation, such as 
RANTES, MIP-1α, MIP-1β, MIP-2 and MCP-1 (55), of which increased amounts are found 
in sarcoidosis BALF (57-59). In active sarcoidosis, AMs produce high amounts of CCL20, 
when stimulated by TNF-α and IL-1β (60). CCL20 is a chemokine with high affi  nity for 
chemokine receptor CCR6, therefore attracting DCs, B cells and specifi c T cell subsets 
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Figure 1
figure 1. A schematic model for granuloma formation in pulmonary sarcoidosis. An unknown airborne-
antigen activates (A) interstitial dendritic cells (DCs), (B) alveolar macrophages (AMs), and (C) alveolar epi-
thelial cells type II (AEC-II) (dark green), simultaneously. This process is initiated by toll-like receptor-2 (TLR-
2) ligands, possibly mycobacterium tuberculosis-derived ESAT-6 or mKatG. (A) The interstitial DCs pick up the 
putative antigen and migrate towards the mediastinal lymph nodes (LN), where they initiate diff erentia-
tion and clonal expansion of T helper (Th)1 and 17 cells. (B) Simultaneously, AMs produce tumor necrosis 
factor-α (TNF-α), which initiates upregulation of activation (HLA-DR and CD80/86) and adhesion (ICAM-1 
and LeuCAM) molecules. Macrophages produce chemokine ligands (MCP-1, CCL20, CXCL10 and CXCL16) 
under stimulation of both TNF-α and natural killer (NK) cell-derived interferon-γ (IFN-γ), thereby attracting 
Th1/17 cells, monocytes, regulatory T cells (Tregs) and B cells. (C) The lung environment is characterized 
by the presence of Th1 and Th17 favoring cytokines, such as IL-6, IL-12, IL-18, IL-23 and TGF-β, produced 
by macrophages, perilymphatic DCs and AEC-II. Persistent stimulation, mediated by antigen presenting 
cells (APCs), leads to continuous cellular recruitment to the site of infl ammation, which leads to granuloma 
formation. Tregs infi ltrating the granuloma fail to diminish the exaggerated immune response, thereby 
contributing to granuloma persistence and integrity.
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towards the lungs (60, 61). Similarly, AM-derived CXCL10 and CXCL16 contribute to 
CXCR3+ and CXCR6+ CD4+ Th cell recruitment (62, 63). 
In a mycobacterial-driven granuloma model, efficient cellular recruitment, mediated 
by AM-derived CXCL10 and CXCL16, depends on interferon-γ (IFN-γ) (53). During the 
early innate response natural killer (NK) cells are important producers of IFN-γ, when 
stimulated by TNF-α, IL-1 and IL-12. In sarcoidosis, the size of a distinct NK cell sub-
population (CD56brightCD94highKIRlow) is increased in the BALF compared with controls 
(64). Furthermore, higher proportions of NK cells were found to correlate with a poor 
outcome (65). 
Once recruited, TNF-α is needed for leucocyte adhesion, since an abrogation of tightly 
formed granulomas in TNF-α-deficient mice is observed following mycobacterial infec-
tion (55). In sarcoidosis, TNF-α induced the expression of intracellular adhesion mol-
ecule-1 (ICAM-1) on AMs, leading to cellular aggregation (66). Additionally, leucocyte 
adhesion molecule (LeuCAM) expression, such as CD11a/b/c and CD18 (67), is increased 
in sarcoid AMs compared with controls. 
Following adhesion, epithelioid histiocytes and monocyte-derived DCs can fuse to 
multinucleated giant cells (MGCs) when stimulated by local cytokines, such as TNF-α, 
GM-CSF, IL-17A, CCL20 and IFN-γ (68, 69). Patient-derived macrophages and monocytes 
show an enhanced potential to form MGCs in vitro, compared with healthy controls and 
other granulomatous diseases (70). 
Importantly, sarcoid-derived AMs have an increased accessory function on autologous 
blood- and lung-derived T lymphocytes, when compared with controls (71-73). Macro-
phages are not capable to migrate to the LN to induce naive T cell activation, making 
them weak APCs. Nonetheless, in sarcoidosis, macrophages might contribute to local 
antigen presentation, enhancing proliferation of chemokine-recruited memory Th cells. 
In summary, macrophages are important for the initial accumulation, aggregation 
and fusion of the cellular building blocks needed for granuloma formation. This process 
is mediated by the strong immune modulatory capacities of TNF-α and assisted by NK 
cells, which produce IFN-γ.
Dendritic cells
Only a few studies investigated the role of DCs in sarcoid granuloma formation (47, 74). 
Our group has shown that granuloma formation surrounding intravenously injected an-
tigen-loaded beads trapped in the lung vasculature is dependent on DC-initiated Th cell 
proliferation within the mediastinal LN (75). In sarcoidosis, an accumulation of mature 
(Fascin+HLA-DR+DC-LAMP+) DCs is found surrounding LN granulomas, adjacent to CD3+ 
lymphocytes, suggesting DC-T cell interaction at this site (76). Mature (CD11c+CD86+) 
DCs are found surrounding granulomas in sarcoid-derived mucosal biopsies (77), further 
supporting a role for DCs in airway and parenchymal granuloma formation. 
28
Chapter 1
An impaired accessory function of ex vivo blood-derived myeloid DCs (mDCs) has 
been suggested to contribute to granuloma formation, as clearance of the putative 
antigen may be ineffective and the immune system turns to granuloma formation as 
a default immunological response (78). In contrast, our group isolated BALF mDCs of 
sarcoidosis patients and found them to be immunocompetent, initiating proliferation 
of allogeneic, naïve T lymphocytes comparable with mDCs from healthy controls (77). 
Similarly, in vitro cultured monocyte-derived DCs (moDCs) showed a comparable ac-
cessory capacity as controls, although they are intrinsically prone to produce TNF-α (77, 
79). Hence, it is most likely that DCs are involved in granuloma formation, instead of 
displaying diminished antigen presenting capacities. 
Differentiation of T lymphocytes depends on the local cytokines surrounding the 
initiating APC (80). Although it is very likely that LN-specific interactions, mediated by 
DCs, are responsible for the initial T cell polarization towards a Th1 and Th17 phenotype 
as observed in sarcoidosis, direct evidence is still lacking.
lymphocytes
Sarcoidosis is characterized as a Th1- (81) and more recently a Th17-mediated disease 
(61, 82), based on the accumulation of IFN-γ, IL-2 and IL-17-producing Th cells in the 
lungs of patients with active sarcoidosis (44, 61, 82-84). 
Th1 differentiation depends on IL-12 and IL-18, which are increased in BALF of 
sarcoidosis patients (85, 86). Alveolar epithelial cells type II (AEC-II) may contribute to 
this Th1-favoring environment, since patient-derived AEC-II produce IL-18 upon TLR-2 
stimulation (87, 88). Additionally, AEC-II may contribute to CXCR3+ Th1 cell recruitment 
by production of CXCL10 (89) .
Th17 differentiation is driven by IL-6 and TGF-β, both produced by sarcoid-derived 
BALF cells (90, 91), whereas survival and proliferation of this subset is IL-23-dependent 
(92-94). Increased expression of the IL-23-receptor and IL-17, both expressed by Th17 
cells, is found in blood-, lung- and LN-derived lymphocytes of active sarcoidosis patients, 
and not in inactive disease (61, 82). Recently, ESAT-6-specific Th17 cells in the BALF of 
sarcoidosis patients were found (95). Additionally, IL-17A is essential for granuloma 
formation in the lung during mycobacterial infection (96) or in chronic granulomatous 
disease (97).
We recently found that the proportions of circulating IL-17A/IFN-γ and IL-17A/IL-4 
double-producing cells are significantly increased in the peripheral blood of patients 
and are present in substantial numbers in BALF (82). Findings in several autoimmune 
diseases have indicated the pathogenic potential of CD4+ Th cells producing both IL-
17 and IFN-γ (98, 99). Processes underlying Th17 cell induction in sarcoidosis remain 
obscure, but the presence of these cells can suggest a role for autoimmune responses in 
sarcoidosis. B lymphocytes and plasma cells are found surrounding sarcoid granulomas 
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(100). Additionally, active sarcoidosis patients have increased serum levels of B-cell-
activating factor (BAFF) (101). Since B cell maturation and function depends on BAFF, 
its aberrant expression can initiate defective selection of autoreactive B cells, leading 
to autoantibody production (101, 102). In sarcoidosis, approximately 30-60% of the 
patients exhibit antinuclear antibody (ANA) positivity (101, 103). 
A SNP in the IL-23 receptor gene has been associated with chronic sarcoidosis (104), 
which may contribute to Th17 cell development in sarcoidosis. Since IL-23 is a heterodi-
mer of the p19 subunit and the p40 subunit of IL-12 (105) the Th1- and Th17-promoting 
cytokines share a common therapeutical target. Ustekinumab, a neutralizing antibody 
against the IL-12/IL-23 p40, was shown to be successful in the Th1/Th17-mediated dis-
eases psoriasis and Crohn’s disease (CD) (106, 107), but not in chronic pulmonary or skin 
sarcoidosis (108, 109). 
gRanUloma InTEgRITy
In the majority of the sarcoidosis patients, granulomas spontaneous resolve within sev-
eral years, without need for therapy. However, a substantial proportion of the patients 
develop chronic progressive disease, whereby granulomas persist and form fibrotic le-
sions, leading to debilitating disease and sometimes death (1, 110). The immunological 
response, determining granuloma sustainment is not well understood. 
Regulatory T cells
Regulatory T cells (Tregs) play an important role in diminishing Th cell specific responses 
and are pivotal for maintenance of self-tolerance and immune homeostasis (111). An 
impaired immunosuppressive function of sarcoid-derived Tregs has been suggested to 
contribute to the on-going, exaggerated immune response, since sarcoid blood-derived 
(CD4+CD25high) Tregs fail to inhibit granuloma growth in an in vitro granuloma culture 
model (112, 113). Subsequently, an impaired immunosuppressive function of both 
blood- and BALF-derived sarcoidosis Tregs has repetitively been described on autolo-
gous and allogeneic healthy Th cell proliferation (114-116). These studies also show that 
sarcoid-derived Tregs fail to inhibit production of TNF-α, IFN-γ and IL-2, contributing to 
granuloma formation, rather than diminishing the immune response (112, 113, 116). It 
remains unknown what mechanism(s) underlies this impaired function. 
Active and persisting sarcoidosis was recently associated with a global CD4+ T cell sub-
set dysfunction (116). Notably, both Th anergy and Treg malfunctioning were restored 
in patients with disease resolution (116). These results highlight the complex interplay 
between pro-inflammatory and anti-inflammatory responses needed for granuloma 
integrity. This fine balance may explain contradictory results with regard to reported 
Treg numbers in the BALF (112-119) (Table 1). Low BALF Tregs (i.e. less immunosup-
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pression) in patients have been associated with a favorable prognosis in a Scandinavian 
population (118). In contrast, a German study reported decreased BALF Treg numbers 
in sarcoidosis patients who develop chronic (active) disease, when compared with con-
trols and patients who develop spontaneous resolution (115). Similarly, CD1d-restricted 
natural-killer T (NKT) cells with immunoregulatory function are greatly reduced in the 
peripheral blood of all sarcoidosis patients, except Löfgren patients (120). 
Taken together, these studies imply different roles for immune regulatory cells in 
sarcoidosis, either contributing to or preventing an on-going, exaggerated immune 
response. Arguably, whereas in the early sarcoid response there may be no need for 
Tregs to inhibit an effective immune response, during persistent stimulation immune 
regulatory cells should function as a natural brake on the exaggerated response to 
prevent immunopathology and autoimmunity. 
Interfering with granuloma integrity
Effective treatment agents used for sarcoidosis interfere with granuloma integrity 
and would ideally prevent fibrogenesis. Glucocorticosteroids (GCs), the main stay of 
sarcoidosis therapy, partially exert their beneficial effect by repression of NF-κB-related 
cytokine gene transcription and induction of lymphocyte apoptosis (121, 122). Using a 
mouse model, Tregs are found to be less sensitive to GC-induced apoptosis compared 
with Th cells, favoring an anti-inflammatory milieu (123, 124). Similarly, anti-TNF agents 
induce monocyte and lymphocyte apoptosis (125-127), while improving Treg numbers 
(123). Interestingly, infliximab, which blocks membrane-bound TNF-α, is uniquely as-
sociated with a high risk of reactivation of latent Mtb infection, whereas etanercept, 
solely blocking secreted TNF-α, is not (29). This phenomenon implies a critical role of 
membrane-bound TNF-α signaling in granuloma integrity (29), which is further sup-
ported by mouse studies (128).
Whether GCs and anti-TNF agents interfere with the delicate Th/Treg balance in pul-
monary sarcoidosis, remains to be elucidated. Research into this field will shed more 
light on the role of Tregs in sarcoid pathology and whether Treg induction holds a prom-
ising new therapeutical strategy. Finally, an interplay between anergic Th cells, IL-10, 
alternatively activated macrophages (M2), CCL18 and lung fibroblasts has recently been 
suggested to contribute to fibrotic remodeling of the lung in chronic sarcoidosis (129). 
These insights yield new therapeutical targets to prevent irreversible organ damage in 
chronic pulmonary sarcoidosis patients.
ConClUSIon
Sarcoidosis is an intriguingly complex granulomatous disorder, characterized by an ex-
aggerated Th1/17 immune response, initiated by APCs, and maintained due to malfunc-
32
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tioning of Tregs. Refining insight into immunological events that determine granuloma 
fate may help identify new therapeutical targets and patients who will benefit such 
therapy in the future.
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To the editor: 
Cytotoxic T-lymphocyte anti gen 4 (CTLA4) is an important suppressor of T-cell-mediated 
immune responses, and has become a major target in tumor therapy (1). Intriguingly, 
various case reports on initiation or exacerbation of sarcoidosis during anti-CTLA4 treat-
ment of metastatic melanoma have recently emerged. This phenomenon is considered 
biotherapy–induced sarcoidosis, as in all reported cases, granuloma lesions occurred 
and progressed during biotherapy employment and disappeared after drug discontinu-
ation (2). In patients with metastatic melanoma, CTLA4 blockade increased circulating 
proportions and absolute numbers of IL-17-producing CD4+ T cells, whereas it only 
marginally changed T helper(Th)1 or Th2 cell percentages (3). Although the effect on 
regulatory T cell (Treg) proportions remains a matter of debate, CTLA4 blockade was 
found to impair Treg-mediated suppression (1). Moreover, in both mice and humans, 
CTLA4 deletion, blockade or dysfunction is strongly associated with the development 
of autoimmune lesions (1), in which Tregs and Th17 cells are known to play a pivotal 
role. Because sarcoidosis is characterized by an abnormal Th1/Th17 cell response and 
impaired Treg function (4), it is conceivable that CTLA4 blockade exacerbates underly-
ing or pre-existent disease. 
These clinical observations provide a rationale to examine CTLA4 expression on CD4+ 
T cells in sarcoidosis in lung-draining mediastinal lymph nodes (MLN), which are an 
important site of primary and memory T-cell activation by dendritic cells. We hypoth-
esize that altered CTLA4 expression contributes to ongoing Th1/Th17 cell responses 
in sarcoidosis. Using flow cytometry, we determined CTLA4 expression on CD4+ T cell 
subsets (for gating strategy, see Figure E1 in the online supplement) in MLN from patient 
with sarcoidosis (n=18) and controls (n=24) (for methods, see Materials and Methods in 
the online supplement and Table E1). 
Activated T cells from sarcoidosis MLN showed decreased CTLA4 expression com-
pared with control MLN (Figure 1A). CTLA4 expression was also decreased on nonacti-
vated memory T cells, but normal on naive T cells (Figure E2). Evaluating Th cell subsets 
showed a significant decrease in CTLA4 expression specifically on sarcoidosis Th17 cells 
(P=0.004) but not on Th1 or Th2 cells (Figures 1B and 1C). Furthermore, proportions of 
Th17 cells were significantly increased in sarcoidosis MLN (Figure 1D), consistent with 
our previous finding of enhanced Th17 cell proportions in peripheral blood and lungs 
of patients (5).
Notably not only Th17 cells but also activated Tregs showed decreased CTLA4 expres-
sion in sarcoidosis MLN compared with controls (P=0.016) (Figure 1B and 1C). Treg 
proportions were not increased (Figure 1E). Intriguingly, as CTLA4 protein expression 
is critical for Treg function (6) and Th17 cells are uniquely sensitive towards CTLA4 co-
inhibition (7), impaired CTLA4 expression on these specific subsets contributes to Th17 
cell differentiation and activation and to ongoing Th(17) cell proliferation.
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Although there is evidence that sarcoidosis MLN parallel the lungs in terms of CD4+ T 
cell (8) and Th17 cell (this manuscript) influx, we also determined CTLA4 expression on 
T cells in broncho-alveolar lavage fluid. Importantly, similar to in sarcoidosis MLN, sar-
coidosis broncho-alveolar lavage fluid memory Th cells showed significantly decreased 
CTLA4 expression compared with disease controls (P<0.0001) (Figure E3). 
CTLA4 expression depends on the strength of T cell stimulation, mediated by the T-
cell receptor and CD28 expression (9). Decreased CTLA4 expression on CD4+ T cells in 
sarcoidosis can therefore be a consequence of ongoing inflammation, leading to loss of 
CD28 expression, as described in chronic beryllium disease (10). However, we only found 
a slight, non-significant decrease of CD28 expression on sarcoidosis Th17 cells compared 
with controls (Figure 1F). Beryllium-responsive CD4+ T cells in the lung-upregulated 
programmed death (PD)-1 reflecting T-cell exhaustion in response to chronic antigenic 
(beryllium) exposure (10). We did not find increased PD-1 expression on sarcoidosis 
Th17 cells (Figure 1G). Taken together, our findings do not support T-cell differentiation 
status or exhaustion as an explanation for low CTLA4 levels, but do suggest a specific 
defect in CTLA4 expression instead.
It is conceivable that genetic changes could underlie impaired CTLA4 protein expres-
sion in sarcoidosis. Genetic variations in the CTLA4 gene are associated with various 
autoimmune disorders (1), and CTLA4 gene mutations have been identified in families 
with common variable immunodeficiency, including patients with granulomatous lung 
disease (6). These mutations led to impaired CTLA4 up-regulation in activated Tregs, 
indicating that two functional CTLA4 alleles are necessary to drive high protein levels 
(6). We found up-regulation of CTLA4 on sarcoidosis activated Tregs compared with 
Th1, Th2, or Th17 cells (Figure 1C). Paired analyses showed that this was significant 
(P=0.001). Furthermore, CTLA4 gene polymorphisms in sarcoidosis were not reported 
to be associated with disease susceptibility but merely with the extent of disease (11). 
Taken together, it is unlikely that genetic mutations within the CTLA gene impair CTLA4 
protein expression in sarcoidosis. 
The mechanisms that regulate CTLA4 expression on individual T-cell subsets remain 
largely unclear to date. The cause of impaired CTLA4 expression in sarcoidosis Tregs 
and Th17 cells may be T-cell non-intrinsic and depend on the local inflammatory micro-
environment. Characterizing cytokine profiles in sarcoidosis MLN might help unravel 
further causes of diminished CTLA4 expression.
In summary, we are the first to demonstrate a significant decrease in CTLA4 expression 
specifically on Tregs and Th17 cells at an important site of T-cell activation in sarcoidosis. 
Because Th17 cell, and not Treg, proportions were increased, impaired CTLA4 expression 
in sarcoidosis could influence the delicate Th cell/Treg balance (4) and contribute to on-
going inflammation. Importantly, our data are in agreement with clinical observations 
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figure 1. Decreased cytotoxic T-lymphocyte 4 antigen (CTLA4) expression on regulatory T cells (Tregs) and 
Th17 cells in sarcoidosis. CTLA4 expression was determined on CD4+ T cells in control and sarcoidosis medi-
astinal lymph nodes. (A) Mean fluorescence intensity (MFI) of CTLA4 on activated (CD45RA-FoxP3int) T cells. 
(B) Flow cytometry analysis of CTLA4 expression on Th1, Th2 and Th17 cells and activated (CD45RA-Fox-
P3high) Tregs of a control patient and a patient with sarcoidosis. (C) MFI of CTLA4 on Th1, Th2, and Th17 cells 
and activated Tregs. (D) Th17 proportions of total memory T cells. (E) Activated Treg proportions of total 
CD4+ T cells. (F) MFI of CD28 on Th17 cells. (G) MFI of programmed death (PD)-1 on Th17 cells. Statistics: Hori-
zontal lines indicate the median, and significance was determined using a Mann-Whitney U test, *P < 0.05 
***P < 0.001. Significance between medians of paired samples was determined using a Wilcoxon signed 
rank test (#P=0.001: sarcoidosis activated Treg vs. sarcoidosis Th1,Th2, or Th17 cells). aTcells = activated T 
cells, aTreg = activated Treg, Ctrl = control, SRC = sarcoidosis. 
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that anti-CTLA4 treatment can exclusively increase Th17 cells (3) and induce sarcoidosis 
(2). 
In conclusion, our data and clinical observations argue for a central role of CTLA4 in 
sarcoidosis pathology. Decreased CTLA4 protein expression on Tregs and Th17 cells 
in sarcoidosis MLN can cause double trouble: on the one hand contributing to Th17 
priming and activation (7), and on the other, impairing Treg-mediated suppression (1). 
The treatment-naive sarcoidosis population studied displayed limited inter-patient vari-
ability regarding CTLA4 expression values, precluding an analysis of their correlation 
with disease prognosis. However, prospective studies can help provide a rationale to 
evaluate CTLA4 Ig (e.g. abatacept) efficacy in sarcoidosis (for a proposed model concern-
ing effects of various CTLA4 expressions on Tregs and Th17 cells and a rationale for the 
effect of CTLA4 Ig treatment in sarcoidosis see Figure E4). 
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SUPPlEmEnTaRy maTERIal
mEThoDS
Study design and subjects
Patients with pulmonary sarcoidosis were included at time of diagnosis. The diagnosis of 
sarcoidosis was made conform the guidelines of the ATS/ERS/WASOG (1). 
Exclusion criteria were use of immunomodulatory medication 3 months prior to 
study inclusion; respiratory tract infection 4 weeks prior to study inclusion; concomitant 
pulmonary disease (including chronic obstructive pulmonary disorder and asthma), 
autoimmune diseases, malignancies, human immunodeficiency virus seropositivity, 
pregnancy, and allergies. 
For this study, 18 sarcoidosis patients donated lymph nodes aspirates from lung 
draining lymph nodes. Control mediastinal lymph nodes were collected from 24 lung 
transplantation donors without signs of pulmonary inflammation (routinely assessed 
by a chest X-ray and bronchoscopy). The cause of death of these donors was a cerebro-
vascular incident (n=16), cardial arrest (n=3), trauma capitis (n=3) or was not specified 
(n=2). Due to limitations in the number of cells isolated per lymph node aspirate per 
patient, we were not able to determine all subset analysis in all patients.
Furthermore, 27 additional sarcoidosis patients, 8 patient with community-acquired 
pneumonia (CAP) and 4 patients with COPD donated BALF for this study. 
The Medical Ethical Committee of the Erasmus University Medical Centre Rotterdam 
approved this study. Written informed consent was obtained from every participant be-
fore study inclusion. Further subject characteristics are shown in Supplementary Table 
E1 (MLN analyses) and Supplementary Table E2 (BALF analyses). 
Study materials
Eosophageal or endobronchial ultrasound guided fine-needle aspiration (EUS- or 
EBUS-FNA) from draining mediastinal lymph nodes was performed with a 22G (or 19G) 
needle. Mediastinal lymph node aspirates were filtered through a 100 μm cell strainer 
(BD Biosciences) and centrifuged. The cells were frozen in 1 ml RPMI 1640 (Gibco), 10% 
Fetal Calf Serum (FCS, Sigma), 10% Dimethyl sulphoxide Hybri-Max (DMSO, Sigma) in 
a cryovial using a 5100 Cryo 1°C Freezing Container (Nalgene) to -80 °C, and stored at 
-150 °C. 
Control mediastinal lymph nodes were collected from lung transplantation donors. 
These lymph nodes are routinely removed from the donor lungs and discarded before 
implantation in the acceptor. Control mediastinal lymph nodes were processed as lymph 
node aspirates. 
Bronchoscopy with BAL was performed as previously described (2) and BALF cells 
were processed as previously described (2). 
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flow cytometry staining
Mediastinal lymph node and BALF cells were stained for extra- and intracellular markers 
using the following antibodies: CD3-APC-eFluor780 (SK7), CD4-AF700 (OKT4), FoxP3-
APC (PCH101), CTLA4-PerCp-eFluor710 (14D3) (eBiosciences) and CCR6-APC (11A9), 
CXCR3-BV711 (1C6/CXCR3), CTLA4-BV421 (BNI3), CD28-BV605 (CD28.2), PD-1-BV711 
(EH12) (BD biosciences) and CCR4-FITC (205410) (R&D) and CXCR3-BV421 (G025H7) 
(Biolegend) and CD45RA-PE-Texas Red (MEM-56) (Invitrogen). Fixable Aqua Dead Cell 
Stain kit for 405 nm (Invitrogen, Molecular Probes) was used as live-dead marker. At least 
100.000 cells per sample were measured on a Flow cytometer LSRII (BD Biosciences), and 
the mean fluorescence intensity of CTLA4, CD28 and PD-1 was standardized to average 
expression in healthy control peripheral blood cells. 
Statistical analyses
Comparisons were performed using a Mann-Whitney U test or Wilcoxon signed rank 
test. P-values were two sided, and analyses were performed using IBM SPSS Statistics 21. 
P < 0.05 was considered statistically significant. 
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Supplementary Figure E1
Supplementary figure E1. Gating strategies to determine CD3+CD4+ T cell subsets. (A) Five CD4+ T cell 
populations were characterized within mediastinal lymph nodes according to CD45RA and intracellular 
FoxP3 expression (3), i.e. CD45RA+FoxP3- naïve T cells, CD45RA-FoxP3- memory T cells, CD45RA-FoxP3int acti-
vated (non-suppressive/-regulatory) T cells, CD45RA+FoxP3int naïve regulatory T cells and CD45RA-FoxP3high 
activated Tregs. The total memory T cell pool consists of memory T cells plus activated T cells. The total 
(non-suppressive/-regulatory) T cell pool consists of naïve T cells plus total memory T cells. (B) Within sev-
eral mediastinal lymph nodes T helper subsets were characterized within the total memory T cells, using 
chemokine receptor expression, i.e. CCR6-CXCR3+ Th1, CCR6-CCR4+ Th2 and CCR6+CCR4+ Th17 cells (4). Ab-
breviations: Treg = regulatory T cells. 
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Supplementary Figure E2
Supplementary figure E2. CTLA4 expression was determined on CD4+ T cells in control and sarcoidosis 
mediastinal lymph nodes. Mean fluorescence intensity of CTLA4 on naïve, memory and activated T cells is 
shown. Statistics: Horizontal lines indicate the median and significance was determined using a Mann-Whit-
ney U test, * P < 0.05. Abbreviations: CTLA4 = cytotoxic T lymphocyte antigen 4, MFI = mean fluorescence 
intensity, Ctrl = control, SRC = sarcoidosis. 
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Supplementary Figure E3
Supplementary figure  E3. CTLA4 expression was determined on CD4+ memory T cells in sarcoidosis 
(n=27) and disease control (i.e. community-acquired pneumonia (n=8: lighter grey) and chronic obstruc-
tive pulmonary disease (n=4: darker grey) patients) BALF. Mean fluorescence intensity of CTLA4 on memory 
CD4+ T cells in MLN and BALF is shown. Sarcoidosis BALF-derived memory CD4+ T cells showed a significant 
decrease of CTLA4 expression compared with disease controls (P < 0.0001). Statistics: Horizontal lines in-
dicate the median and significance was determined using a Mann-Whitney U test, *** P < 0.0001. Abbre-
viations: CTLA4 = cytotoxic T lymphocyte antigen 4, MFI = mean fluorescence intensity, BALF = broncho-
alveolar lavage fluid, Ctrl = control, SRC = sarcoidosis. 
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Supplementary figure E4. A proposed model for the effect of CTLA4 expression by Tregs and Th17 cells 
in healthy control (A), anti-CTLA4-treated (B) and sarcoidosis (C) mediastinal lymph nodes, and a rationale 
for the effect of CTLA4 Ig treatment in sarcoidosis (D). (A) Healthy Tregs highly express CTLA4 and indirectly 
inhibit T cell activation via CD80/86 engagement on APCs. This leads to restricted CD80/86 ligand avail-
ability on APCs, inducing tolerance (5). Healthy control Th17 cells highly express CTLA4 which competes 
with CD28-ligand binding, since CTLA4 interacts with CD80/86 with higher affinity and avidity than does 
CD28 (5). Therefore, healthy Th17 cells are sensitive towards CTLA4 co-inhibition, leading to suppressed 
Th17 differentiation, activation or proliferation (6). (B) Anti-CTLA4 treatment (e.g., ipilimumab) leads to 
enhanced CD80/86 ligand availability on APCs and decreased competition with CD28-ligand binding on 
Th17 cells. This can increase Th17 cell differentiation, activation and therefore enhance their proportions 
(7), contributing to IRAEs, including biotherapy-induced sarcoidosis (8). (C) Sarcoidosis Tregs show de-
creased CTLA4 protein expression (Figure 1B/C) leading to enhanced CD80/86 ligand availability on APCs 
(Trouble 1). Additionally, sarcoidosis Th17 cells show decreased CTLA4 protein expression (Figure 1B/C), 
leading to impaired competition with CD28-ligand binding on Th17 cells and therefore enhanced Th17 
differentiation, activation and increased Th17 proportions (Figure 1D) (9) (Trouble 2). (D) Using a CTLA4-Ig 
fusion protein (e.g., abatacept) in sarcoidosis will bind to CD80/86 with high affinity and therefore restrict 
ligand CD80/86 availability on APCs (5). Additionally, it will compete with CD28-ligand binding on Th17 
cells, leading to suppressed Th17 cell responses in sarcoidosis. Abbreviations: Treg = regulatory T cell, APC 
= antigen presenting cell, Th = T helper, CTLA4 = cytotoxic T lymphocyte antigen 4, TCR = T cell receptor, 
IRAEs = immune-related adverse events. 
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Supplementary Table E1. Study subject characteristics MLN samples
Subject characteristics Controls
(n=24)
Sarcoidosis 
(n=18)
Median age (min-max) 47 (15-70) 45 (24-75)
Sex (Male/Female) 6/18 12/6
Scadding Stage (n (% of total))
Stage 0 3 (16,7)
Stage I 7 (38,9)
Stage II 5 (27,8)
Stage III 1 (5,6)
Unknown 2 (11,1)†
Diagnosis was assessed by (n (% of total))
E(B)US-FNA 16 (88,9)
Mediastinoscopy 2 (11,1)
Extrathoracic involvement  (n (% of total))
No/Yes 5/13 (27,8/72,2)
Skin 5 (27,8)
Eyes 7 (38,9)
Articular $ 8 (44,4)
Central nervous system 1 (5,6)
Other (nasopharynx, parotis, thyroid) 3 (16,7)
Residual radiological activity at 6 months following diagnosis (n (% of total))
No 2 (11,1)
Yes 11 (61,1)
No chest X-ray and/or CT thorax 4 (22,2)
Lost to follow up 1 (5,6)
Need for treatment within 6 months following diagnosis (n (% of total)) 
No 11 (61,1)
Yes 6 (33,3)
Lost to follow up 1 (5,6)
† One patient had Stage I and the other patient had Stage II sarcoidosis, determined by CT scan. $ Self-
reported articular involvement. 
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Supplementary Table E2. Study subject characteristics BALF samples 
Subject characteristics Controls (n=12) Sarcoidosis (n=27)
Median age (min-max) 54 (18-80) 42 (24-73)
Sex (Male/Female) 7/5 15/12
Scadding Stage (n (% of total))
Stage 0 2 (7,4)
Stage I 11 (40,7)
Stage II 13 (48,1)
Stage III 0 (0,0)
Unknown 1 (3,7)†
Diagnosis was assessed by (n (% of total))
E(B)US-FNA 4 (14,8)
TBB-EBB 15 (55,6)
BAL CD4/CD8 > 3,5 8 (29,6)
Extrathoracic involvement  (n (% of total))
No/Yes 12/15 (44,4/55,6)
Skin 1 (3,7)
Eyes 8 (29,6)
Articular $ 8 (29,6)
Central nervous system 0 (0,0)
Other (submandibular LN and parotis) 1 (3,7)
Residual radiological activity at 6 months following diagnosis (n (% of total))
No 0 (0,0)
Yes 18 (66,7)
No chest X-ray and/or CT thorax 4 (14,8)‡
Lost to follow up 5 (18,5)
Need for treatment within 6 months following diagnosis (n (% of total)) 
No 16 (59,3)
Yes 6 (22,2)
Lost to follow up 5 (18,5)
† This patient had Stage I sarcoidosis, determined by CT scan. 
$ Self-reported articular involvement. 
‡  Two patients had spontaneous resolution as determined with radiology at 2 years follow up and disease 
course of 2 patients is yet to be determined at 2 years follow up. 
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aBSTRaCT
Background: Impaired regulatory T cell (Treg) function is thought to contribute to ongo-
ing inflammatory responses in sarcoidosis, but underlying mechanisms remain unclear. 
Moreover, it is not known if increased apoptotic susceptibility of Tregs may contribute to 
an impaired immunosuppressive function in sarcoidosis. Therefore, the aim of this study 
is to analyze proportions, phenotype, survival, and apoptotic susceptibility of Tregs in 
sarcoidosis. 
methods: Patients with pulmonary sarcoidosis (n=58) were included at time of diag-
nosis. Tregs were analyzed in broncho-alveolar lavage fluid and peripheral blood of 
patients and healthy controls (HC). 
Results: In sarcoidosis patients no evidence was found for a relative deficit of Tregs, 
neither locally nor systemically. Rather, increased proportions of circulating Tregs 
were observed, most prominently in patients developing chronic disease. Sarcoidosis 
circulating Tregs displayed adequate expression of FoxP3, CD25 and CTLA4. Remarkably, 
in sarcoidosis enhanced CD95 expression on circulating activated CD45RO+ Tregs was 
observed compared with HC, and proportions of these cells were significantly increased. 
Specifically sarcoidosis Tregs - but not Th cells - showed impaired survival compared 
with HC. Finally, CD95L-mediated apoptosis was enhanced in sarcoidosis Tregs.
Conclusion: In untreated patients with active pulmonary sarcoidosis, Tregs show im-
paired survival and enhanced apoptotic susceptibility towards CD95L. Increased apop-
tosis likely contributes to the insufficient immunosuppressive function of sarcoidosis 
Tregs. Further research into this field will help determine whether improvement of Treg 
survival holds a promising new therapeutic approach for chronic sarcoidosis patients. 
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InTRoDUCTIon
Sarcoidosis is a multisystem granulomatous disorder of unknown cause, often affecting 
the lungs (1). The disease is characterized by an exaggerated T helper (Th)1/Th17 re-
sponse upon exposure to one or several antigens in genetically susceptible individuals 
(2, 3). Clinical presentation and disease prognosis vary greatly. Although the majority of 
the patients undergo spontaneous resolution, a substantial proportion develops chron-
ic, progressive disease with need for therapy (1). Factors that determine granuloma fate 
remain to be elucidated (1, 3). 
Failure of immune regulatory mechanisms to limit duration of inflammation has been 
suggested to contribute to persisting granulomatous responses in sarcoidosis (4), and 
may explain the need for immunosuppressive drugs. Effective immunosuppressive 
agents for (chronic) sarcoidosis include corticosteroids and anti-TNF agents (5). Interest-
ingly, these drugs can induce Th cell apoptosis, while sparing or even inducing regula-
tory T cell (Treg) proportions and function (6-10), thereby favoring an anti-inflammatory 
milieu. 
Tregs are an indispensable subset of T cells with strong immunosuppressive capacities 
on a wide range of immune cells, including Th cells, B cells, and antigen presenting cells 
(11). They have a fine sensitivity for immune dynamics, mediated by interleukin (IL)-2 
signaling, and can quickly adjust their numbers and function during immune challenge 
(12). Upon activation, Th cells produce IL-2, which contributes to Treg proliferation and 
survival (12). Appropriate Treg function is required to terminate the immune response 
after antigen eradication, thus preventing (redundant) continuing inflammation (12). 
Importantly, defective Treg function contributes to induction, sustainment or progres-
sion of various autoimmune diseases, including rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE), but also granulomatous disorders such as antineutrophil 
cytoplasmic antibody-associated vasculitis (AAV) and hypersensitivity pneumonitis (HP) 
(13-15). 
The role of Tregs in the pathogenesis of sarcoidosis remains controversial. An impaired 
immunosuppressive function of sarcoidosis peripheral blood (PB) Tregs has been report-
ed consistently (4, 16-18). Furthermore, broncho-alveolar lavage fluid (BALF)-derived 
Treg suppressive efficacy was found to increase during short-term inhaled vasoactive 
intestinal peptide (VIP)-treatment in pulmonary sarcoidosis, which was also associated 
with amelioration of clinical symptoms (i.e. dyspnea and cough) (19). Decreased inhibi-
tion of Th cell proliferation and cytokine production by Tregs therefore likely contributes 
to the ongoing and exaggerated immune responses seen in sarcoidosis. Since contra-
dictory results have been reported about Treg proportions with respect to Th cells in 
both BALF and PB of sarcoidosis patients (See for review: (3)), it remains to be determined 
what mechanism(s) underlies this impaired immunosuppressive function (3). 
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Pro- and anti-apoptotic pathways play an important role in Treg homeostasis (12). 
Intriguingly, in sarcoidosis granulomas and PB increased proportions of activated (i.e. 
CD45RO+FoxP3high) proliferating Tregs are found (4). The significance of this finding for 
sarcoidosis pathogenesis remains unclear, since CD45RO+FoxP3high Tregs are described 
to be both more suppressive and more sensitive towards apoptosis in healthy individu-
als (20). Although it has been suggested that increased apoptotic susceptibility of Tregs 
may contribute to an impaired immunosuppressive function in sarcoidosis (4), it remains 
unknown if survival of patient-derived Tregs is affected.
Therefore, the aim of this study is to analyze proportions, phenotype, survival, and 
apoptotic susceptibility of sarcoidosis Tregs. Our results demonstrate that in patients 
with active pulmonary sarcoidosis, Tregs show impaired survival and enhanced apop-
totic susceptibility towards CD95L.
mEThoDS
Study design and subjects
Patients with pulmonary sarcoidosis were included at time of diagnosis. The diagnosis of 
sarcoidosis was made conform the guidelines of the ATS/ERS/WASOG (1). 
Exclusion criteria were use of immunomodulatory medication 3 months prior to 
study inclusion; respiratory tract infection 4 weeks prior to study inclusion; concomitant 
pulmonary disease (including chronic obstructive pulmonary disorder and asthma), 
autoimmune diseases, malignancies, human immunodeficiency virus seropositivity, 
pregnancy, and allergies. 
For this study, in total 58 newly diagnosed sarcoidosis patients donated PB and/or 
BALF. Due to limitations in the number of cells isolated per patient, we were not able to 
perform all experiments on all patients. Furthermore, 47 healthy controls donated PB 
and 5 healthy controls underwent bronchoscopy with BAL for this study.
The Medical Ethical Committee of the Erasmus MC Rotterdam approved this study. 
Written informed consent was obtained from every participant before study inclusion. 
Further subject characteristics are shown in Additional file: Table E1. 
Study materials
Bronchoscopy with BAL and mucosal biopsy was performed as previously described 
(21). BALF cells, mucosal biopsies and PB were processed as previously described (21).
flow cytometry staining
BALF cells and PBMCs were stained for extra- and intracellular markers using the follow-
ing antibodies: CD3-APC-eFluor780 (SK7), CD4-AF700 (OKT4), CD45RO-FITC (UCHl-1), 
CD95-APC (DX2), FoxP3-APC (PCH101) (eBiosciences) and CD25-PE (M-A251), CD25-PE-
Impaired Treg survival in sarcoidosis
63
Cy7 (M-A251), CD127-V450 (hIL7R-M21) anti-CTLA-4-BV421 (BNI3) (BD biosciences) and 
CD45RA-PE-Texas Red (MEM-56) (Invitrogen). Fixable Aqua Dead Cell Stain kit for 405 nm 
(Invitrogen, Molecular Probes) was used as live-dead marker. Cells were measured on a 
Flow cytometer LSRII (BD Biosciences).
Suppression assays
Th cells and Tregs were sorted from PBMCs using a human CD4+CD25+ Regulatory T 
Cell Isolation Kit (MACS, Miltenyi Biotec). Th cells were labeled with carboxyfluorescein 
succinimidyl ester (CFSE, Molecular Probes) according to manufacturer’s protocol. CFSE-
labeled Th cells were stimulated with Anti-Biotin MACSiBead™ Particles (MACS, Miltenyi 
Biotec) and co-cultured with unlabeled Tregs. Th cell division was quantified based on 
serial halving of CFSE intensity, using algorithms provided by FlowJo software (Treestar). 
Cytokine measurements in supernatants of co-cultures were performed using the Bio-
Plex Pro Human Cytokine 17-plex Panel (Biorad), run on a Luminex 100 System (Luminex 
Corporation), according to manufacturer’s protocol.
Survival and apoptosis assays
CD25low-intCD127highTh cells and CD25int-highCD127lowTregs were isolated from PBMCs 
using the BD FACSAria Cell Sorter (BD Biosciences) and cultured with 20 ng/ml recombi-
nant human IL-2 (hIL-2; R&D systems). Survival was determined with DAPI Nucleic Acid 
Stain (Life Technologies)-negative cells. To measure Treg survival and apoptosis in co-
culture with Th cells, CD4+ T cells were isolated from PBMCs using the human CD4+ T cell 
isolation kit (MACS, Miltenyi Biotec), cultured with 20 ng/ml hIL-2 and examined using 
the FITC Annexin V Apoptosis Detection Kit I (BD biosciences). To assess Treg apoptotic 
susceptibility, CD4+ T cells were cultured either with 20 ng/ml hIL-2 or with hIL-2 and 500 
ng/ml soluble CD95L (recombinant human soluble FasL, Enzo Life Sciences).
Statistical analyses
Comparisons were performed using a Mann-Whitney U test or Wilcoxon matched pairs 
test. Correlations were analyzed using Spearman’s rank-order correlation test. P-values 
were two sided, and analyses were performed using IBM SPSS Statistics 21. P < 0.05 was 
considered statistically significant. 
RESUlTS
Increased proportions of circulating Tregs in patients developing chronic 
sarcoidosis
Conflicting results have been reported with regard to Treg proportions in lungs and PB of 
sarcoidosis patients (3). Since a relative deficit of Tregs has been suggested to contribute 
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to a persisting granulomatous response in chronic sarcoidosis (19, 22), we first quanti-
fied CD25int-highFoxP3high Tregs in BALF and PB of active sarcoidosis patients and healthy 
controls by flow cytometry. No evidence was found for a relative deficit of Tregs in BALF 
of untreated patients with active sarcoidosis compared with healthy control BALF (Ad-
ditional file: Figure E1), suggesting an intact migration of Tregs towards site of inflamma-
tion. Rather, in PB of these patients increased proportions of CD25int-highFoxP3high Tregs 
were found (Figure 1A and 1B). Interestingly, we determined the disease course of a 
subgroup of our study cohort with 2 years clinical follow-up, and found that in patients 
developing chronic sarcoidosis, but not in patients undergoing spontaneous resolution, 
significantly increased Treg proportions were detected at time of diagnosis, compared 
with healthy controls (Figure 1C). 
In summary, in untreated patients with active sarcoidosis, no evidence was found for a 
relative deficit of Tregs, neither systemically nor at the site of inflammation. In contrast, 
significantly increased proportions of circulating Tregs were observed, most promi-
nently in patients developing chronic disease. These data show that Treg homeostasis is 
affected in active sarcoidosis, which could contribute to disease course. 
Circulating Tregs of sarcoidosis patients express adequate levels of foxP3, 
CD25 and CTla4
Since no numeral deficit of Tregs was found in patients at time of diagnosis, we ques-
tioned whether malfunctioning of circulating sarcoidosis Tregs is associated with an 
altered suppressive phenotype. Therefore, we analyzed circulating CD25int-highFoxP3high 
Tregs of active sarcoidosis patients and healthy controls for expression of forkhead box 
P3 (FoxP3), CD25 and cytotoxic T lymphocyte antigen 4 (CTLA4) (three proteins pivotal 
for adequate Treg function (11)) by flow cytometry. 
We confirmed that PB-derived CD25+ Treg suppressive capacity on autologous Th 
proliferation and cytokine production was significantly less in sarcoidosis compared 
with healthy controls (Additional file: Figure E2). Circulating CD25int-highFoxP3high Tregs 
of patients showed a trend towards increased expression levels of FoxP3 (Figure 2A). 
Furthermore, CD25 and CTLA4 expression (downstream molecules of FoxP3) were 
significantly increased on PB CD25int-highFoxP3high Tregs of sarcoidosis patients compared 
with healthy controls (Figure 2B and 2C).
These data suggest that the impaired suppressive capacity of sarcoidosis PB-derived 
Tregs is not mediated by decreased expression of FoxP3 and its downstream molecules. 
Rather, a significant increase in CD25 and CTLA4 expression was found on circulating 
Tregs from sarcoidosis patients compared with healthy controls. 
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activated CD45Ro+ Tregs from sarcoidosis patients highly express CD95
In healthy individuals, increased CD25 and CTLA4 expression on circulating Tregs has 
been associated with an activated, apoptotic-prone Treg population (20). Therefore, 
increased CD25 and CTLA4 expression on sarcoidosis PB-derived Tregs could point 
towards increased apoptosis, counteracting their functionality. In order to analyze their 
apoptotic phenotype, CD45RO and CD95 (FAS; death receptor) expressing Th cells and 
Tregs were examined in PB of healthy controls and patients (Figure 3A). 
Within the PB Treg, but not Th cell population, proportions of CD45RO and CD95 
expressing cells were significantly increased in sarcoidosis patients compared with 
healthy controls (Figure 3B). The majority of CD45RO+ Tregs were CD95+ in both patients 
and controls (Figure 3A) and their proportions strongly correlated (P < 0.0001, R = 0.87) 
(Figure 3C). Importantly, surface expression of CD95 was significantly increased on sar-
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Figure 1
figure 1. Increased proportions of circulating Tregs in patients developing chronic sarcoidosis. Treg pro-
portions were determined in PB of HCs and SRC patients. (A) Representative flow cytometry analysis of an 
HC and SRC patient to determine Tregs in PB. (B) PB Treg proportions. (C) Subgroup analyses of PB Treg pro-
portions in patients undergoing disease resolution, or developing (non-) active chronic disease. Statistics: 
Horizontal lines indicate the median and significance was determined using a Mann-Whitney U test, ** P < 
0.01. Abbreviations: PB = peripheral blood, HC = healthy control, SRC = sarcoidosis. 
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coidosis CD45RO+ Tregs compared with healthy control CD45RO+ Tregs, whereas CD95 
expression on CD45RA+ Tregs was low and not different between healthy controls and 
patients (Figure 3D). 
Altogether, increased proportions of circulating, activated CD45RO+ Tregs were de-
tected in sarcoidosis. Importantly, these activated CD45RO+ Tregs highly express CD95 
in patients compared with controls, suggesting altered apoptotic susceptibility. 
Impaired survival of sarcoidosis Tregs
We questioned whether sarcoidosis-derived circulating Tregs would display altered sur-
vival. To investigate survival of sarcoidosis Th cells and Tregs, we isolated CD25low-intCD-
127high Th cells and CD25int-highCD127low Tregs from PB of patients and healthy controls. 
Proportions of CD25int-highFoxP3high Tregs, as measured in the PB of our study subjects 
(Figure 1), strongly correlated with proportions CD25int-highCD127low Tregs (data not 
shown). These data underlined previously published data that CD4+CD25int-highCD127low 
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Figure 2
figure 2. Adequate expression of FoxP3, CD25 and CTLA4 on sarcoidosis circulating Tregs. FoxP3, CD25 
and CTLA4 expression was determined on circulating CD25int-highFoxP3high Tregs of HC and SRC patients 
by flow cytometry. (A-C) Mean fluorescence intensity of FoxP3 (A), CD25 (B) and CTLA4 (C). Mean fluores-
cence intensity was standardized to average expression in healthy control peripheral blood cells. Statistics: 
Horizontal lines indicate the median and significance was determined using a Mann-Whitney U test, * P < 
0.05 ** P < 0.01. Abbreviations: FoxP3 = forkhead box P3 , CTLA4 = cytotoxic T lymphocyte antigen 4, HC = 
healthy control, SRC = sarcoidosis. 
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Figure 3
figure 3. Activated CD45RO+ Tregs from sarcoidosis patients highly express CD95. The proportions of 
CD45RO and CD95 expressing Th cells and Tregs were determined in PB of HCs and SRC patients. (A) Rep-
resentative flow cytometry analysis of an HC and SRC patient to determine the proportions CD45RO+, CD-
95high and double positive Tregs (gated on CD3+CD4+CD25int-highCD127low.). (B) Proportions of CD45RO+ and 
CD95high Th cells and Tregs. (C) Correlation between proportions CD45RO+ Tregs and CD95high Tregs in PB. 
Open dots represent HC Tregs and closed dots represent SRC patients. (D) Mean fluorescence intensity of 
CD95 on CD45RA+ and CD45RO+ Tregs. Statistics: Horizontal lines indicate the median and significance was 
determined using a Mann-Whitney U test, * P < 0.05. Correlation was analyzed using Spearman’s rank-order 
correlation test. Regression line with R and P-value are shown in the plot. Abbreviations: Th = T helper, CD95 
= Fas; death receptor, PB = peripheral blood, HC = healthy control, SRC = sarcoidosis. 
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(sortable) can be used as surrogate marker for CD4+CD25int-highFoxP3high Treg isolation 
and functional studies (23).
Isolated cells were cultured with IL-2 and spontaneous survival was measured at 
72 hours. Both healthy- and sarcoidosis-derived Tregs showed decreased survival 
compared with isolated Th cells (Additional file: Figure E3), confirming that Tregs are 
an apoptotic-prone population. Importantly, patient-derived Tregs showed significantly 
decreased survival compared with healthy control Tregs (Figure 4A). This impaired sur-
vival was Treg-specific, since sarcoidosis-derived Th cells showed comparable survival to 
their healthy counterparts (Additional file: Figure E3). The survival defect of sarcoidosis 
Tregs was not restored when co-cultured with autologous Th cells (Figure 4B and 4C 
(upper plot)). Moreover, increased proportions of apoptotic Tregs (annexin V+ and low 
FSC values) were observed in sarcoidosis (Figure 4B and 4C (lower plot)). 
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Figure 4
figure 4. Impaired survival of sarcoidosis Tregs. Isolated Tregs (purity >97%) were cultured with recom-
binant human IL-2. (A) Percentage alive Tregs at 72 hours of culture. Horizontal line indicates the median. 
Significance was determined using a Mann-Whitney U test, ** P < 0.01. (B) Representative flow cytometry 
analysis of an HC and SRC patient after 12 hours co-culture with autologous Th cells to determine Treg 
survival and apoptosis. (C) Survival (above) and apoptosis (below) graph of Tregs cultured for 48 hours with 
autologous Th cells. Dots indicate mean +/- SEM of 3 HCs and 3 SRC patients. One representative experi-
ment is shown of 3 independent experiments. Abbreviations: HC = healthy control, SRC = sarcoidosis. 
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These data provide evidence for an impaired survival of sarcoidosis Tregs, associated 
with increased apoptotic susceptibility. 
Increased sensitivity of sarcoidosis Tregs towards CD95l-mediated apoptosis
Since increased CD95 expression was observed on sarcoidosis CD45RO+ Tregs (Figure 3) 
alongside impaired survival and increased apoptosis (Figure 4), we investigated apop-
totic susceptibility of freshly isolated CD4+ T cells towards soluble CD95L. Although both 
0 102 103 104 105
0
102
103
104
105
6.65
0 102 103 104 105
0
102
103
104
105
4.43
- CD95L + CD95L
Fo
xP
3
CD25
FoxP3
SRC
HC
 = 33,4 % CD95L induced apoptosis
0 102 103 104 105
0
102
103
104
105 5.4
0 102 103 104 105
0
102
103
104
105 12.2
FoxP3
 = 55,7 % CD95L induced apoptosis
A.
- CD95L + CD95L
0
5
10
15
20
** *
Tr
eg
s 
in
 c
ul
tu
re
(%
 o
f C
D
3+
C
D
4+
)
SRCHC
- CD95L + CD95L
B. C.
HC Tregs SRC Tregs
0
20
40
60 *
%
 C
D
95
L 
in
du
ce
d 
ap
op
to
si
s
CHAPTER 3
Figure 5
figure 5. Increased sensitivity of sarcoidosis Tregs towards CD95L-mediated apoptosis. Freshly isolated 
Tregs were analyzed for apoptotic susceptibility towards soluble CD95L. (A) Representative flow cytometry 
analysis of an HC and SRC patient after 20 hours of culture with IL-2 only or with IL-2 and soluble CD95L. 
Numbers indicate percentage of CD25+FoxP3+ Tregs in culture. Induced apoptosis by CD95L was calculated, 
using the following formula: ((% CD25+FoxP3+ Tregs cultured with IL-2 - % CD25+FoxP3+ Tregs cultured with 
IL-2 and CD95L)/(% CD25+FoxP3+ Tregs cultured with IL-2))*100%. (B) Percentage Tregs in culture of 9 HCs 
and 7 SRC patients after 20 hours. Paired data is shown of the Treg cultures without or with soluble CD95L. 
(C) Percentage CD95L-induced apoptosis in HC and SRC Tregs. Statistics: Horizontal lines indicate the me-
dian. Significance was determined using a Mann-Whitney U test (C) or Wilcoxon matched pairs test (B), * P < 
0.05 ** P < 0.01. Abbreviations: CD95L = CD95 ligand, HC = healthy control, SRC = sarcoidosis. 
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healthy control and sarcoidosis Tregs were sensitive towards CD95L-mediated apoptosis 
(Figure 5A and 5B), CD95L-induced apoptosis was significantly enhanced in sarcoidosis 
Tregs compared with healthy controls (Figure 5C). 
These data provide evidence for increased susceptibility of sarcoidosis Tregs towards 
CD95L-mediated apoptosis. 
DISCUSSIon
In this study, for the first time, we provide evidence for an increased apoptotic susceptibil-
ity and impaired survival of sarcoidosis Tregs. Untreated patients with active pulmonary 
sarcoidosis showed enhanced CD95 expression levels on circulating activated CD45RO+ 
Tregs at time of diagnosis. Additionally, proportions of CD95+ and CD45RO+ circulat-
ing Treg were significantly increased. Furthermore, sarcoidosis Tregs were specifically 
more susceptible towards CD95L-induced apoptosis compared with healthy controls. 
Increased apoptosis likely contributes to the insufficient immunosuppressive function 
of sarcoidosis Tregs. 
Failure of Treg-mediated immunosuppression is widely reported in autoimmune dis-
eases (13) as well as granulomatous disorders, including AAV and HP (14, 15). In sarcoid-
osis, impaired immunosuppression by Tregs has been found both in active and in chronic 
disease (4, 16-18). It has been suggested to contribute to granuloma persistence (4) and 
was reported to recover during disease resolution (18). Decreased immunosuppression 
by Tregs on Th cells may either result from deregulated Tregs (decreased proportions 
and/or malfunctioning), resistance of Th cells towards suppression or a combination of 
both (13). We confirmed an impaired immunosuppressive function of PB-derived Tregs 
on Th cell proliferation and cytokine production. Although our assays cannot exclude 
that sarcoidosis Th cells contribute to this phenomenon, a previous study showed that 
sarcoidosis Th cells were responsive towards the suppressive capacity of healthy Tregs 
(18). Furthermore, we did not find evidence for a numeral deficit of Tregs, neither sys-
temically nor in the lungs of untreated patients with active pulmonary sarcoidosis at 
time of diagnosis. Rather, we and others (4, 18) found increased proportions of circulat-
ing Tregs in active sarcoidosis patients. 
Importantly, we are the first to report that increased proportions of circulating Tregs 
at time of diagnosis are mainly attributable to patients who develop chronic disease and 
not patients who undergo spontaneous resolution. Interestingly, Prasse et al. previously 
found significantly decreased Treg proportions in lungs of patients who develop chronic 
active disease compared with controls, but not in patients who undergo spontaneous 
resolution (19). Taken together, these data suggest that enhanced circulating Treg 
proportions in sarcoidosis reflect impaired migration towards the site of inflammation. 
Alternatively, during homeostatic conditions Tregs rapidly adjust their numbers in 
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response to IL-2 variations, directly reflecting Th cell activity. Therefore, in agreement 
with published findings (12), it is also conceivable that at time of diagnosis in sarcoidosis 
patients circulating Treg proportions expand as a result of local Treg failure, specifically 
in patients who will develop chronic sarcoidosis. Therefore, the numbers of circulating 
Tregs at the time of diagnosis potentially serve as a new biomarker indicating need for 
immunosuppressive drugs that restore immune homeostasis. To further address this 
issue prospective studies are warranted. 
To the best of our knowledge, it thus far remained unclear what mechanism(s) un-
derlies Treg dysfunction in PB of active sarcoidosis patients. We did not find differences 
in FoxP3 expression or diminished expression of its downstream molecules CD25 or 
CTLA4 in circulating Tregs of sarcoidosis patients. Interestingly, we found that Tregs 
in lymph nodes from sarcoidosis patients have reduced CTLA4 expression, compared 
with controls (24), indicating that CTLA4 expression levels are differentially regulated 
between compartments. Thus, despite adequate Treg proportions and expression of 
FoxP3-downstream effector molecules, sarcoidosis-derived PB Tregs fail to suppress 
autologous Th cell responses. 
Pro- and anti-apoptotic pathways govern Treg homeostasis (12). In this study a Treg-
specific survival defect was found in sarcoidosis patients, whereby CD95L-mediated 
apoptosis was increased. Although factors determining T cell sensitivity towards CD95L-
mediated apoptosis remain to be fully elucidated, T cell activation status and CD95 
expression appear critical (25). Indeed, our data argue that in sarcoidosis circulating 
activated CD45RO+ Tregs highly expressing CD95 compared with control CD45RO+ 
Tregs, can contribute to impaired Treg survival. 
Our finding that in sarcoidosis Tregs are hypersensitive towards CD95L-mediated 
apoptosis parallels earlier findings in SLE (26) and adds to our previously described 
similarities between sarcoidosis and systemic autoimmune disorders, which include 
the involvement of pathogenic IFN-γ-producing Th17 cells (27, 28). In SLE increased 
sensitivity of Tregs towards CD95L-mediated cell death was proposed to exacerbate 
the extent of tissue damage during flares (26). Increased Treg apoptosis in sarcoidosis 
might hamper restoration of the immune balance and contribute to the development 
of (chronic) sarcoidosis. Interestingly, CD95 signaling has previously been suggested 
to contribute to chronic sarcoidosis pathology, since an activating CD95 promotor 
polymorphism (-670A) has been associated with disease severity in Afro-American 
patients (29). This -670A variant in the CD95 gene promotor has also been associated 
with SLE and was shown to influence CD95 gene expression, whereby the A (instead 
of the G) allele induces increased CD95 transcription (30). It is tempting to speculate 
that increased transcription of CD95 in sarcoidosis, mainly affecting activated CD45RO+ 
Tregs due to their physiological CD95 expression (25), contributes to the development 
of chronic sarcoidosis. Importantly, increased Treg sensitivity towards CD95L-mediated 
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apoptosis does not seem to be a general consequence of chronic inflammation, since it 
was excluded in multiple sclerosis and granulomatosis with polyangiitis (31, 32). 
Previously it has been suggested that decreased apoptosis of antigen-specific T cells 
might contribute to granuloma persistence in sarcoidosis (22). However, sarcoidosis-
derived BALF and PB T cells highly express CD95 (33, 34) and show signs of apoptosis 
(35). Lymphocytes infiltrating and surrounding sarcoid granulomas express CD95L 
(35), and increased amounts of soluble CD95L are found in BALF and serum of patients 
(36). Most interesting, patients with chronic sarcoidosis and need for therapy show an 
increased expression of CD95 on BALF and PB T cells (including CD45RO on PB T cells) 
at time of diagnosis compared with patients undergoing spontaneous resolution of 
disease (34). These data imply that increased apoptosis of T cells contributes to ongo-
ing inflammation. However, the role of CD95L-mediated apoptosis in the homeostasis 
of pro- and anti-inflammatory T cell subsets (i.e. Th cells versus Tregs, respectively) in 
sarcoidosis thus far remained unclear (35). In this study, for the first time, evidence is 
provided for a Treg specific survival defect, which can lead to an imbalance between 
pro-inflammatory Th cells and properly functioning anti-inflammatory Tregs, resulting 
in on going inflammation.
The anti-TNF agent infliximab is known to induce Treg functionality in RA (7). Induction 
of Treg survival may very well contribute to its therapeutic effect as observed in patients 
with chronic sarcoidosis (5). Investigation of Treg proportions present in or around the 
granulomas, their functional capacities, and apoptosis susceptibility during the natural 
course of disease and in response to therapy should further unravel the role of Tregs 
in the development of chronic sarcoidosis. Research into this field will help determine 
whether improvement of Treg survival, e.g. by other immunosuppressive drugs, such as 
rapamycin (37, 38), holds a promising new therapeutic approach for chronic sarcoidosis 
patients. 
ConClUSIon
In conclusion, this study is the first to demonstrate a role for deregulated Treg survival, 
mediated by CD95-signaling, in untreated patients with active pulmonary sarcoidosis. 
Increased apoptosis likely contributes to the insufficient immunosuppressive func-
tion of sarcoidosis Tregs. Further research into this field will help determine whether 
improvement of Treg survival holds a promising new therapeutic approach for (chronic) 
sarcoidosis patients. 
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Supplementary Figure E1
Supplementary figure E1. Treg proportions were determined in BALF of HCs and SRC patients. (A) Rep-
resentative flow cytometric analysis of an HC and SRC patient to determine Treg proportions in BALF. (B) 
BALF Treg proportions. Statistics: Horizontal lines indicate the median and significance was determined 
using a Mann-Whitney U test. Abbreviations: BALF = broncho-alveolar lavage fluid, HC = healthy control, 
SRC = sarcoidosis.
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Supplementary Figure E2
Supplementary figure E2. (See legend on next page)
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Supplementary figure E2. Freshly isolated Th cells were CFSE-labeled, TCR-stimulated and cultured with-
out or with autologous Tregs. (A) Flow cytometry analysis of one HC and SRC patient after 4 days of culture. 
(B) Percentage suppression by Tregs on autologous Th cell proliferation. Percentage suppression was cal-
culated as follows: ((%divided Th cells only - %divided Th cells co-cultured with Tregs)/(%divided Th cells 
only))*100%. Horizontal lines indicate the median and significance was determined using a Mann-Whitney 
U test, * P < 0.05. (C-D) Amount of IL-2 (C) or IFN-γ (D) measured in culture supernatant of suppression assays 
at day 4. Paired data is shown of Th cell cultures without or with autologous Tregs. Significance was deter-
mined using a Wilcoxon matched pairs test, * P < 0.05. Abbreviations: Th = T helper, CFSE = carboxyfluores-
cein succinimidyl ester, TCR = T cell receptor, HC = healthy control, SRC = sarcoidosis, NS = not significant.
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Supplementary Figure E3
Supplementary figure E3. Isolated Th cells and Tregs were cultured with recombinant human IL-2. Per-
centage alive Th cells and Tregs at 72 hours of culture is shown. Horizontal line indicates the median. Sig-
nificance was determined using a Mann-Whitney U test, * P < 0.05 ** P < 0.01. Abbreviations: Th = T helper, 
HC = healthy control, SRC = sarcoidosis, NS = not significant. 
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Supplementary Table E1. Study subject characteristics 
Subject characteristics healthy controls (n=47) Sarcoidosis (n=58)
Age (y)* 36 (19-59) 44 (17-81)
Sex (Male/Female/Unknown†) 23/22/2 31/27/0
Ethnicity (n (%))
White 34 (72,3) 35 (60,3)
Black 2 (4,3) 12 (20,7)
Asian 2 (4,3) 6 (10,3)
Hispanic 0 (0) 1 (1,7)
Unknown† 9 (19,1) 4 (6,9)
Scadding Stage (n (%))
Stage 0 5 (8,6)
Stage I 25 (43,1)
Stage II 21 (36,2)
Stage III 3 (5,2)
Stage IV 0 (0,0)
Unknown 4 (6,9)‡
CD4/8 ratio BALF (n=46)* 4,3 (0,5 – (>)10)
BALF lymphocytes (n=46)* 25,0 (0 - 84)
Diagnosis was assessed by (n (%))
Trans- and/or endobronchial biopsy 18 (31,0)
E(B)US-FNA 17 (29,3)
BALF alveolitis + CD4/CD8 ratio > 3.5 22 (38,0)
Mediastinoscopy 1 (1,7)
Disease course§ (n (%))
Resolution 5 (8,6)
Non-active chronic 15 (25,9)
Active chronic 8 (13,8)
Lost to follow up 12 (20,7)
Not yet determined 18 (31,0)
Study subject characteristic. * Median (minimum-maximum). † Anonymous blood donors. ‡ Two of these 
patients had Stage I and two had Stage II sarcoidosis, determined by CT scan. § Disease course of a sub-
group of patients (n=28) was determined 2 years after study inclusion. Resolution of disease was defined 
by the absence of abnormalities on the chest X-ray and clinical symptoms (n=5). Patients with residual ab-
normalities on chest X-ray, but without need for treatment were designated as non-active chronic (n=15); 
and patients with need for treatment (n=8) as active chronic (Prasse et al., Am J Respir Crit Care Med. 2010; 
182: 540-548). 
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aBSTRaCT
Rationale: Pulmonary sarcoidosis is classically defined by T-helper (Th) cell type 1 
inflammation (e.g., interferon (IFN)-γ production by CD4+ effector T cells). Recently, 
interleukin (IL)-17A-secreting cells have been found in lung lavage, invoking Th17 im-
munity in sarcoidosis. Studies also identified IL-17A-secreting cells that expressed IFN-γ, 
but their abundance as a percentage of total CD4+ cells was either low or undetermined. 
objective: Based on evidence that Th17 cells can be polarized to Th17.1 cells to produce 
only IFN-γ, our goal was to determine whether Th17.1 cells are a prominent source of 
IFN-γ in sarcoidosis. 
methods: We developed a single-cell approach to define and isolate major Th-cell 
subsets using combinations of chemokine receptors and fluorescence-activated cell 
sorting. We subsequently confirmed the accuracy of subset enrichment by measuring 
cytokine production. 
measurements and main Results: Discrimination between Th17 and Th17.1 cells 
revealed very high percentages of Th17.1 cells in lung lavage in sarcoidosis compared 
with controls in two separate cohorts. No differences in Th17 or Th1 lavage cells were 
found compared with controls. Lung lavage Th17.1-cell percentages were also higher 
than Th1-cell percentages and approximately 60% of Th17.1-enriched cells produced 
only IFN-γ. 
Conclusions: Combined use of surface markers and functional assays to study CD4+ T 
cells in sarcoidosis revealed a marked expansion of Th17.1 cells that only produce IFN-γ. 
These results suggest that Th17.1 cells could be misclassified as Th1 cells and may be the 
predominant producer of IFN-γ in pulmonary sarcoidosis, challenging the Th1 paradigm 
of pathogenesis. 
IFN-γ-producing Th17.1 cells
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InTRoDUCTIon
Sarcoidosis is a granulomatous disease in which the inflammation is thought to be 
driven in part by activated T-helper (Th) type 1 effector T cells (1-4). The idea that Th1 
cells play a key role in sarcoidosis is largely based on experimental observations of 
increased numbers of CD4+ effector T cells, which produce interferon-γ (IFN-γ), in sar-
coidosis bronchoalveolar lavage (BAL) fluid (3, 5-7). After the recent discovery of a new 
class of Th cells, Th17 cells, several investigators have used a variety of flow cytometry 
gating strategies to identify interleukin-17A (IL-17A)-producing cells in BAL fluid from 
patients with sarcoidosis (8-13). Several of these studies also identified IL-17A-secreting 
cells that expressed IFN-γ, but their abundance as a percentage of total CD4+ cells was 
either low or undetermined (9, 11, 12). 
Recent studies in Crohn’s disease identified a subset of IFN-γ-producing Th17 cells, 
called Th17.1 cells. This subset expressed a specific pattern of chemokine receptors and 
exhibited functional attributes indicating that they were proinflammatory and resistant 
to corticosteroids (14). Therefore, identification of these cells in sarcoidosis would have 
important implications for treatment approaches. 
Th17.1 cells are thought to be derived from classically polarized Th17 cells. Many stud-
ies show that Th17 cells are plastic and can be polarized to differentiate into a Th1-like 
phenotype in which they produce significant IFN-γ (15-19). In vitro experiments have 
shown that cytokines prevalent in sarcoidosis, IFN-γ and IL-12, promote this transforma-
tion (18). The nomenclature for this “Th1-polarized Th17 subset” is not uniform, and these 
cells have been referred to Th17/Th1 (20, 21), Th1/17 (22), and Th17.1 cells to capture 
their transformed state (14). We refer to this Th17 subset as Th17.1 to be consistent with 
prior studies that used chemokine receptor expression as part of their definition for these 
cells (14, 23). Because the majority of Th17.1 cells produce only IFN-γ, we hypothesized 
that Th17.1 cells have largely been misclassified as Th1 cells because measurement of 
cytokine production has been the usual method for defining Th1 and Th17 cells. For 
example, production of IL-17A has been used to define “Th17” cells (8-13), and therefore 
the proportions of Th17 cells that produced only IFN-γ would be completely missed. 
To address whether Th17.1 cells could be a predominant source of IFN-γ in pulmonary 
sarcoidosis, we used definitions for Th cells based on the latest immunology (14), which 
consisted of a combination of three chemokine receptors, CCR4, CCR6 and CXCR3. We 
first applied single-cell sorting techniques using chemokine receptor expression to 
isolate cells from paired blood and lung samples from sarcoidosis and controls. We then 
confirmed appropriate cytokine secretion in the sorted and enriched populations of Th 
cell subsets. These techniques allowed for a high degree of cell separation in which to 
study Th subsets (and subsets within subsets) and make new observations in sarcoid-
osis, such as finding that IFN-γ-producing Th17.1 cells are the predominant effector cell 
in sarcoidosis BAL in two separate cohorts. 
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Subjects
Participants in the U.S. cohort underwent written informed consent and the study was 
approved by the University of California, San Francisco Committee on Human Research. 
Sarcoidosis diagnosis was based on consistent clinical features, absence of alternative 
diagnoses, and biopsy of the lung or mediastinal lymph nodes showing non-caseating 
granulomas according to accepted criteria (24). Exclusion criteria included a smoking 
history, cancer, chronic infections, autoimmune diseases, other pulmonary diseases, 
or organ transplant. Subjects underwent chest X-ray, high-resolution chest computed 
tomography (CT) scan, BAL and blood collection. Noncontrast axial images (1.25 mm) 
were obtained supine during full inspiration for a 10-second breath hold. Imaging pro-
tocol was defined by the National Institute of Health (NIH) study (NCT01831739). Organ 
involvement was determined as described previously (25). Healthy control data were 
obtained from a concurrent study (NCT01484691) to measure the same immunological 
parameters. 
The validation cohort, referred to as the Erasmus MC cohort, consisted of newly 
diagnosed pulmonary sarcoidosis European patients using the same diagnostic and 
exclusionary criteria (24). In addition, patients could not be taking immunomodulatory 
medication in the three months before enrollment, however a smoking history was ac-
cepted. The control group consisted of individuals who underwent bronchoscopy for 
community-acquired pneumonia or chronic obstructive pulmonary disease. The Medical 
Ethical Committee of the Erasmus MC (Rotterdam, the Netherlands) approved this study.
Bal and peripheral blood mononuclear cells
The bronchoscopy protocol with BAL was developed by the NIH study, Genomic Re-
search in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (NCT01831739). Cells were 
resuspended in 0.1% bovine serum albumin + 2mM ethylenediaminetetraacetic acid 
in phosphate-buffered saline (PBS) and immediately processed for flow cytometry. 
Peripheral blood mononuclear cells (PBMCs) were isolated as described previously (26).
flow cytometry and sorting
For surface staining, BAL cells and PBMCs were incubated with fluorescent antibodies 
(CD3 [BD Horizon, San Jose, CA], CCR4 [BD Pharmingen, San Jose, CA], CD127, CD4, CD25 
and CCR6 [eBioscience, San Diego, CA], and CD45RO, CD45RA and CXCR3 [Biolegend, San 
Diego, CA]), and CD1d-tetramer-PBS57 [NIH Tetramer Facility, Atlanta, GA] for 30 min-
utes at 4°C using methods recommended by the manufacturers. Viability was measured 
using Propidium Iodide (BD Bioscience, San Jose, CA). We used the ARIA II fluorescence 
activated cell sorter (FACS) to isolate CCR4- and CCR6-positive and –negative cells (BD 
Biosciences). FACS sorting was performed using a number of gating strategies: we gated 
IFN-γ-producing Th17.1 cells
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on live cells, followed by lymphocytes, singlets, non-invariant natural killer T cells, CD4+ 
T cells, nonregulatory T cells, and effector cells (Figures 1A & 1B). CCR6+, CCR4+CCR6−, 
and CCR4−CCR6− effector cells were sorted into separate chambers to analyze cytokine 
function. Figures 1A & 1B show the three-gate sorting strategy. After discovery of the 
high prevalence of IFN-γ-producing CCR6+ cells, a fourth gate was added to sort effector 
T cells into four chambers based on chemokine expression: CCR4+CCR6+, CCR4+CCR6−, 
CCR4−CCR6+, and CCR4−CCR6−. CXCR3 was used in the FACS-sorting panel and functional 
panel to allow more stringent gating of Th17, Th17.1, Th1, and Th2 populations as de-
fined in Table 1 and Figure E1 in the online supplement, and as previously described (14). 
Samples from the European cohort were analyzed similarly (see the online supplement). 
Cell stimulation and cytokine analysis 
Freshly isolated cells were stimulated at 37°C for 4 hours in 10 nM Phorbol 12-myristate 
13-acetate, 1 mM ionomycin, and 5mg/mL brefeldin A. Antibody staining against CXCR3 
(eBioscience), and live/dead Amcyan stain (Invitrogen, Grand Island, NY) was performed 
for 30 minutes at 4°C. Cells were fixed in 2% paraformaldehyde and permeabilized (BD 
Biosciences) for intracellular cytokine staining of IL-17A, IL-4, and IFN-γ (eBioscience). 
Additional details are provided in the online supplement. 
Statistical analysis
FlowJo 9 (FlowJo, Ashland, OR), JMP 10 (SAS Institute, Cary, NC), and GraphPad Prism 6 
(GraphPad Software, San Diego, CA) software were used. Normality was measured using 
Shapiro-Wilk test. Two group comparisons were made using an unpaired Student’s t test 
or rank sum test as appropriate. Chi-square analysis was used to assess sex, race, and 
ethnicity differences, and Student’s t test for age. A P-value less than 0.05 was consid-
ered significant.
RESUlTS
Patient characteristics
A total of 35 patients with sarcoidosis and 18 healthy controls were enrolled in the U.S. 
cohort. Patients with sarcoidosis had pulmonary disease (Table 2) and met criteria for 
chronic disease (lack of disease resolution by 2 yr after diagnosis (27)). There were no 
significant differences in sex between groups, however the control population was 
Table 1. T effector cell subset phenotypes
CCR4-/CXCR3+ CCR4+/CXCR3-
CCR6- Th1 Th2
CCR6+ Th17.1 Th17
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Figure 1
figure 1. Flow cytometry sorting strategy and comparative analysis of CD4+ T cell subsets. Peripheral blood 
mononuclear cells (PBMCs) and bronchoalveolar lavage (BAL) cells were stained and analyzed by an LSRII 
Fortessa cytometer (BD Biosciences). (A and B) Representative sample is shown for blood (A) and BAL cells 
(B) from a sarcoidosis patient. Lymphocytes were analyzed using the following series of sub-gates: live 
IFN-γ-producing Th17.1 cells
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younger, on average. Both groups consisted of more white than African American sub-
jects or those of other races. Six patient with sarcoidosis were on immunosuppression for 
progressive pulmonary disease at enrollment. Three patients were taking 20 mg or less 
of prednisone daily; two patients were taking 15 mg of methotrexate weekly, and one 
of these was also taking infliximab. One patient was taking 50 mg of azathioprine daily. 
We found no significant differences between T cell profiles of these 6 patients compared 
with those not taking immunosuppression. Fewer subjects were Stage I compared with 
Stages II/III and IV. Fibrosis was confirmed in Stage IV patients by CT scanning. There was 
a trend in decreasing lung function with increasing stage (Table 3). Average BAL fluid 
return was 114 ml (60-169 ml) with 77% (69-81%) alveolar macrophages, 22% (17-30%) 
lymphocytes, and 1% (0-3%) neutrophils.
cells, lymphocytes, singlets, non-invariant natural killer (iNKT), CD4 T cells (CD4+CD3+), nonregulatory T cells 
(CD4+CD127+CD25− T cells), memory effector cells (CD45RA−/CD45RO+ CD4+T cells), and three sub-popula-
tions of memory effector cells using CCR4 and CCR6. We excluded iNKT cells (CD1d tetramer-PBS57), regula-
tory T cells (CD4+CD3+CD127−CD25+) and naïve T cells (CD4+CD3+CD45RA+CD45RO−) from the CD4+ popula-
tion. (C) CD4+ T cells as a percentage of lymphocytes are significantly increased in the lungs of patients with 
sarcoidosis (**P = 0.0019), and decreased in the blood (*P = 0.012). (D) Effector cells as a percentage of CD4+ 
T cells are significantly increased in both the lungs (**P = 0.0015) and the blood (**P = 0.0004) of patients 
with sarcoidosis. (E) There are essentially no naïve cells in the lungs and a significant decrease of naïve cells 
as a percentage of CD4+ T cells in the blood of sarcoidosis patients (***P < 0.0001). Data are expressed as 
mean (histogram bars) ± SEM. Overlaid dots represent individual patient values. BAL: n = 32 subjects with 
sarcoidosis and 9 control subjects; PBMC: n = 35 subjects with sarcoidosis and 18 control subjects. FSC = 
forward scatter; PI = propidium iodide; SSC = side scatter; T regs = T regulatory cells. 
Table 2. Demographics and clinical characteristics
  Control Sarcoidosis P value
Number 18 35
Female* 9 (50%) 16 (46%) 0.78
Age (median, range) 30 (25-54) 53 (32-69) <0.01
Immunosuppression - 6 (17%) -
Stage, I/II-III/IV - 5/17/13 -
Lung/heart/LN/eye/skin 35/2/4/1/2
Race
African American* 3 (17%) 3 (9%) 0.39
Caucasian* 11 (61%) 31 (89%) 0.02
Other* 4 (22%) 1 (3%) 0.03
Ethnicity
Hispanic* 1 (6%) 2 (6%) 0.98
* Percentage of total in parentheses unless otherwise stated 
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A second validation cohort from Europe, the Erasmus MC cohort, consisted of 30 
subjects with sarcoidosis and 12 disease control subjects, eight of whom underwent 
bronchoscopy for community-acquired pneumonia and four patients with chronic 
obstructive pulmonary disease. The control group showed a trend towards older age 
(Table 4). There were no statistically significant differences in sex or age between groups. 
The majority of the patients were white. One patient had Lofgren syndrome. Patients 
with sarcoidosis were newly diagnosed and not on immunosuppressive treatment. The 
lymphocyte percentages were consistent with alveolitis (Table 4).
CD4+ T-cell analysis and enrichment of T helper subsets using chemokine 
receptor expression
Sarcoidosis is characterized by abnormal increase of IFN-γ-producing BAL CD4+ T cells 
(2, 3, 28). Our goal was to use chemokine receptor expression to define and distinguish 
among Th17 subsets to understand their full capacity to produce IFN-γ and how numer-
ous they were (14, 23). We used single-cell analysis and FACS-sorting to isolate these 
Th subset populations (Figures 1A & 1B). We use the terminology “enriched” subsets to 
acknowledge that these populations cannot be 100% pure, but we show, using cytokine 
measurements, that the purities are very high.
As expected, we found that CD4+ T cells (as a % of lymphocytes) were markedly 
increased in BAL from patients with sarcoidosis compared with healthy control sub-
jects (Figure 1C). In contrast, we found that CD4+ T cells were decreased in the blood 
in sarcoidosis compared with control, consistent with the idea of CD4+ T cells homing 
to the lungs from the blood (2). Decreased circulating CD4+ T-cell numbers have been 
associated with more severe forms of sarcoidosis, including decreased pulmonary func-
Table 3. Clinical characteristics by radiographic stage of disease
Total n = 35 Stage I 
(n=5)
Stage II/III
(n=17)
Stage IV
(n=13)
Age (median, range) 53 (37-71) 53 (34-68) 58 (34-71)
Female, n 3 (60%) 8 (47%) 5 (38%)
Race, n
Caucasian 5 14 12
African American 0 3 0
Other 0 0 1
Current immunosuppression use 0 3 3
Forced Expiratory Volume, 1 sec (FEV1) † 101% ± 24% 98% ± 14% 91% ±18%
Forced Vital Capacity (FVC) † 102% ± 21% 100% ± 10% 97% ± 14%
Diffusing Capacity (DLCO) † 80% ± 22% 80% ± 11% 75% ± 9%
†Data are presented as average values expressed as percent predicted
± Standard Deviation
IFN-γ-producing Th17.1 cells
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tion (29). In support of this idea, we also found that patient with sarcoidosis with fibrosis 
on chest CT scan had significantly lower numbers of CD4+ T cells in the blood compared 
to those without fibrosis (Figure E2). As anticipated, there were essentially no naive cells 
(CD3+CD4+CD1d−CD25loCD45RA+CD45RO−) in the BAL fluid in any participant (Figure 
1E); in the blood, naive cells as a percentage of CD4+ T cells were significantly decreased 
in sarcoidosis compared with control, as has been recently observed in a separate cohort 
(30). Effector memory cells (CD3+CD4+CD1d−CD25loCD45RA−CD45RO+) as a percentage 
of CD4+ T cells were significantly increased in sarcoidosis BAL (average, ~83%) compared 
with controls (Figure 1D). This expansion of effector memory cells is consistent with the 
idea of antigen-driven stimulation, as has been suggested by prior findings of oligo-
clonal expansion of T cells expressing specific αβ T-cell receptor genes in the lung and 
blood in sarcoidosis (31, 32).
Within the population of effector memory cells, we found that, on average approxi-
mately 50% of the CD4+ T effector cells in the lung expressed CCR6 (Figure 2). Almost 
one-third of patient with sarcoidosis had over approximately 60% CCR6+ effector cells in 
the BAL. Although CCR6 is expressed on other cell types, it is a marker for Th17 cells, and 
this finding supports the hypothesis that large numbers of Th17 cells (or their subsets) 
are present in sarcoidosis BAL (33). In contrast, we did not find an increase in the per-
Table 4. Demographics and clinical characteristics for the Erasmus MC cohort 
  Control Sarcoidosis P value
Number 12 30
Female* 5 (42%) 12 (40%) 0.92
Age (median, range)* 57 (18-80) 43 (24-70) 0.07
Immunosuppression† - 0 
Stage, I/II-III/IV/CT - 11/16/0/3§ -
Lung/heart/LN/eye/skin 30/0/0/9/2
Smoking, never/former/current/unknown - 16/8/4/2 -
Race*
African - 2 (7%) -
Caucasian - 19 (63%) -
Asian - 4 (13%) -
Unknown - 5 (17%) -
Ethnicity*
Hispanic - 1 (3%) -
Lymphocyte % BALF (median, range), (average, SD) - 27% (3-68%), 32% (±21%) -
CD4/CD8 ratio BALF (median, range), (average, SD) - 4.4 (0.5-14.34), 5.2 (±3.4) -
*Percentage of total in parentheses unless otherwise stated
†Patients were newly diagnosed and not on immunosuppressive treatment 
§Three subjects found to have mediastinal and hilar lymph node involvement by CT scan
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centage of CCR4+ eff ector cells in the lungs of patients with sarcoidosis compared with 
control subjects (P = 0.25). 
functional analysis of Th-cell CCR4/CCR6 subset enrichments
We next assessed the accuracy of the Th subset enrichment strategy by stimulating the 
FACS-sorted CCR4 and CCR6 subsets and measuring production of IL-4, IL-17A, and IFN-
γ. The CCR4−CCR6− population produced IFN-γ and virtually no IL-4 or IL-17A, consistent 
with Th1 characteristics (Figure 3). The CCR4+CCR6− eff ector cells produced IL-4 with 
little to no production of IL-17A or IFN-γ, supporting Th2 characteristics. Finally, the 
CCR6+ eff ector cells produced IL-17A as expected, but in addition, a signifi cant percent-
age also produced IFN-γ, and a very small population showed polyfunctional capacity 
to produce both IL-17A and IFN-γ. These data demonstrate the presence of at least three 
functionally diverse Th17 cells in sarcoidosis: a large percentage of CCR6+ cells that only 
produced IFN-γ, a smaller percentage of cells that produce only IL-17A, and a very small 
percentage of cells able to produce both IFN-γ and IL-17A. 
Discrimination of Th cell subsets using CXCR3, CCR6, and CCR4 
Given the large sub-population of IFN-γ-producing CCR6+ cells we analyzed the expression 
of CXCR3, a chemokine receptor known to be expressed on Th1 and Th17.1 cells (14, 34). 
Adding CXCR3 to our analysis allowed for more stringent gating strategy to determine 
the percentages of Th1, Th17, and Th17.1 subsets (Table 1 and Figure E1) as well as to 
measure cytokine production. Functional analysis of both BAL and PBMC confi rmed 
IFN-γ production with no signifi cant IL-17A production by the sorted Th1-enriched 
(CCR6−CCR4−CXCR3+) population (Figure 4). In comparison, we found marked production 
of IFN-γ by Th17.1-enriched cells (CCR6+CCR4−CXCR3+), but only a small percentage of 
figure 2. Signifi cant increases in CCR6+ eff ector 
cells, consistent with the Th17 lineage, in sar-
coidosis. Bronchoalveolar lavage (BAL) cells and 
peripheral blood mononuclear cells (PBMCs) 
were stained and analyzed by fl ow cytometry as 
described in Methods. As a percentage of CD4+ 
T cells, CCR6+ eff ector cells are signifi cantly in-
creased in both the lungs (**P = 0.0006) and the 
blood (**P = 0.0051) of patients with sarcoidosis 
compared with control subjects. Data are shown 
as mean (histogram bars) ± SEM. Overlaid dots 
represent individual patient values. BAL: n = 32 
subjects with sarcoidosis and 9 control subjects; 
PBMC: n = 35 patients with sarcoidosis and 18 
control subjects. 
IFN-γ-producing Th17.1 cells
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Figure 3
figure 3. Isolation of discrete T-helper (Th)-cell populations from peripheral blood mononuclear cells 
(PBMCs) using FACS-sorting confi rmed accurate separation and revealed that CCR6+ cells demonstrated 
diff erent patterns of cytokine secretion. FACS-sorted cells were stimulated and stained with fl uorescent an-
tibodies, as described in Methods. Shown is a representative sarcoidosis (A) and healthy control (B) sample 
of FACS-sorted PBMC eff ector cell subsets demonstrating predicted patterns of cytokine secretion for Th1 
(CCR6−CCR4−) and Th2 (CCR4+CCR6−) cells. FACS-sorted CCR6+ eff ector cells show increased frequencies of 
cells expressing IFN-γ or IL-17 and a small frequency of cells expressing both cytokines. FACS = fl uores-
cence-activated cell sorter. 
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Th17.1 cells were capable of IL-17A expression (Figure 4, row “Th17.1-enriched”). In con-
trast to Th17.1 cells, the Th17-enriched cells (CCR6+CCR4+CXCR3−) showed essentially no 
production of IFN-γ and an increased capacity to produce IL-17A compared with Th17.1 
(Figure 4, row “Th17-enriched”). Figure E3 compiles the functional data for PBMC samples 
from all subjects with sarcoidosis and demonstrates the striking diff erences in cytokine 
production between the Th17 subsets. Thus, these data show that we have identifi ed three 
discernible populations of Th cells, namely, Th1, Th17, and Th17.1 in human sarcoidosis, 
and, specifi cally, that a large population of Th17.1 cells produce only IFN-γ. 
figure 4. T-helper (Th) 17.1 cells showed co-production of IFN-γ and IL-17A to a small extent but signifi cant 
production of IFN-γ, which was not found for Th17 cells. Shown are representative dot plot images display-
ing IFN-γ versus IL-17A production from FACS-sorted eff ector cell subsets from subjects with sarcoidosis 
(A-C) and a healthy control subject (D). After FACS-sorting by surface markers, the memory eff ector cell 
subsets were stimulated, fi xed, permeabilized and stained intracellularly for cytokines, and analyzed by 
fl ow cytometry. These methods revealed marked diff erences in IL-17 and IFN-γ cytokine production be-
tween Th17- and Th17.1-enriched cells. In the broncho-alveolar lavage (BAL) samples, too few events fell 
within the CCR4+ gate to quantify CCR6+CCR4+CXCR3− “Th17-enriched” cells and CCR6−CCR4+CXCR3− “Th2-
enriched”. Functional stimulation assays were not available from healthy control BAL samples due to a pau-
city of available cells. FACS = fl uorescence-activated cell sorter. 
IFN-γ-producing Th17.1 cells
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We next compiled the functional data from the sarcoidosis cohort to compare cyto-
kine production between BAL and PBMC and Th1 and Th17.1 cells. We found that a re-
markably high percentage (average, ~60%) of Th17.1-enriched cells from BAL produced 
IFN-γ (Figure 5A). Importantly, the frequency of the Th17.1 cells producing IFN-γ was just 
as high as that measured from Th1-enriched cells. The percentage of IFN-γ-producing 
Th1 and Th17.1 cells were also similar in the PBMC compartment (Figure 5A). Figure 
5B shows that the frequency of Th17.1 cells producing IL-17 was modest (~5% of total 
Th17.1 sorted cells in both BAL and PBMC) as predicted from the individual FACS plots 
shown in Figure 4. Finally, the frequency of Th17.1 cells capable of co-production of 
IL-17A and IFN-γ was even lower (~2% or lower; Figure 5C). Taken together, these data 
show a much greater capacity for Th17.1 cells to produce IFN-γ alone compared to IL-
17A or both cytokines together, supporting the hypothesis that Th17.1 cells expressing 
only IFN-γ could have been misclassified as Th1 cells. 
Th17.1, but not Th1 or Th17, cells are increased in sarcoidosis
Sarcoidosis is characterized as a Th1-mediated disease. However, we found no signifi-
cant differences in the percentage of Th1 cells in both BAL and blood in patients with 
sarcoidosis compared with control subjects (Figure 6A). Furthermore, the size of the Th1 
population in BAL was low in both groups (~20% of CD4+ T cells in BAL) (Figure 6A). Con-
sistent with our hypothesis, we found, on average, that approximately 30% of the CD4+ 
T cells in sarcoidosis BAL were Th17.1 cells, which was significantly increased compared 
with control subjects and not found for Th17 cells, respectively (Figure 6B & 6C). Th17.1 
cells accounted for up to 60% of all the BAL CD4+ T cells in some subjects. In sarcoidosis 
figure 5. T-helper (Th) 17.1-enriched cells were equipotent in their ability to produce IFN-γ compared with 
Th1-enriched cells. Bronchoalveolar lavage (BAL) and peripheral blood mononuclear cells (PBMCs) were 
FACS-sorted and subsequently stimulated and stained for intracellular cytokines, as described in Methods. 
(A-C) Functional data collected from flow cytometry from patients with sarcoidosis were compiled and 
displayed. (A) Percentage of cells producing IFN-γ only. (B) Percentage of cells producing IL-17A only (BAL, 
**P = 0.0056; PBMC, ***P < 0.0001). (C) Percentage of polyfunctional cells producing both IL-17A and IFN-γ 
(PBMC **P = 0.0024). Data are expressed as mean (histogram bars) ± SEM. Overlaid dots represent individual 
patient values. Sarcoidosis BAL: n =14, and PBMC: n =15. FACE = fluorescence-activated cell sorter. 
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Figure 6
figure 6. T-helper (Th) 17.1 cells from sarcoidosis bronchoalveolar lavage (BAL) fl uid were signifi cantly in-
creased in two separate sarcoidosis cohorts and present in higher percentages compared with Th1 cells. 
BAL cells and peripheral blood mononuclear cells (PBMCs) were stained, FACS-sorted, and acquisition 
data was analyzed to include all three chemokine receptors to defi ne Th1 and Th17.1 cells, as described 
in Methods, Table 1 and Figure E1. (A) There were no signifi cant diff erences in the percentages of Th1 cells 
(CCR6−CCR4−CXCR3+ eff ector cells) in the blood or lungs of patients with sarcoidosis compared with healthy 
control subjects. (B) The percentages of Th17 cells (defi ned CCR6+CCR4+CXCR3− eff ector cells) are signifi -
cantly increased in the blood of patients with sarcoidosis (**P = 0.0002), but not in the lungs, compared 
with healthy control subjects. (C) The percentages of Th17.1 cells (defi ned CCR6+CCR4−CXCR3+) were sig-
nifi cantly increased in the lungs of patients with sarcoidosis (**P = 0.0016), but not in the blood. (D) The 
percentages of Th17.1 cells were markedly increased in the BAL of patients with sarcoidosis from the Eras-
mus MC cohort compared with similarly aged disease control subjects (***P < 0.0001). Data are expressed 
as mean (histogram bars) ± SEM. Overlaid dots represent individual patient values. U.S. cohort: BAL: n = 32 
subjects with sarcoidosis and 9 control subjects; PBMC: n = 35 subjects with sarcoidosis and 18 control 
subjects. Erasmus MC cohort: BAL: N=30 subjects with sarcoidosis and 12 control subjects. FACS = fl uores-
cence-activated cell sorter. 
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blood, we found the opposite pattern: Th17 cells were increased, but Th17.1 cells were 
not. Since the U.S. control group was younger than the patients with sarcoidosis (Table 
2), we also studied a second cohort of European control subjects and newly diagnosed 
patients with sarcoidosis that were better matched for age (Table 4). Figure 6D displays 
the marked expansion of Th17.1 cells in patients with sarcoidosis compared with the 
disease control subjects, which validates the U.S. cohort findings. 
DISCUSSIon
Sarcoidosis is a classic Th1-mediated disease (35-37). Given the evidence for plasticity 
of Th17 cells towards a Th1 phenotype (14, 17-20, 22, 23, 34, 38-40), we speculated that 
the intense IFN-γ inflammation in the lungs of patients with sarcoidosis could transform 
Th17 cells into cells with characteristics of Th1 cells. These cells have been referred to 
as Th17.1, and large subpopulations of them have been shown to produce only IFN-γ. 
Using methods that are highly accurate in discriminating subsets of Th cells (14), we 
identified two separate Th17 subsets in sarcoidosis, namely, Th17 and Th17.1. These 
subsets express different chemokine receptors and demonstrate different cytokine 
effector functions. Importantly, Th17.1 cells have shown pathogenic characteristics, 
such as up-regulation of proinflammatory cytokines and corticosteroid resistance (14), 
demonstrating the importance of identifying this Th subset in sarcoidosis. We found 
that Th17.1 cells were markedly expanded in sarcoidosis BAL, and were present in even 
higher frequencies than classical Th1 cells. Furthermore, sarcoidosis Th17.1-enriched 
cells were equipotent in their ability to produce IFN-γ compared with Th1 cells. We also 
analyzed Th17.1 cells from a separate European cohort, which validated the original ob-
servations. Taken together, these findings stimulate questions regarding the established 
view that Th1 cells are the major contributor in sarcoidal inflammation. This study also 
demonstrates the importance of detailed characterization of human T cells, because 
Th17.1 cells, which are skewed to produce only IFN-γ, have likely been misclassified as 
Th1 cells due to their cytokine profiles. Ultimately, functional studies of CD4+ T cells in 
sarcoidosis, without regard to more detailed distinction of the type of Th subset, may be 
misleading. 
Direct comparison of the frequencies of Th17 and Th17.1 effector cell subsets between 
the blood and BAL compartment identified significant elevations of Th17-enriched 
cells in the blood, but not the BAL, of subjects with sarcoidosis compared with control 
subjects. Conversely, Th17.1-enriched cells were significantly increased in the BAL, but 
not in the blood, when compared with healthy control subjects. This observation could 
relate to plasticity of Th17-cell subsets in vivo if they are transiting from blood to the 
inflamed lung (36, 41, 42). Interesting prior research supports our results by finding 
elevated expression of CCR6 on CD4+ T cells in sarcoidosis, but this study did not use 
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immunophenotyping assays that would allow for identification of the full population 
of Th17.1 cells or identify the marked differences in cytokine production of Th17.1 cells 
compared with Th17 cells (43). Other studies focused on CD4+ cells that secreted IL-17 or 
IFN-γ without incorporation of multiple phenotypic markers and FACS-sorting, resulting 
in the possible misclassification of Th17.1 cells as Th1 cells (9, 11, 12). By highlighting 
the heterogeneity of IFN-γ-producing cells in this chronic human disease, our results 
suggest the more general conclusion that lymphocytes in vivo, especially in chronic 
diseases, may be more heterogeneous than those observed in controlled experimental 
models. 
Studies such as that by Ramesh and colleagues (14) provide insight into the complicated 
functional role of Th17-cell subsets. The authors asked why patients with Crohn’s disease 
receiving Secukinumab, a fully humanized anti-IL-17A monoclonal antibody, developed 
exacerbations of their disease (44), even though IL-17A is thought to be an important 
contributor of gut inflammation. Using human blood and gut tissue, they showed that 
Th17.1 cells (which the authors defined as CCR6+CXCR3hiCCR4loCCR10−CD161+MDR1+) 
expressed a pro-inflammatory transcriptional signature that mimicked disease-inducing 
Th17 subsets in mice and also predicted increased responsiveness to IL-23, which is 
thought to be a regulator of pathogenic Th17 function (14). In contrast, a study examin-
ing T cells expressing CCR6+CXCR3+CCR4− (i.e., Th17.1 cells) found that their circulating 
numbers were increased in patients with latent tuberculosis infection compared with 
control subjects (45). The authors performed RNA sequencing of these cells and found 
lineage-specific signatures of both Th1 and Th17 cells, which would be expected, but 
also differential expression of genes associated with susceptibility to tuberculosis, and 
enhanced T-cell activation and cell survival (45). Thus, the functional complexity of Th17 
subsets appears to relate to the local inflammatory signals and, although considered 
pathogenic in one inflammatory disease, they may be necessary for eradication of the 
infection in another. Further studies are needed to understand the role of Th17-cell 
subsets, their cellular products, and the regulators of Th17 pathology (e.g. IL-23) in 
sarcoidosis to make sense of results from existing studies (46) and facilitate the develop-
ment of more effective therapies. 
Our study has some potential limitations. We found that Th17.1-cell numbers were 
markedly increased in sarcoidosis BAL as compared with that from two control groups, 
whereas Th1 cell numbers were not. However, each control group has a potential limita-
tion. Our first control group was comprised of healthy control subjects, but they were 
somewhat younger, on average, than those in our sarcoidosis group. Our second control 
group was comprised of control subjects with disease rather than healthy control sub-
jects. Nonetheless, we did not find any expansion of Th17.1 cells in BAL in either of these 
control groups and we believe the consistency of our findings across these two control 
groups is supportive of our general conclusions.
IFN-γ-producing Th17.1 cells
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In summary, we isolated CD4+ T effector cells by their chemokine receptors to under-
stand their distribution and functional attributes in the BAL and blood of sarcoidosis to 
uncover significantly elevated frequencies of BAL Th17.1 cells. It is likely that these cells 
have been misclassified as Th1 cells in sarcoidosis. These new findings raise questions 
about prior assumptions of disease pathogenesis and may provide new directions for 
clinical studies and treatment targets. We also need to learn more about their presence 
in granulomatous tissues and what role(s) they play in disease progression. 
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SUPPlEmEnTaRy maTERIal
mEThoDS
Subjects
Participants underwent written informed consent and the study was approved by the 
UCSF Committee on Human Research. Sarcoidosis diagnosis was based on consistent 
clinical features, absence of alternative diagnoses and biopsy of the lung or medias-
tinal lymph nodes showing non-caseating granulomas according to accepted criteria 
(1). Patients were excluded for the following conditions: a history of smoking, cancer, 
chronic infections (hepatitis, HIV, TB, etc.), autoimmune diseases (Crohn’s, Lupus, etc.), 
other pulmonary diseases or organ transplant. After enrollment, patients underwent a 
chest X-ray, high-resolution chest computed tomography (CT) scan, BAL and blood col-
lection. Fibrosis was determined on the basis of lung scarring by chest CT scan analysis. 
Healthy control subject data were obtained from a concurrent study (study number 
NCT01484691) to evaluate the same immunological parameters. 
The validation cohort referred to as “Erasmus MC cohort” consisted of 30 newly diag-
nosed European patients in which the pulmonary sarcoidosis diagnosis was based on 
the same criteria as above (1). Exclusion criteria included conditions described above in 
addition to use of immunomodulatory medication three months prior to study enroll-
ment, however a smoking history was accepted. The control group consisted of 12 age-
matched individuals, eight of whom underwent bronchoscopy for community-acquired 
pneumonia and four patients with COPD. The Medical Ethical Committee of the Erasmus 
MC Rotterdam approved this study.
Bronchoalveolar lavage 
Subjects underwent bronchoscopy with BAL following the procedures set forth by the 
protocol committee of the NIH-funded study, Genomic Research in Alpha-1 Antitrypsin 
Deficiency and Sarcoidosis (ClinicalTrials.gov Identifier: NCT01831739). Cells were 
resuspended in FACS buffer (0.1% BSA + 2mM EDTA in PBS), counted and immediately 
processed for flow cytometry. 
Peripheral blood mononuclear cell (PBmC) isolation
PBMCs were isolated from peripheral blood (collected in EDTA tubes) by Ficoll density 
centrifugation as previously described (2) and processed immediately for flow cytom-
etry. 
IFN-γ-producing Th17.1 cells
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flow cytometry and sorting
For surface staining, BAL cells and PBMCs were incubated with fluorescent antibodies 
(CD3 [BD Horizon], CCR4 [BD Pharmingen], CD127, CD4, CD25 and CCR6 [eBioscience], 
CD45RO, CD45RA and CXCR3 [Biolegend]), and CD1d-tetramer-PBS57 [NIH Tetramer 
Facility] for 30 minutes at 4°C in the dark using methods recommended by the manufac-
turers. After incubation, cells were washed, and viability was measured using Propidium 
Iodide (BD Bioscience). To FACS-sort CCR4 and CCR6 positive and negative expressing 
cells, we gated on live cells, followed by lymphocytes, singlets, non-invariant natural 
killer T (iNKT) cells, CD4 T cells, non-regulatory T cells, and effector cells (Figure 1A & B). 
CCR6+, CCR4+CCR6−, and CCR4−CCR6− effector cells were sorted into separate chambers 
and used in phenotypic and functional studies. Figure 1A & 1B show our three-gate 
sorting strategy. After discovery of the high prevalence of IFN-γ-producing CCR6+ cells, 
a fourth gate was added to sort effector T cells into four chambers based on chemokine 
expression: CCR4+CCR6+, CCR4+CCR6−, CCR4−CCR6+, and CCR4−CCR6−. CXCR3 was used 
in the FACS-sorting panel and functional panel to allow for a more stringent gating such 
that Th1-enriched cells were defined by CCR6−CCR4−CXCR3+, Th2-enriched defined by 
CCR6−CCR4+CXCR3−, Th17-enriched defined by CCR6+CCR4+CXCR3−, and Th17.1-enriched 
defined by CCR6+CCR4−CXCR3+ (Table 1) (3). Titration of each reagent and “Fluorescence 
Minus One” controls (4) were used for optimization and placement of gates. One million 
events were recorded for analysis during FACS acquisition. 
Cell stimulation & cytokine analysis 
After overnight rest in RPMI 1640 + 10% FBS (Hyclone), 1% pen/strep, 1% glutamine at 
37°C, the FACS-sorted effector cells subsets were stimulated at 37°C for 4 hours in 10 
nM PMA and 1 mM ionomycin in the presence of 5mg/mL brefeldin A. Cells were stained 
for surface markers, CCR6, CCR4, and CXCR3 (eBioscience), and live/dead Amcyan stain 
(Invitrogen) for 30 minutes at 4°C in the dark and washed. Cells were fixed in 2% para-
formaldehyde for 20 minutes on ice and permeabilized (BD Biosciences) for 10 minutes 
at RT prior to intracellular cytokine staining for IL-17A, IL-4, and IFN-γ (eBioscience). 
Cells were washed and analyzed immediately. Data analysis included determining the 
percentage of each effector subset making one or all of the above cytokines. As was 
done for the phenotypic analysis of each subset, we again used 3 chemokine recep-
tors to define Th1-, Th2-, Th17-, and Th17.1-enriched groups (Table 1) and report their 
respective production of cytokines.
methods for validation Erasmus mC cohort: flow cytometry staining and Th17.1 
analyses
Bronchoscopy with BAL and processing of fluid and cells performed as previously de-
scribed (5). BAL fluid cells were stained for intra- and extracellular markers using the 
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following antibodies: CD3-APC-eFluor780 (SK7), CD4-AF700 (OKT4), FoxP3-PE (236A/
E7), CTLA4-PerCp-eFluor710 (14D3) (eBiosciences) and CCR6-APC (11A9), CXCR3-
BV711 (1C6/CXCR3) (BD biosciences) and CCR4-FITC (205410) (R&D) and CXCR3-BV421 
(G025H7) (Biolegend) and CD45RA-PE-Texas Red (MEM-56) (Invitrogen). Fixable Aqua 
Dead Cell Stain kit for 405 nm (Invitrogen, Molecular Probes) was used as live-dead 
marker. At least 100,000 cells per sample were measured on a Flow cytometer LSRII 
(BD Biosciences). In sarcoidosis and disease control BAL fluid we identified subsets of 
CD45RA−FoxP3low/intermediate total memory T helper cells (6) on the basis of chemokine-re-
ceptor expression (3, 7-9), as we have previously shown in mediastinal lymph nodes (10). 
We determined CCR6− T helper cell subsets (CCR4−CXCR3+ Th1 cells and CCR4+CXCR3− 
Th2 cells) and CCR6+ T helper cell subsets (CCR4+CXCR3− Th17 cells, and CCR4−CXCR3+ 
Th17.1 cells). 
CT scanning
Patients underwent computed tomography (CT) performed on a General Electric 64 
multidetector CT scanner. 1.25-mm noncontrast axial images were obtained while 
supine during full inspiration for a 10 s breath hold. Radiation settings were adjusted 
to body mass index. Imaging protocol was defined by the NIH-funded study, Genomic 
Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (ClinicalTrials.gov Identifier: 
NCT01831739).
Statistical analysis
Data were analyzed using FlowJo 9, JMP 10 and GraphPad Prism 6 software. Normality 
was measured using Shapiro-Wilk test. Differences between two groups were analyzed 
using an unpaired student t-test with Welch’s correction or Rank sum test as appropriate. 
Chi-square analysis was used for gender, race and ethnicity, and a student t-test was 
used for the age. For all statistical tests, a P-value < 0.05 was considered significant.
IFN-γ-producing Th17.1 cells
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Supplementary Figure E1
Supplementary figure E1. Flow cytometry gating strategy using all three chemokine receptors to deter-
mine percentages of T helper subsets. CXCR3 was used in the FACS-sorting and functional panels to allow 
more stringent gating of Th17, Th17.1, Th1, and Th2 populations as defi ned in Table 1. 
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Supplementary Figure E2
Supplementary figure E2. Absolute CD4+ T cell count in the blood of sarcoidosis patients, with and with-
out fi brosis. Absolute CD4 counts were obtained on sarcoidosis participants on the same day their radiol-
ogy images were performed. On average, the counts were found to be signifi cantly higher in the patients 
without evidence of fi brosis compared to the fi brotic patients. **P = 0.0002. 
CHAPTER 4
Supplementary Figure E3
Supplementary figure E3. Compilation of the functional data for PBMC samples from all sarcoidosis sub-
jects demonstrates the marked diff erences in cytokine production between Th17 subsets. PBMC cells were 
FACS-sorted and subsequently stimulated and stained for intracellular cytokines as described in Meth-
ods. (A-C) Functional data from sarcoidosis patients were compiled and displayed. (A) Percentage of cells 
producing IFN-γ only. (B) Percentage of cells producing IL-17A only. (C) Percentage of polyfunctional cells 
producing both IL-17A and IFN-γ. These data show three discernible populations of Th cells, namely, Th1, 
Th17, and Th17.1 in human sarcoidosis and specifi cally that a large percentage of Th17.1 cells produce only 
IFN-γ. Data are expressed as mean histogram bars ± SEM. Overlaid dots represent individual patient values. 
Sarcoidosis PBMC: n =15. 
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aBSTRaCT
Background: We reported that T helper 17.1 (Th17.1) cells are responsible for the exag-
gerated IFN-γ production in pulmonary sarcoidosis, but it is currently unknown where 
these cells are induced.
methods: Using flow cytometry, proportions, proliferation, and activation status of 
CCR6- Th subsets (CCR4-CXCR3+Th1 and CCR4+CXCR3-Th2) and CCR6+ Th17-lineage sub-
sets (CCR4+CXCR3-Th17, CCR4+CXCR3+ double-positive (DP) and CCR4-CXCR3+Th17.1) 
were compared between mediastinal lymph nodes (MLN) from treatment-naive sarcoid-
osis patients and healthy controls, and within broncho-alveolar lavage fluid (BALF) from 
patients. 
Results: Higher proportions of CCR6+ Th17-lineage subsets were detected in sarcoid-
osis MLN than in control MLN. Sarcoidosis BALF contained predominantly Th17.1 cells, 
whereby proportions were significantly higher in patients developing chronic disease 
than in patients undergoing resolution. Sarcoidosis CCR6+ DP cells exhibited a high 
fraction of proliferating Ki-67+ cells and displayed lower CTLA4 expression in sarcoidosis 
MLN compared with controls. Th17.1 cells in sarcoidosis MLN exhibited significantly 
reduced CD28 expression. 
Conclusion: Our data are the first to support a model in which sarcoidosis CCR6+ Th17-
lineage cells are polarized in the MLN, which show plasticity towards Th17.1 cells in the 
lung microenvironment, where their presence correlates with development of chronic 
disease. This study provides a new perspective on sarcoidosis pathogenesis and thera-
peutic targets.
Th17-lineage cells in sarcoidosis mediastinal lymph nodes
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InTRoDUCTIon
Sarcoidosis is a multisystem granulomatous disorder of unknown cause, predominantly 
affecting the lungs (1). Sarcoidosis was initially characterized as a CD4+ T helper (Th)1-
mediated immunological response upon exposure to a likely poorly degradable anti-
genic stimulus, leading to granuloma formation (1). Immunological characterizations 
included non-caseating granulomas with enhanced local expression of Th1-cytokines/
chemokines, such as interleukin (IL)-2, interferon (IFN)-γ, IL-12, IL-18 and IFN-γ-induced 
protein (IP)-10 (C-X-C motif chemokine ligand 10 (CXCL10)) (2-6), and clonal expansion 
of Th cells reflecting a chronic antigenic nature of stimulation (7). 
Over the last years, IL-17-producing cells were detected in sarcoidosis patients dur-
ing active and progressive pulmonary disease (8-10). Both lung and circulating Th cells 
from patients showed increased IL-17 and IL-23 receptor (IL-23R) expression (8-10). We 
and others found significantly increased proportions of IL-17A/IFN-γ-double-producing 
memory Th cells within sarcoidosis peripheral blood (PB) and broncho-alveolar lavage 
fluid (BALF) (9-11). Interleukin-17A/IFN-γ-double-producers are described to be patho-
genic in human chronic inflammatory disorders, including Crohn’s disease (CD) (12, 13) 
and juvenile idiopathic arthritis (JIA)(14). Proportions of IL-17A+/IFN-γ+ Th cells in sar-
coidosis BALF increased with Scadding stage (11), suggesting a role in disease prognosis.
Evidence has accumulated that IL-17A+/IFN-γ+ Th cells (Th17/Th1) express both Th17-
associated markers, including C-C chemokine receptor type 6 (CCR6), CD161, IL-23R and 
RAR-related orphan receptor (ROR)γt, and Th1-associated markers, such as C-X-C motif 
chemokine receptor 3 (CXCR3), IL-12Rβ2 and TBX21 (T-bet)(12-21). These IL-17A+/IFN-γ+ 
Th cells originally derive from IL-17A-single-positive Th cells (Th17) and can develop 
into IFN-γ-single-positive cells (12-21). Hence, there are two types of IFN-γ-producing 
Th cells, i.e. CCR6- Th1 cells and CCR6+ Th17-derived cells. The latter are referred to as 
Th17.1 cells, based on CCR6 and CXCR3 chemokine-receptor expression (13, 15, 20, 21) 
(see Figure E1 for subset clarification). 
Insight in the role of Th17-Th17.1 cell plasticity in sarcoidosis lungs is highly relevant 
since human Th17.1, and not Th17 cells, were specifically found to have a pathogenic 
signature and to highly express the multi-drug resistance type 1 membrane transporter 
(MDR1), enhancing steroid resistance (13). Importantly, we recently reported that Th17.1 
cells rather than Th1 cells are responsible for the exaggerated IFN-γ production in pul-
monary sarcoidosis (22). Since Th17.1 cells are primarily thought to derive from Th17 
cells (12-21), Th17 cell plasticity could take place in pulmonary sarcoidosis.
Lung-draining mediastinal lymph nodes (MLN) have become an attractive clinical site 
for sarcoidosis diagnosis, since detection of granulomas is more accurate in MLN than 
in lung (23). Clinical findings in pulmonary sarcoidosis suggest that the first granulomas 
are formed within MLN (24), and enhanced CD4+ T-cell and Th17-lineage cell presence 
in sarcoidosis MLN (25) reflects the pulmonary immunological response. Classifying Th 
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subsets in MLN will increase insight in the primary Th cell response that occurs in pul-
monary sarcoidosis. Therefore, in the current study we investigated the distribution and 
proliferative capacities of CCR6+ Th17-lineage subsets in MLN and BALF to gain insight 
into Th17/Th17.1 cell induction in pulmonary sarcoidosis.
mEThoDS
Study design and subjects
Patients with pulmonary sarcoidosis were included at time of diagnosis. The diagnosis of 
sarcoidosis was made conform to the guidelines of the ATS/ERS/WASOG (1). 
Exclusion criteria were use of immunomodulatory medication 3 months prior to 
study inclusion; respiratory tract infection 4 weeks prior to study inclusion; concomitant 
pulmonary disease (including chronic obstructive pulmonary disorder and asthma), 
autoimmune diseases, malignancies, human immunodeficiency virus seropositivity, 
pregnancy, and allergies. 
For this study, in total 55 sarcoidosis patients donated BALF, MLN-derived fine-needle 
aspiration (FNA) or PB. Disease course of a subgroup of patients was determined 2 years 
after study inclusion. Resolution of disease was defined by the absence of abnormali-
ties on chest X-ray and clinical symptoms. Patients with residual abnormalities on chest 
X-ray, but without need for treatment were designated as non-progressive chronic; and 
patients with need for treatment as progressive chronic. 
Control MLN were collected from 22 lung transplantation donors without signs of 
pulmonary inflammation (routinely assessed by a chest X-ray and bronchoscopy). 
The Medical Ethical Committee of the Erasmus University Medical Centre Rotterdam 
approved this study. Written informed consent was obtained from every participant be-
fore study inclusion. Further subject characteristics are shown in Supplementary Table 
E1. 
Study materials
Bronchoscopy with BAL was performed as previously described(9). BALF cells and PB 
were processed as previously described (9). 
Esophageal or endobronchial ultrasound guided (EUS- or EBUS)-FNA from draining 
MLN were performed with a 22G (or 19G) needle. MLN aspirates were filtered through a 
100 μm cell strainer (BD Biosciences) and centrifuged. Cells were stored at -150 °C. 
Control MLN were collected from lung transplantation donors. Control MLN were 
processed as lymph node aspirates. 
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flow cytometry 
BALF, MLN and PB mononuclear cells were stained for intra- and extracellular markers 
using the antibodies shown in Supplementary Table E2. Fixable Aqua Dead Cell Stain kit 
for 405 nm (Invitrogen, Molecular Probes) was used as live-dead marker. At least 100.000 
cells per sample were measured on a Flow cytometer LSRII (BD Biosciences), and the 
mean fluorescence intensity of cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed 
cell death protein 1 (PD-1), CD28, CD25 and CD278 (inducible T-cell costimulator (ICOS)) 
was standardized to average expression in healthy control PB cells. 
Statistical analyses
Comparisons were performed using a Mann-Whitney U test or Wilcoxon signed rank 
test. P-values were two-sided, and analyses were performed using IBM SPSS Statistics 21. 
P<0.05 was considered statistically significant. 
RESUlTS
Predominant presence of Th17.1 cells in sarcoidosis Balf
We recently found an increased presence of Th17.1 cells in sarcoidosis BALF compared 
with controls (22). Because Th17.1 cells are primarily thought to be progeny of Th17 
cells(12-19), we aimed to quantify all CCR6+ Th subpopulations in sarcoidosis BALF. T 
helper subsets of CD45RA-FoxP3low/int total memory Th cells (Figure E2) were identified on 
the basis of chemokine-receptor expression (Figure E1) in BALF of 36 sarcoidosis patients. 
We quantified two CCR6- Th cell subsets (CCR4-CXCR3+ Th1 cells and CCR4+CXCR3- Th2 
cells) and three CCR6+ Th cell subsets (CCR4+CXCR3- Th17 cells, CCR4+CXCR3+ double-
positive (DP) Th cells and CCR4-CXCR3+ Th17.1 cells), as depicted for a representative 
sarcoidosis BALF in Figure 1A. Within CCR6+ Th cells, CCR4+CXCR3+ DP cells likely reflect 
an intermediate stage between Th17 and Th17.1 cells(20, 21, 26), expressing both RORγt/
IL-17A and T-bet/IFN-γ in patients with rheumatoid arthritis (RA) (26). 
In sarcoidosis Th17.1 cell proportions were higher than either Th1, Th2, Th17 or DP 
cells (Figure 1B) and thus represented the most predominant Th population in BALF 
(Figure 1C). Interestingly, the proportions of CCR6+ DP cells were higher than Th17 cells 
(P < 0.0001). 
Together, these data show a predominance of Th17.1 cells and the presence of 
CCR6+ DP cells in sarcoidosis BALF.
Specific increase of all CCR6+ Th17-derived cell subpopulations in sarcoidosis 
mln
Next, we quantified and classified total memory Th cells according to chemokine-
receptor expression (Figure E1), both in sarcoidosis MLN (n=17) and in control MLN 
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(n=22). A representative gating strategy is shown for one control and one sarcoidosis 
MLN in Figure 2A. Similar to sarcoidosis BALF (22), sarcoidosis MLN contained higher 
proportions of CCR6+ Th cells than control MLN (Figure 2B). We found that all Th17-
derived subsets, e.g. Th17 (25), CCR6+ DP and Th17.1 cells were significantly increased 
in sarcoidosis compared with control MLN (Figure 2C/D). In sarcoidosis MLN, Th1 cell 
proportions were significantly decreased compared with controls, although Th1 cells 
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Figure 1
figure 1. Predominant presence of Th17.1 cells in sarcoidosis BALF. CCR6- T-cell subsets (CCR4-CXCR3+ Th1 
cells and CCR4+CXCR3- Th2 cells) and CCR6+ T-cell subsets (CCR4+CXCR3- Th17 cells, CCR4+CXCR3+ DP Th 
cells and CCR4-CXCR3+ Th17.1 cells) were determined in CD45RA-FoxP3low/int total memory CD4+ T cells (see 
Figure E2 for gating strategy) from sarcoidosis BALF (n=36). (A) Representative flow cytometry analysis of 
BALF from one sarcoidosis patient. (B) Proportions of Th1, Th2, Th17, CCR6+ DP and Th17.1 cells of total 
memory CD4+ T cells. Horizontal lines indicate median values. Significance was determined using a Wil-
coxon signed rank test. *** P ≤ 0.001 (represents sarcoidosis Th17.1 cells versus either sarcoidosis Th1,Th2 or 
Th17 or DP cells). (C) A pie-chart showing mean percentages of Th1, Th2, Th17, CCR6+ DP, Th17.1 and unclas-
sified cells (which include CCR6-CCR4-CXCR3- cells, CCR6-CCR4+CXCR3+ cells and CCR6+CCR4-CXCR3- cells) of 
total memory CD4+ T cells. Abbreviations: CCR = C-C chemokine receptor, CXCR = CXC chemokine receptor, 
BALF = broncho-alveolar lavage fluid, DP = double-positive, Th = T helper, SRC = sarcoidosis. 
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remained (like in controls) the most prominent memory T-cell population in sarcoidosis 
MLN (Figure 2C/D).
Taken together, these data show that sarcoidosis MLN contain increased proportions 
of Th17.1 cells compared with controls, paralleling the lungs (22). However, in contrast 
to sarcoidosis BALF, sarcoidosis MLN additionally contain increased proportions of 
Th17.1 precursor cells, i.e. Th17 and CCR6+ DP cells. These data indicate enhanced Th cell 
differentiation towards CCR6+ Th17-lineage cells in sarcoidosis MLN. 
CCR6+ DP cells are highly proliferative in sarcoidosis
The specific increase in all CCR6+ Th cells in sarcoidosis MLN could be caused by en-
hanced proliferation, which we assessed using the proliferation marker Ki-67.
Proportions of proliferative CD4+ memory T cells were significantly increased in sar-
coidosis MLN compared with controls (Figure 3A). Interestingly, specifically CCR6+ DP 
cells and Th17.1 cells exhibited high fractions of proliferating Ki-67+ cells compared with 
controls (Figure 3B/C). This was particularly striking for the Th17.1 subpopulation, which 
in controls contained only very few Ki-67+ cells. However, CCR6+ DP cells contained the 
highest fraction of proliferating cells (~15%, which was significantly higher than any 
of the other T-cell subsets in sarcoidosis MLN (Figure 3C). In sarcoidosis BALF not the 
predominant Th17.1 cells (22), but rather the suggested precursors (12-21, 26) Th17 and 
CCR6+ DP subsets were highly proliferative (Figure 3D). 
In summary, ex-vivo phenotyping identified CCR6+ DP cells as a highly proliferative Th 
subset in both MLN and BALF of sarcoidosis patients 
Both Th17 cells and CCR6+ DP cells show decreased CTla4 expression
Since proliferative capacity depends on co-inhibitory CTLA4 and PD-1, and co-stimu-
latory CD28 signals, we determined their expression on Th17-derived subpopulations. 
Strikingly, both Th17 cells (25) and CCR6+ DP cells showed decreased CTLA4 expression 
in sarcoidosis MLN compared with controls (Figure 4A). PD-1 expression was lower on all 
Th17-lineage cells in sarcoidosis, however only significantly in Th17 cells compared with 
controls (Figure 4B). In sarcoidosis MLN, all CCR6+ Th cells subsets showed lower CD28 
expression than Th1 cells (Figure 4C). Compared with controls, sarcoidosis Th17.1 cells 
showed significantly lower CD28 expression (Figure 4C). No changes were observed in 
ICOS or CD25/IL-2R expression (Figure E3). 
Thus, sarcoidosis CCR6+ DP cells, which are highly proliferative in sarcoidosis, also 
show significantly decreased CTLA4 expression compared with controls (25). 
higher Th17.1 and lower Th17 cell proportions in Balf than mln in sarcoidosis
Findings above suggest Th17 plasticity towards Th17.1 cells in pulmonary sarcoidosis, 
since we observed increased proportions of all CCR6+ Th cells in MLN and only Th17.1 
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cells in BALF, and CCR6+ DP cells, which likely reflect an intermediate Th17 and Th17.1 
cell population (20, 21, 26), are highly proliferative in sarcoidosis-affected organs (Figure 
3B-D). 
To gain further insight into the in-vivo behavior of Th17-derived CCR6+ populations, 
we compared their proportions within sarcoidosis PB, MLN, and BALF. Remarkably, in 
sarcoidosis patients, the proportions of memory Th cells that were CCR6+ increased from 
~19% in PB, to ~31% in MLN and to ~75% in BALF (Figure 5A). Whereas Th17 cell propor-
tions were significantly lower in BALF than in MLN and PB (Figure 5B), Th17.1 cells were 
significantly higher (Figure 5D). Proportions of CCR6+ DP cells were similar in MLN and 
BALF, but were significantly higher in BALF than PB (Figure 5C). Finally, CCR6- Th1 cell 
proportions were lower in sarcoidosis BALF compared with MLN (Figure 5E). 
In conclusion, whereas Th17.1 cell proportions were significantly higher in sarcoidosis 
BALF than MLN, Th17 and Th1 cell proportions were significantly lower. CCR6+ DP cells 
were also higher in sarcoidosis lungs than PB. Taken together, these data suggest that 
Th17.1 cells arise from Th17/CCR6+ DP cells, indicating a role for Th17 cell plasticity in 
sarcoidosis, specifically in the lungs. 
higher Balf Th17.1 cell proportions in patients developing chronic disease 
than in patients undergoing resolution
As Th17.1 cells are described to be pathogenic, we questioned whether proportions of 
Th17.1 cells in BALF would associate with disease prognosis. Therefore, we determined 
the disease course of a subgroup (n=25) of our study cohort at ~2 years clinical follow-
up. Interestingly, in patients developing chronic sarcoidosis, and specifically progressive 
chronic sarcoidosis with need for treatment, significantly higher BALF Th17.1 propor-
tions were detected at time of diagnosis, compared with patients undergoing resolution 
(Figure 6A). In contrast, Th1 proportions were lower in patients developing progressive 
chronic disease than patients undergoing disease resolution (Figure 6B), resulting in an 
(See figure on previous page.)
figure 2. Specific increase of all CCR6+ Th cell populations in sarcoidosis MLN. CCR6- T-cell subsets (CCR4-CX-
CR3+ Th1 cells and CCR4+CXCR3- Th2 cells) and CCR6+ T-cell subsets (CCR4+CXCR3- Th17 cells, CCR4+CXCR3+ 
DP Th cells and CCR4-CXCR3+ Th17.1 cells) were determined in CD45RA-FoxP3low/int total memory CD4+ T 
cells (see Figure E2 for gating strategy) from control (n=22) and sarcoidosis MLN (n=17). (A) Representative 
flow cytometry analysis of MLN from one control and one sarcoidosis patient. (B) Proportions of CCR6+ total 
memory T cells. (C) Proportions of Th1, Th2, Th17, CCR6+ DP and Th17.1 cells of total memory CD4+ T cells. 
(D) Pie-chart showing mean percentages of Th1, Th2, Th17, CCR6+ DP, Th17.1 and unclassified cells (which 
include CCR6-CCR4-CXCR3- cells, CCR6-CCR4+CXCR3+ cells and CCR6+CCR4-CXCR3- cells) of total memory 
CD4+ T cells. Statistics: Horizontal lines indicate the median values; significance was determined using a 
Mann-Whitney U test, ** P <0.01 *** P < 0.001. Abbreviations: CCR = C-C chemokine receptor, CXCR = CXC 
chemokine receptor, MLN = mediastinal lymph nodes, DP = double-positive, Th = T helper, Ctrl = control, 
SRC = sarcoidosis. 
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figure 3. CCR6+ DP cells are highly proliferative in sarcoidosis. Expression of Ki67 was determined ex-vivo in 
Th1, Th17, CCR6+ DP and Th17.1 cells in control and sarcoidosis MLN, and sarcoidosis BALF. (A) Proportions 
Ki67+ total memory T cells (data are from 15 controls and 13 patients). (B) Representative flow cytometry 
analysis of Th17, CCR6+ DP and Th17.1 cells in MLN from one control and one sarcoidosis patient. (C) Pro-
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increased Th17.1/Th1 ratio within BALF of patients developing chronic disease (Figure 
6C). Although non-significant, Th17 proportions also showed a trend to be lower in pa-
tients developing chronic disease than in patients undergoing resolution (Figure E4A), 
and patients developing progressive chronic disease showed a higher Th17.1/Th17 ratio 
within BALF (Figure E4B). 
In conclusion, these data suggest that development of chronic disease is associ-
ated with Th17.1 cells, but not with Th1 or Th17 cells in sarcoidosis BALF, highlighting a 
pathogenic role for Th17.1 rather than Th1 or Th17 cells in the development of (chronic) 
pulmonary sarcoidosis. 
DISCUSSIon
Our study supports a model in which sarcoidosis Th17-lineage cells are induced in MLN 
and manifest plasticity towards Th17.1 cells in the (lung) granulomatous microenviron-
ment, where they are particularly critical for development of chronic disease. 
Since it was recognized that Th17 cells display considerable plasticity and can produce 
IFN-γ, it has become increasingly clear that Th17 cells, rather than Th1 cells, play a key 
role in the development of autoimmune diseases (21, 27). Interferon-γ-producing Th17 
cells, or so called Th17.1 cells, are described to be pathogenic in several autoimmune 
diseases and chronic inflammatory disorders, including CD (12, 13) and arthritis (14). 
In a previous study we clarified that specifically CCR6+ Th17.1 cells rather than classical 
CCR6- Th1 cells are the key source for IFN-γ production in sarcoidosis BALF (22). Here, 
we found that in sarcoidosis MLN not only Th17.1 cells, but all CCR6+ Th cell subsets, 
including Th17 and CCR6+ DP cells were significantly enhanced compared with control 
MLN. Since Th17 and CCR6+ DP cells can be precursor cells of Th17.1 cells, these data 
are consistent with the hypothesis that initial Th17-lineage subset differentiation occurs 
within sarcoidosis MLN (24). 
Although Th17.1 cells were abundantly present within sarcoidosis affected-organs, we 
identified CCR6+ DP cells as the subset with the highest fraction of proliferating cells. 
Furthermore, sarcoidosis CCR6+ DP cells showed decreased co-inhibitory CTLA4 expres-
sion compared with controls, likely contributing to increased proliferative capacity. 
Previously, we have also observed a reduced CTLA4 expression in sarcoidosis MLN Th17 
cells (25). Aberrant expression of co-inhibitory receptors, such as CTLA4 (25) and PD-1 
portions of Ki67+ cells in control (n=10) and sarcoidosis MLN (n=9). Horizontal lines indicate median values. 
Significance was determined using a Mann-Whitney U test. Significance between median values of paired 
samples was determined using a Wilcoxon signed rank test (# P < 0.05: sarcoidosis DP cells versus either 
sarcoidosis Th1,Th17 or Th17.1). (D) Proportions of Ki67+ cells in sarcoidosis BALF (n=13). Horizontal lines 
indicate median values. Significance was determined using a Wilcoxon signed rank test, * P < 0.05 *** P < 
0.001. Abbreviations: DP = double-positive, Th = T helper, Ctrl = control, SRC = sarcoidosis. 
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Figure 4
figure 4. CCR6+ DP cells show decreased CTLA4 expression. Expression of CTLA4, PD-1 and CD28 was de-
termined ex-vivo in Th1, Th17, CCR6+ DP and Th17.1 cells in control and sarcoidosis MLN. (A) Mean fluores-
cence intensity of CTLA4 (data are from 17 controls and 13 patients). (B) Mean fluorescence intensity of 
PD-1 (data are from 17 controls and 13 patients). (C) Mean fluorescence intensity of CD28 (data are from 
10 controls and 9 patients). Statistics: Data are presented as boxplots and whiskers that show the 10-90 
percentile of the data. Significance was determined using a Mann-Whitney U test, * P < 0.05 *** P < 0.001. 
Mean fluorescence intensity was standardized to average expression in healthy control PB cells. Abbrevia-
tions: CTLA4 = cytotoxic T lymphocyte antigen 4, PD-1 = programmed cell death protein 1, MFI = mean 
fluorescence intensity, DP = double-positive, Th = T helper, Ctrl = control, SRC = sarcoidosis. 
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figure 5. Increase of Th17.1 cell and decrease of Th17 cell proportions within sarcoidosis BALF compared 
with MLN. Proportions Th1, Th17, CCR6+ DP and Th17.1 cells were determined in total memory CD4+ T cells 
from sarcoidosis PB, MLN and BALF. (A) Proportions of CCR6+ total memory T cells. (B-D) Proportions of Th17, 
CCR6+ DP and Th17.1 cells of total memory CD4+ T cells. (E) Proportions of Th1 cells of total memory CD4+ 
T cells. Statistics: Horizontal lines indicate median values and significance was determined using a Mann-
Whitney U test, * P < 0.05 ** P < 0.01 *** P < 0.001. Data are from 35 (PB), 17 (MLN) and 36 (BALF) patients. 
Abbreviations: CCR = C-C chemokine receptor, PB = peripheral blood, MLN = mediastinal lymph nodes, 
BALF = broncho-alveolar lavage fluid, DP = double-positive, Th = T helper. 
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(Figure 4B) on specific T- cell subsets in sarcoidosis is very likely to be part of disease 
pathogenesis, since clinical treatment with anti-CTLA4/anti-PD-1 has been associated 
with development of sarcoid-like granulomas in MLN of cancer patients (25). Th17.1 
cells are thought to be highly differentiated cells, which would be confirmed by their 
low CD28 expression. These findings are in agreement with Th17 plasticity towards a 
differentiated Th17.1 phenotype, where CCR6+ DP cells represent an intermediate stage 
(20, 21, 26). 
Comparing different involved immunological compartments in sarcoidosis provided 
further support for Th17 cell plasticity towards Th17.1 cells, as specifically Th17.1 cells 
were augmented in sarcoidosis lungs compared with MLN and PB (19). In joints of pa-
tients with JIA, Th17.1 cell fractions were also found increased compared with PB and 
shared clonal ancestry with Th17 cells (14). 
Taken together, our data support a model in which Th17 cells are primed within 
sarcoidosis MLN and show plasticity towards pathogenic Th17.1 cells at chronically in-
flamed sites (14, 19) such as sarcoidosis lungs, but also granulomatous parts of the MLN. 
High levels of cytokines, such as IL-12 or IL-23, which can induce a Th17 shift towards 
Th17.1 cells are found in sarcoidosis lungs (14, 17, 19, 28). Increased protein expression 
of IL-12 (p70 and p40) is found consistently within sarcoidosis lungs (4, 6, 29). Although 
IL-23p19 expression in sarcoid lungs remains uncertain, high expression of IL-12p40 
compared with IL-12p70 may very well indicate elevated levels of IL-23 (29), since IL-
12p40 is also a subunit of IL-23 (21). Notably, IL-23 transcription was enhanced in sarcoid 
skin lesion compared with controls (30), and serum amyloid A (SAA), an antigen that was 
speculated to contribute to development of chronic (pulmonary) sarcoidosis (31), has 
been described to increase IL-23 production by dendritic cells (32). Strikingly, BALF IL-
12p40 protein levels are highest in patients developing chronic disease (33). Neverthe-
less, our data do not exclude the possibility of additional selective Th17.1 cell migration 
towards sarcoidosis lungs (19), attracted by high local co-expression of IP-10/CXCL10 
(5) and CCL20 (34). To provide further evidence for enhanced Th17-Th17.1 plasticity in 
sarcoidosis, future studies could focus on T-cell receptor repertoire distribution within 
sarcoidosis CCR6+ Th cell populations in different immunological compartments and 
should aim to identify indispensable contributors to sarcoidosis Th17 plasticity. 
Interestingly, we found significantly higher Th17.1 cell proportions at time of di-
agnosis in lungs of patients who develop chronic disease compared to patients who 
underwent resolution. Together with our previous finding of increased BALF Th17.1 
cells proportions in a population that included progressive patients who are on first-, 
second- and/or third-line therapy (22), these data strongly argue for a pathogenic role 
for Th17.1 cells in the development/progression of pulmonary sarcoidosis. Remarkably, 
two independent single-nucleotide polymorphisms (SNPs) within the IL23R gene locus 
were found to predispose for (chronic) sarcoidosis (35, 36) and IL-23R expression is 
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essential for conversion of Th17 cells towards pathogenic Th17.1 cells during chronic 
inflammation in mice (17, 37). The most recent genome-wide association study (GWAS) 
identified one SNP within the putative promoter region of the IL23R gene, which might 
influence IL-23R expression (36). The functional prediction and protein network analyses 
of the identified candidate susceptibility genes provided a prominent role for IL-23/
Th17-signaling pathway in the genetic etiology of the sarcoidosis (36). Together with our 
data, this implies that genetic variations within the IL23R gene or other genes involved 
in the IL-23/Th17-signaling pathway may predispose for (chronic) sarcoidosis, by sup-
porting the conversion of Th17 to Th17.1 cells or by stabilizing Th17.1 cells. Therefore, 
specific targeting of IL-23R signaling, e.g. by Tildrakizumab/Guselkumab (anti-IL-23p19) 
which was recently described to be successful in psoriasis (38), might be a promising 
new therapeutic approach in (chronic) sarcoidosis.
However, additional prospective studies investigating CCR6+ Th17-lineage function, 
such as cytokine production, in sarcoidosis patients with a distinct disease prognosis are 
needed to address the functional complexity of Th17-lineage cells. This is highlighted 
by recently reported findings in Löfgren’s disease (39), a subtype of acute sarcoidosis 
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Figure 6
figure 6. Higher BALF Th17.1 cell proportions in patients developing chronic disease than patients un-
dergoing resolution. Disease course of a subgroup of patients (n=25) was determined 2 years after study 
inclusion and flow cytometric analyses. Resolution of disease (n=7) was defined by the absence of abnor-
malities on the chest X-ray and clinical symptoms. Patients with residual abnormalities on chest X-ray, but 
without need for treatment were designated as non-progressive chronic (n=11); and patients with need 
for treatment as progressive chronic (n=7). (A-B) Proportions Th17.1 and Th1 cells of total memory CD4+ T 
cells at time of diagnosis. (C) Ratio of the proportions of Th17.1 versus Th1 cells. Statistics: Horizontal lines 
indicate median values and significance was determined using a Mann-Whitney U test, * P < 0.05 ** P < 0.01. 
Abbreviations: Th = T helper. 
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whereby patients are unlikely to develop chronic disease. In these patients lung 
T-bet+RORγT+ CD4+ T cells, co-expressing CCR6 and CXCR3, were associated with a favor-
able disease outcome (39). Löfgren BALF however contained higher levels of favorable 
Th17 cytokines such as IL-17A, IL-10 and IL-2, but lower levels of IFN-γ compared with 
non-Löfgren patients, likely contributing to the favorable prognosis in Löfgren patients 
(39). 
In conclusion, this study is the first to show evidence that sarcoidosis Th17 cells are 
induced in MLN and supports a model in which they manifest plasticity towards Th17.1 
cells in the lung granulomatous microenvironment, where they are particularly critical 
for development of chronic disease. Our findings provide a new perspective on sarcoid-
osis pathogenesis and the potential of new therapeutic targets.
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Supplementary Figure E1
Supplementary figure  E1. Th cell subset classification according chemokine-receptor expression. Th 
cell subsets can be classified according to chemokine-receptor expression (1-5). CCR6- memory T cells 
subsets, including CCR4-CXCR3+ Th1 cells and CCR4+CXCR3- Th2 cells; and CCR6+ T cell subsets, which in-
clude CCR4+CXCR3- Th17 cells, CCR4+CXCR3+ DP Th cells and CCR4-CXCR3+ Th17.1 cells. Th17.1 cells (i.e. 
IFN-γ-producing Th17 cells) contain both IL-17A+/IFN-γ+ (Th17/Th1) cells and IFN-γ-single-positive cells. 
CCR6+CCR4+CXCR3+ DP cells are thought to reflect an intermediate Th17 and Th17.1 cell population (3, 4, 
6). Abbreviations: CCR = C-C chemokine receptor, CXCR = CXC chemokine receptor, DP = double-positive, 
Th = T helper. 
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Supplementary Figure E2
Supplementary figure  E2. Gating strategy to determine CD3+CD4+ T cell subsets. Five CD3+CD4+ T 
cell populations were characterized according to CD45RA and intracellular FoxP3 expression (7), i.e. 
CD45RA+FoxP3- naïve T cells, CD45RA-FoxP3- memory T cells, CD45RA-FoxP3int activated (non-suppressive/-
regulatory) T cells, CD45RA+FoxP3int naïve regulatory T cells and CD45RA-FoxP3high activated Tregs. The total 
memory T cell pool consists of memory T cells plus activated T cells. The total (non-suppressive/-regulatory) 
T cell pool consists of naïve T cells plus total memory T cells. Abbreviations: Treg = regulatory T cells. 
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Supplementary Figure E3
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Supplementary Figure E3
Supplementary figure E3. Expression of ICOS and CD25 in Th1, Th17, CCR6+ DP and Th17.1 cells in control 
and sarcoidosis mediastinal lymph nodes. (A) Mean fluorescence intensity of ICOS (data are from 7 controls 
and 4 patients) (B) Mean fluorescence intensity of CD25 (data are from 15 controls and 13 patients). Statis-
tics: Data are presented as boxplots and whiskers show the 10-90 percentile of the data. Mean fluorescence 
intensity was standardized to average expression in healthy control PB cells. Abbreviations: ICOS = Inducible 
T-cell costimulator, MFI = mean fluorescence intensity, DP = double-positive, Th = T helper, Ctrl = control, 
SRC = sarcoidosis.
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Supplementary Figure E4
Supplementary figure E4. Quantification of Th subset ratios in various patient groups. Disease course of a 
subgroup (n=25) of patients was determined 2 years after study inclusion. Resolution of disease (n=7) was 
defined by the absence of abnormalities on the chest X-ray and clinical symptoms. Patients with residual 
abnormalities on chest X-ray, but without need for treatment were designated as non-progressive chronic 
(n=11); and patients with need for treatment as progressive chronic (n=7) (8). (A) Proportions Th17 cells 
of total memory CD4+ T cells at time of diagnosis. (B) Ratio of proportions Th17.1 versus Th17 cells. Statis-
tics: Data are presented as boxplots and whiskers that show the 10-90 percentile of the data. Significance 
was determined using a Mann-Whitney U test. Abbreviations: BALF = broncho-alveolar lavage fluid, Th = T 
helper, SRC = sarcoidosis. 
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Supplementary Table E1. Study subject characteristics 
Subject characteristics mln Ctrl
(n=22)
Sarcoidosis
(n=55)
Median age (min-max) 47 (15-70) 43 (24-75)
Sex (Male/Female) 6/16 36/19
Scadding Stage (n (% of total))
Stage 0 5 (9)†
Stage I 20 (36)
Stage II 23 (42)
Stage III 4 (7)
Unknown 3 (6)††
Diagnosis was assessed by (n (% of total))
TBB-EBB 17 (31)
BALF CD4/CD8 > 3,5 8 (15)
E(B)US-FNA 26 (47)
Other (e.g. mediastinoscopy, other biopsy) 4 (7)
Extrathoracic involvement (n (% of total))
No/Yes 21/34
Skin 8 (15)
Eyes 16 (29)
Articular$ 22 (40)
Central nervous system 3 (6)
Other 6 (11)
† Three patients had Stage I and two patients had Stage II sarcoidosis, determined by CT scan. †† Two pa-
tients had Stage I and one patient had Stage II sarcoidosis, determined by CT scan. $ Self-reported articular 
involvement. Abbreviations: TBB: transbronchial biopsy, EBB: endobronchial biopsy, BALF: broncho-alveolar 
lavage fluid, E(B)US-FNA: Esophageal or endobronchial ultrasound guided fine-needle aspiration.  
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Supplementary Table E2. Overview antibodies 
Company antigen fluor chrome Clone
eBiosciences CD3 APC-eFluor780 SK7
CD4 AF700 OKT4
FoxP3 PE 236A/E7
CTLA4 PerCp-eFluor710 14D3
BD biosciences CCR6 APC 11A9
CXCR3 BV711 1C6/CXCR3
Ki67 Pe-Cy7 B56
CD28 BV605 CD28.2
PD-1 BV786 EH12.1
PD-1 BV711 EH12.1
CD25 PE-Cy7 M-A251
CD25 BV650 M-A251
CD278 (ICOS) BV650 DX29
R&D CCR4 FITC 205410
Biolegend CXCR3 BV421 G025H7
Invitrogen CD45RA PE-Texas Red MEM-56
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T-cell Immunology in Sarcoidosis: Disruption of a 
Delicate Balance between Helper and Regulatory 
T cells
‘The true sign of intelligence is not 
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Albert Einstein
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aBSTRaCT
Purpose of review
Although the etiology of sarcoidosis is not yet completely understood, immunological 
changes within the T-cell compartment are characteristic for an exaggerated antigen-
driven immune response. In this review, we describe the most recent findings on T-cell 
subset responses and regulation in sarcoidosis. We discuss how future immunological 
research can advance the field to unravel pathobiological mechanisms of this intrigu-
ingly complex disease.
Recent findings
Research into the field of T-cell plasticity has recently challenged the long-held T helper 
type (Th1) paradigm in sarcoidosis and striking parallels with autoimmune disorders 
and common variable immunodeficiency were recognized. For instance, it was dem-
onstrated that Th17.1 cells rather than Th1 cells are responsible for the exaggerated 
interferon (IFN)-γ production in pulmonary sarcoidosis. Furthermore, impaired regula-
tory T-cell (Treg) function and alterations within the expression of co-inhibitory recep-
tors that control T-cell responses, such as PD-1, CTLA4 and BTNL2, raise new questions 
regarding T-cell regulation in pulmonary sarcoidosis. 
Summary
It becomes increasingly clear that Th17(.1) cells and Tregs are key players in sarcoidosis 
T-cell immunology. New findings on plasticity and co-inhibitory receptor expression by 
these subsets help build a more comprehensive model for T-cell regulation in sarcoidosis 
and will finally shed light on the potential of new treatment modalities. 
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InTRoDUCTIon
Sarcoidosis is a complex systemic inflammatory disease of unknown etiology character-
ized by the presence of noncaseating granulomas in various organs, with pulmonary 
involvement in more than 90% of patients (1). In pulmonary sarcoidosis, granulomas are 
most commonly found in the alveolar septa, near lymphatic vessels and in lung-draining 
lymph nodes. Granulomas consist of a core of histiocytes, that is differentiated tissue 
macrophages and multinucleated giant cells, surrounded by lymphocytes, especially 
CD4+ T helper (Th)-cells (2). In 30-50% of sarcoidosis cases, progression towards active 
chronic disease is seen with need for therapy (3). 
Sarcoidosis etiology is incompletely understood, but immunological changes within 
the T-cell compartment are characteristic for an exaggerated antigen-driven immune 
response (4). Immunological changes include enhanced local expression of Th1/Th17 
cytokines and chemokines, dysfunctional regulatory T-cell (Treg) responses, and oligo-
clonal expansion of Th cells consistent with chronic antigenic stimulation. Candidate 
T-cell targets may be pathogen-derived (e.g. mycobacterial 6-kDa early secreted anti-
genic target (ESAT-6) or catalase-peroxidase (KatG)) or auto-antigens (e.g. vimentin and 
zinc finger protein 688 (ZNF688)) (5, 6). Alternatively, pulmonary infections may initiate 
local pathogen-specific T-cell responses cross-reacting with sarcoidosis-associated au-
toantigens, referred to as molecular mimicry (7). Although it was traditionally believed 
that memory T cells can only be stimulated in an antigen-dependent manner, recently it 
became clear that they can also be activated by key cytokines without the need for T-cell 
receptor (TCR) stimulation (8, 9).
In this review, we describe recent findings on T-cell subset responses and regulation 
in sarcoidosis. It is well accepted that regulatory mechanisms within T cells and the bal-
ance between T-cell subsets is critical to maintain tolerance and prevent inappropriate 
activation. Moreover, emerging evidence for T-cell plasticity raise new questions within 
sarcoidosis etiology. We end with speculations on how future immunological research 
can advance the field to unravel pathobiological mechanisms of this intriguingly com-
plex disease. 
T-cell response in sarcoidosis
In sarcoid granulomas CD4+ T-cells are abundantly present and play a key pathogenic 
role (2). Naive Th cells are primed by TCR stimulation through peptide/HLA-DR complex 
from an antigen-presenting cell (APC), whereby proliferation occurs before lineage 
specification begins. Concomitant with their activation, naive T cells undergo differen-
tiation under the influence of cytokines, resulting in the induction of lineage-specific 
transcription factors, and epigenetic modifications at the cytokine loci, which then 
result in subset-specific cytokine production and lineage commitment. Consequently, 
different Th subsets have been identified based on their cytokine secretion: Th1 cells 
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mainly produce interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), Th2 
cells interleukin-4 (IL-4), IL-5, and IL-13, and Th17 cells IL-17A and IL-22 (10). Furthermore, 
Tregs dampen inflammatory responses through cell-cell interaction and secretion of IL-
10 and transforming growth factor beta (TFG-β). However, it has become increasingly 
clear that Th cells do not always commit to one lineage, but maintain flexibility to change 
subset type or to increase the range of cytokines that they produce (11). Additionally, 
differentiated Th cells can adopt mixed phenotypes, whereby stable hybrid cells co-
express lineage-specific transcription factors and co-produce cytokines characteristic 
for two opposing differentiation programs (12-14). Discoveries in the field of T-cell plas-
ticity have recently challenged long-held paradigms on T-cell responses in sarcoidosis. A 
schematic model including novel findings on T-cell responses in sarcoidosis is shown in 
Figure 1 and discussed in text below.
T helper cells
Sarcoidosis was thought to be a Th1-cell-driven disease, because of high expres-
sion of IFN-γ in Th cells and the presence of Th1-skewing cytokines IL-12 and IL-18 
in granulomatous organs (15-17). Subsequently, next to IFN-γ-producing cells, the 
presence of IL-17-producing cells was recognized in sarcoidosis patients during active 
and progressive pulmonary disease (18-23). Although their fractions remained lower 
than IFN-y-producing cells, both lung and circulating Th cells from patients showed 
significantly increased IL-17 and IL-23 receptor (IL-23R) expression compared with 
controls (18-20). However, it became clear that stringent classification of Th lineages 
based on cytokine production is unsuitable, as cells were found that produce cytokines 
of both the Th1 and Th17 lineage. Significantly increased proportions of IL-17A+/IFN-γ+ 
double-producing memory Th cells were observed within sarcoidosis peripheral blood 
and broncho-alveolar lavage fluid (BALF) (18-21). In sarcoidosis BALF, the proportions 
of IL-17A+/IFN-γ+ Th cells also increased with Scadding stage (21). Intriguingly, IL-17A+/
IFN-γ+ double-producers are described to be pathogenic in various human chronic 
auto-immune inflammatory disorders, such as Crohn’s disease and rheumatoid arthritis 
(RA) (24, 25). In these diseases, considerable progress has been made concerning the 
origin of IL-17A+/IFN-γ+ double-producing Th cells (26). It is generally believed that they 
originate from IL-17-single-positive Th cells (Th17) which are subsequently exposed to 
Th1-skewing cytokines, such as IFN-γ and IL-12 (25, 27). They express the chemokine 
receptor 6 (CCR6), CD161, IL-23R and RAR-related orphan receptor (ROR)γt, as well as 
IL-12Rβ2 and T-box transcription factor (TBX21)(T-bet). Furthermore, IL-17A+/IFN-γ+ Th 
cells can develop into IFN-γ-single-positive Th cells. Thus, two types of IFN-γ-producing 
Th cells exist, i.e. CCR6- Th1 cells and CCR6+ Th17-derived cells. The latter are referred to 
as Th17.1 cells based on CCR6 expression (Th17-lineage) in combination with CXC-motif 
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chemokine receptor 3 (CXCR3) (Th1-lineage) (24-26, 28, 29). Accordingly, expression of 
chemokine receptors can be used to define the origin of IFN-γ-producing cells. 
In collaboration with the group of dr. Koth, we have recently demonstrated that 
Th17.1 cells rather than Th1 cells are responsible for the exaggerated IFN-γ produc-
tion in pulmonary sarcoidosis (Figure 1), challenging the Th1 paradigm (30). In two 
independent sarcoidosis patient cohorts, including newly-diagnosed patients versus 
progressive patients, lung Th17.1-cell proportions were strikingly increased compared 
with controls (30). These findings raise new questions in the field, such as the role of 
these cells in disease development and treatment. For instance, both IFN-γ and IL-17 are 
essential in granuloma formation and multinucleated giant cell fusion (31-33) (Figure 1). 
Human Th17.1, and not Th17 cells, have a pathogenic signature and highly express the 
multi-drug resistance type 1 membrane transporter (MDR1) (24). MDR1+ Th17.1 cells are 
refractory to glucocorticoids that are used to treat clinical (auto)-immune disease and 
sarcoidosis (24). Although the pathogenic signature of human Th17.1 cells is character-
ized by high expression of IL23R, CSF2 (granulocyte-macrophage colony-stimulating 
factor (GM-CSF)), CCL20, and TBX21 (T-bet) (24, 34), classical Th17 cells display a non-
pathogenic Th17-signature that includes IL10, MAF, and AHR transcription (24)(Figure 
1). Interestingly, while IL-17 can influence the expression of proinflammatory cytokines 
such as TNF-α (35) and is able to mature granuloma formation (31), it was also found 
that HLA-DR3.01+ Löfgren patients have an increase in IL-17 in BALF compared with 
non-Löfgren sarcoidosis patients (22), suggesting that classical Th17 cells in sarcoidosis 
can exhibit a non-pathogenic phenotype. In Crohn’s disease, the non-pathogenic role 
for Th17 cells was recognized, as clinical trials with blocking IL-17A or IL-17RA showed 
exacerbation of symptoms in some cases (36, 37). Lastly, IL-23R expression is essential 
for conversion of Th17 cells towards pathogenic Th17.1 cells during chronic inflamma-
tion (38), and functional prediction and protein network analyses identified a prominent 
role for IL-23/Th17-signaling pathway in the genetic etiology of sarcoidosis (39, 40). 
Although involvement of IFN-γ-producing Th17 cells point to a striking parallel be-
tween sarcoidosis and RA/Crohn’s disease, it cannot be taken as evidence for an autoim-
mune etiology of sarcoidosis, as pathogens such as Candida albicans can also induce 
IFN-γ-producing Th17-cells (41). However, one of the outstanding questions that remain 
in sarcoidosis is why specific T cells are driven into the Th17 lineage. In this context, 
it is interesting that IFN-γ can promote B-cell-activating factor (BAFF) production by 
monocytes (42) and strikingly BAFF is needed for APC-driven Th17-cell differentiation 
in vitro in RA (43). This has relevance for sarcoidosis, since elevated serum BAFF levels 
are observed (42, 44). It is currently unclear whether increased BAFF levels in sarcoidosis 
affect B-cell selection or activity. However, peri-granuloma localization of B cells and 
plasma cells (45) may indicate the involvement of antigen-specific B cells. 
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Regulatory T cells
Tregs are a subpopulation of T cells that control the immune system, maintain tolerance 
to self-antigens, and abrogate autoimmune disease. A role for Tregs in the pathogen-
esis of sarcoidosis has long been suggested (46, 47), although there is inconsistency 
in the reported findings. Depending on the affected-organ and time of evaluation 
(e.g. at time of diagnosis or during progressive/chronic disease), either an increase or 
decrease in their proportions in BALF or peripheral blood have been shown (2, 48, 49). 
However, decreased immunosuppressive function of Tregs from sarcoidosis patients has 
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figure 1. T-cell activation in pulmonary sarcoidosis. T-cell activation is initiated by antigenic peptide pre-
sentation in HLA-DR on APCs recognized by their responsive TCR on T cells. Possible antigens in sarcoidosis 
are thought to be of mycobacterial origin, auto-antigens or even molecular mimicry of pathogens. Memory 
Th cells might also be activated through a TCR-independent manner, for example, by key cytokines. IL-17-
producing Th cells have been recognized in the pathobiological response in sarcoidosis and come in dif-
ferent flavors, being either benign (Th17 cells, expressing also IL-10, AHR and MAF) or pathogenic (Th17.1 
cells, expressing next to Th17-lineage markers such as RORγt and CCR6, markers from the Th1-lineage, such 
as T-bet, CXCR3). Th17.1 cells are also capable of producing a sarcoidosis key cytokine, IFN-γ, either solely 
or together with IL-17. IFN-γ, next to IL-12 and IL-23, also promotes the conversion of Th17 cells into Th17.1 
cells. IFN-γ and IL-17 both promote granuloma formation and fusion of multinucleated giant cells. Tregs 
in sarcoidosis have a terminally differentiated phenotype shown by CD45RO and CD15s expression, are 
apoptosis-prone probably because of increased Fas expression, and consequently have impaired immuno-
suppressive function. Abbreviations: APC = antigen presenting cell, CCR6 = chemokine receptor 6, CXCR3 
= C-X-C chemokine receptor 3, FoxP3 = forkhead box P3, GM-CSF = granulocyte-macrophage colony-stim-
ulating factor, HLA = human leukocyte antigen, IFN-γ = interferon gamma, IL = interleukin, MDR1 = multi 
drug resistant receptor 1, RORγt = RAR-related orphan receptor, T-bet = T-box transcription factor TBX21, 
TCR = T-cell receptor, TGF-β = transforming growth factor beta, Th = T helper, Treg = regulatory T-cell.
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consistently been observed (47, 49-53). On the basis of CD45RA and forkhead box P3 
(FoxP3) expression Tregs can be classified into naïve (CD45RA+FoxP3int) and activated 
(CD45RA-FoxP3high), both having the capacity to reduce T-cell responses (54). In sar-
coidosis patients, especially activated Tregs are increased in peripheral blood (54) and 
express CD15s (sialyl Lewis x), a ligand for the selectins CD62E and CD62P (55). CD15s 
expression is highly specific for activated, terminally differentiated, and the most sup-
pressive FoxP3high Tregs (55). Particularly in sarcoidosis patients, these CD15s+FoxP3+ 
Tregs were reported to be increased, however whether their immunosuppressive capac-
ity was altered was not investigated (55). As CD15s+ Tregs are terminally differentiated, 
it is plausible that they are ‘exhausted’ in sarcoidosis, as suggested before (50). Interest-
ingly, Tregs from sarcoidosis patients were recently found to express more CD45RO and 
Fas, both pointing towards an activated and apoptotic-prone phenotype (49). Since 
sarcoidosis Tregs indeed displayed impaired survival compared with control Tregs, this 
may contribute to their insufficient immunosuppressive capacities (49). Loss of T-cell 
regulation in sarcoidosis can also be caused by a reduced number and exhaustion of 
invariant natural killer T cells, an additional regulatory lymphocyte (56-58).
Early developmental programs of induced Tregs and Th17-cells show that these cell 
types are intimately linked. This is reflected by the lineage-specific transcription factors 
FoxP3 and RORγt, which are both downstream of TGFβ signaling (59). Differentiation of 
Tregs is not static and Tregs can differentiate into Th17 cells (60). Even IL-17-secreting 
Tregs are observed and they exert suppressive capacities in vitro but lose this capac-
ity upon stimulation with the pro-inflammatory cytokines IL-1β and IL-6 (61). As both 
loss of Treg function and induction of Th17 cells are observed in sarcoidosis, and since 
pathogenic conversion of FoxP3+ T cells into Th17 cells has been found in autoimmune 
arthritis (62), it would be worthwhile to investigate the plasticity of Tregs towards Th17 
cells and the presence of IL-17-producing Tregs in sarcoidosis. 
T-cell regulation in sarcoidosis
Little is known about underlying mechanisms leading to the above described exag-
gerated Th-cell response and Treg impairment in sarcoidosis (Figure 1). Both regula-
tory mechanisms within T cells (e.g. by checkpoint inhibitors) and the balance between 
proinflammatory and anti-inflammatory T cells are critical to maintain tolerance and 
prevent inappropriate activation.
Co-stimulatory and co-inhibitory receptors on T cells play a pivotal immune-regulatory 
role, as they determine the functional outcome of TCR signaling and consequently T-cell 
proliferation and cytokine production. Alterations in the expression of co-inhibitory 
receptors that keep T-cell responses in check, such as cytotoxic T-lymphocyte antigen 
4 (CTLA4), butyrophilin-like 2 (BTNL2) and programmed death-1 (PD-1), have recently 
been described in the context of sarcoidosis. 
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CTLA4 is an important suppressor of T-cell–mediated immune responses by compet-
ing with CD28 for the shared ligands CD80 and CD86 expressed on APCs. As CTLA4 
has a higher affinity for CD80/86 relative to CD28, CTLA4 restrains CD28 signaling (63). 
Therefore, while CD28 engagement promotes T-cell proliferation and differentiation, 
CTLA4 engagement attenuates T-cell responses. A possible role of CTLA4 in sarcoidosis 
pathogenesis linked to the Th17 subset was first suggested by the striking phenomenon 
of ‘biotherapy-induced sarcoidosis’. In several case reports, cancer patients receiving 
CTLA4 checkpoint inhibition (e.g. ipilimumab treatment) developed granulomas (64, 
65). Interestingly, in patients receiving CTLA4 blockade the numbers and proportions of 
circulating IL-17–producing Th cells increased (66). Although it remains unclear whether 
Treg proportions are affected, CTLA4 blockade is known to impair Treg-mediated sup-
pression (63). As in sarcoidosis abnormal Th17-cell and Treg responses are observed (2), 
we analyzed CTLA4 expression and intriguingly found that specifically Th17 cells and 
Tregs in sarcoidosis mediastinal lymph nodes (MLN) displayed decreased CTLA4 expres-
sion (64). Solely Th17-cell proportions in sarcoidosis MLN were increased, whereas Treg 
proportions remained unaffected (64). Decreased CTLA4 expression is likely to impair 
Treg immuno-regulatory function and specifically induce proinflammatory Th17 dif-
ferentiation and proliferation, and thus to cause ‘double trouble’ (Figure 2) (64). Hereby, 
it is conceivable that reduced CTLA4 expression aggravates underlying or pre-existent 
disease, or alternatively that it is driving the disease. 
BTNL2 negatively regulates T-cell activation independently of CD28 and CTLA4. It 
promotes de-novo FoxP3 expression during T-cell activation and the development of 
suppressive Tregs (67). A splicing variant in the BTNL2 gene has been associated with sar-
coidosis (68) and a recent meta-analysis showed that BTNL2 rs2076530 polymorphism 
even contributes to the risk of sarcoidosis (69). Strikingly, CTLA4 and BTNL2 gene muta-
tions have also been identified in families with common variable immunodeficiency 
(CVID), including patients with granulomatous lung disease that shows some striking 
resemblance with sarcoidosis (70, 71). Additionally, coding and loss-of-function variants 
in BTNL2 have been associated with susceptibility to other immune related disorders 
such as RA and Crohn’s disease (72, 73), in which Th17 cells and Th17.1 cells are also 
important drivers of disease. Whether BTNL2 expression, like CTLA4 (74), is important 
in Th17 lineage commitment needs further investigation. However, in the view of the 
closely developmental programs of Tregs and Th17 cells and the role of BTNL2 in driving 
Tregs (67), its importance in Th17-cell development is plausible. 
Thus, hypothetically, due to decreased CTLA4/BTNL2 expression, decreased suppres-
sion of T(h17)-cell function occurs, leading to on-going inflammation (64). However, 
during active disease, increased proportions of PD-1-expressing cells have been found 
within Th cells in sarcoidosis peripheral blood and BALF compared with healthy controls 
(75). Sarcoidosis IL-17-producing Th cells highly expressed PD-1 (75); however, it remains 
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unknown whether PD-1 expression is increased compared with BALF control IL-17+ T 
cells. Paradoxically to these findings, recently sarcoid-like granulomas were observed 
in MLN and skin in a patient receiving anti-PD1 treatment (65). Strikingly, in a small 
sarcoidosis patients cohort a trend towards decreased PD-1 expression was observed on 
Th17 cells in MLN (64). Co-inhibitory receptor expression is likely differentially regulated 
in sarcoidosis-affected organs, since expression of co-inhibitory receptors depends on 
the strength of T-cell stimulation, mediated by TCR and CD28 expression (76). These 
data highlight the need for further studies to clarify co-inhibitory receptor expression of 
distinct Th subsets in different sarcoidosis-affected organs. Also, clarification of conflict-
ing results regarding the co-stimulatory receptor CD28 in sarcoidosis (51, 64, 77, 78) 
is warranted in order to devise a comprehensive model explaining impaired immune 
regulation in sarcoidosis. Whereas an impaired T-cell function in response to TCR stimu-
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figure 2. Effect of reduced CTLA4 expression on Tregs and Th17 cells in sarcoidosis mediastinal lymph 
nodes. (A) In healthy controls Tregs highly express CTLA4 and indirectly inhibit T-cell activation via CD80/86 
engagement on APCs, leading to restricted CD80/86 ligand availability on APCs, inducing tolerance (63). 
Also Th17 cells highly express CTLA4, which competes with CD28-ligand binding. Therefore, Th17 cells 
are sensitive towards CTLA4 co-inhibition, leading to suppressed Th17 differentiation, activation and/or 
proliferation in healthy individuals (74). (B) Biotherapy-induced sarcoidosis by anti-CTLA4 treatment (e.g. 
ipilimumab) leads to enhanced CD80/86 ligand availability on APCs and decreased competition with CD28-
ligand binding on Th17-cells. This can increase Th17-cell differentiation and activation. (C) In sarcoidosis 
patients, Tregs show decreased CTLA4 protein expression leading to enhanced CD80/86 ligand availability 
on APCs (Trouble 1) and thus a reduced anti-inflammatory response. Additionally, sarcoidosis Th17 cells 
show decreased CTLA4 protein expression, leading to impaired competition with CD28-ligand binding on 
Th17 cells and therefore enhanced Th17-cell differentiation and activation (Trouble 2). Abbreviations: APC = 
antigen presenting cell, CTLA4 = cytotoxic T lymphocyte antigen 4, HLA = human leukocyte antigen, TCR = 
T-cell receptor, Th = T helper, Treg = regulatory T-cell. Figure adapted from Broos et al. (64). Reprinted with 
permission of the American Thoracic Society. 
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lation was previously found in active sarcoidosis (53), but spontaneous IL-2 and IFN-γ 
production is highly increased compared with controls; Th cells in sarcoidosis may have 
become less dependent on CD28 signaling as is observed in chronic beryllium disease, 
resulting in dysregulated PD-1 and CTLA4 pathways (79, 80). 
Finally, co-inhibitory and co-stimulatory receptors differentially affect function and 
proportions of distinct T-cell subsets, which is critical to maintain tolerance and prevent 
inappropriate activation. Interestingly, it was recently found that Treg/Th17 cell ratios 
are higher in peripheral blood of sarcoidosis patients who remained stable after cortico-
steroid withdrawal compared with relapsing patients (81). Furthermore, during relapse 
treatment with corticosteroids and methotrexate the proportions of Tregs increased, 
Th17 cells decreased, and Th1 cells and Th2 cells remained stable (81). Since Treg/Th17 
ratios also inversely correlated with serum angiotensin converting enzyme levels, and 
positively correlated with lung function parameters, these data, together with above-
described recent findings in sarcoid T-cell immunology, highlight that Th17 and Treg 
cells are key players in sarcoidosis pathogenesis (Figure 1 and Figure 2).
ConClUSIon
These recent immunological findings in pulmonary sarcoidosis highlight the need for 
an in-depth characterization of T-cell subsets. Experimental findings in other chronic 
inflammatory diseases, such as RA and Crohn’s disease, can help determine the most 
relevant markers to identify T-cell subsets. Once T-cell subsets can be accurately charac-
terized and isolated, T-cell function and regulation in sarcoidosis warrant careful review-
ing, since current results sometimes remain contradictory, such as the role of checkpoint 
inhibitors that we have highlighted above. 
Future directions: how can we get ‘from the core to a cure’?: Because sarcoidosis is char-
acterized by an immune paradox, that is, a hyperactive immune system at site of inflam-
mation and anergy in peripheral blood (47), it is important to clarify Th-cell function and 
regulation in different sarcoid-affected organs in order to build a comprehensive model 
of the in-vivo behavior and dynamics of different Th-cell subsets in sarcoidosis. This will 
also help on-going endeavors to identify candidate antigens in sarcoidosis. If key players 
of (chronic) sarcoidosis are well defined, sophisticated studies that have already recently 
taken place in Löfgren patients (5), can help analyze the structure of the TCR and use 
prediction models to identify new candidate antigens. For example, in-depth charac-
terization of TCR specificity in HLA-DR3.01+ Löfgren patients has led to identification of 
new peptides, such as vimentin, as potentially involved antigens (5). While the search 
for the Holy Grail, that is, the antigen, remains essential, it is obvious that T-cell plasticity 
warrants further attention and research, because determinants of T-cell plasticity may 
turn out to be promising new therapeutical targets in (chronic) sarcoidosis. 
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Note added in proof: During the publication processes of this review, a new paper of 
specific interest was published by Kaiser et al. (82), showing that also in BALF of Löfgren 
patients T-bet+RORγt+ CD4+ T cells, co-expressing CCR6 and CXCR3, were significantly 
increased. Interestingly, cytokine production was more heterogeneous, with higher 
IL-17A, IL-10 and IL-2, but lower IFN-γ, which may contribute to a favorable prognosis in 
Löfgren patients. 
key points
- Th17(.1) cells and Tregs are key players in sarcoidosis T-cell immunology
- Th17.1 cells, rather than Th1 cells, are the main source of IFN-γ in sarcoidosis-affected 
organs.
- T-cell plasticity likely occurs in granulomatous tissues of sarcoidosis patients
- Sarcoidosis likely advances due to an imbalance between co-inhibitory and co-
stimulatory molecules on Th17 cells and Tregs. 
- Clarification of Th-cell characteristics, function and regulation in different sarcoid-
affected organs can help build a comprehensive model of the in-vivo behavior and 
dynamics of different Th-cell subsets in sarcoidosis. 
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aBSTRaCT
Background: Prednisone is used as first-line therapy for pulmonary sarcoidosis. What 
dosing strategy has the best balance between effect and side-effects is largely unknown. 
Therefore, we analyzed change in forced vital capacity (FVC) and weight during differ-
ent prednisone doses used in daily practice for treatment naïve pulmonary sarcoidosis 
patients.
methods: Multilevel models were used to describe FVC and weight change over time. 
Correlations were calculated using linear regression models. 
Results: Fifty-four patients were included. FVC changed over time (P < 0.001), with an 
average increase of 9.6% predicted (95% CI: 7.2 to 12.1) at 12 months. Weight changed 
significantly over time (P < 0.001), with an average increase of 4.3 kg (95% CI: 3.0 to 5.6) 
at 12 months. There was little correlation between prednisone dose and FVC change 
at 3, 12 and 24 months, while weight increase correlated significantly with cumulative 
prednisone dose at 24 months. In patients treated with a high cumulative prednisone 
dose, baseline FVC was on average lower (P = 0.001) compared to low dose treated 
patients, while no significant differences were observed in need for second/third-line 
therapy or number of exacerbations. A strategy leading to a low cumulative dose at 12 
months was defined by rapid dose tapering to 10 mg/day within 3.5 months. 
Conclusions: These results suggest that prednisone therapy aimed at improving or 
preserving FVC in newly treated pulmonary sarcoidosis can often be reduced in dose, 
and highlight the need for prospective trials carefully monitoring treatment efficacy of a 
lower dose treatment regimen, characterized by early dose tapering. 
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InTRoDUCTIon
Sarcoidosis is a multisystem, granulomatous disease affecting the lungs in 90% of the 
cases (1). Approximately 30-50% of the patients develop progressive and debilitating 
disease with need for therapy (1, 2). The recommended first-line therapy for pulmonary 
sarcoidosis is prednisone (1, 3-5). Although prednisone treatment in pulmonary sarcoid-
osis is reported to induce short-term benefits on clinical symptoms and inflammation, it 
remains unclear whether the therapy modifies long-term progression of the disease (4). 
Therapy should therefore primarily be aimed at symptom relief, inflammation control to 
prevent (further) organ damage and improving patient’s quality of life while avoiding 
unnecessary side effects (6-9).
A meta-analysis of corticosteroids for pulmonary sarcoidosis concluded that evidence 
for the best corticosteroid treatment strategy is lacking (4). The suggested initial predni-
sone dose varies between 20-40 milligrams (mg) (1) or 0,5 mg per kilogram (kg) (5) per 
day for 1-3 months. Subsequently, prednisone dose should be tapered to a maintenance 
dose of 5-10 mg/day, which is commonly continued for 6-12 months before discontinua-
tion (1, 5). As these guidelines include a broad range in recommended prednisone doses, 
variation in treatment regimen in clinical practice is suspected, varying from low- to 
high-dose treated patients. Prolonged high dose corticosteroid therapy is associated 
with numerous side effects, including weight gain, diabetes and osteoporosis (7, 10). 
What dosing strategy has the best balance between effect and side-effects is largely 
unknown. Therefore, in this study we aimed to evaluate treatment effect on forced vital 
capacity (FVC) (effect) and weight (side-effect) of different prednisone doses used in 
daily practice. 
mEThoDS
Study design
This study is a multicenter retrospective study, performed in one academic sarcoidosis 
referral center (Erasmus MC) and three regional training hospitals (Franciscus Gasthuis, 
Ikazia hospital and Amphia hospital) in the Netherlands. Medical records were reviewed 
for demographic and diagnostic data, organ involvement, radiographic Scadding 
stage, prednisone dose, weight, pulmonary function parameters and exacerbations. An 
exacerbation was determined as an increase in daily prednisone dose from 5-10 mg/
day maintenance dose to ≥ 20 mg/day. Data that was available up to 5 years follow-
ing therapy initiation were collected per patient. Individual prednisone regimens were 
analyzed. Weight was collected from pulmonary function records. 
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Patients
Treatment naïve sarcoidosis patients, in whom prednisone therapy was started for a 
pulmonary indication between January 2000 and December 2013, were included in this 
study. Patients were identified by screening medical records of patients that were in 
hospital-specific databases that track sarcoidosis diagnosed patients over time. Patients 
were included when they met standard criteria for diagnosis of the disease (1), were 
treatment naive and had a treatment indication for pulmonary sarcoidosis as determined 
by the treating physician. Patients were excluded when they were: 1. primarily treated 
for a non-pulmonary indication; 2. treated solely with methotrexate for a pulmonary 
indication; and 3. when there were less than two hospital visits documented. 
Ethical requirements
Formal consultation with the Medical Ethical Committee of the Erasmus MC learnt 
that, under the Dutch act for medical research involving human subjects (Wet Medisch 
Onderzoek), approval of this study by the Medical Ethical Committee was not required. 
The local institution review board of all participating centers approved with registration 
number MEC-2014-089.
Statistical analysis
The comparison of means of continuous variables were tested with the student t test, 
the categorical variables were tested with the X2 or the Fisher exact test. Absolute 
changes in FVC and weight were used as outcome in multilevel models. Log time ap-
peared to be an adequate transformation to enter as fixed factor in the model, while 
patient functioned as a random intercept. For different points in time we analyzed the 
correlation between cumulative prednisone dose and the absolute change in outcome 
between start of treatment and the specific time point. Correlations were calculated 
using linear regression models. 
FVC is shown as mean percent (%) predicted (± standard deviation (SD)) or as mean 
absolute change of % predicted (including a 95% confidence interval (CI)) compared 
to baseline. Weight is shown as mean kg (± SD) or as mean absolute change (including 
95% CI) in kg compared to baseline. Prednisone dose is shown as mean daily dose in 
milligrams (mg) or as cumulative dose in mg. 
For pulmonary function tests the European Community for Steel and Coal 1993 pre-
diction equations were used in all hospitals.
Statistical analyses were performed using SPSS (version 21.0.0.1) and R software (ver-
sion 3.2.2). Figures were created with R software. A P-value < 0.05 was considered as 
statistically significant. 
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RESUlTS
Patients
A total of 54 treatment naïve sarcoidosis patients that were initiated on prednisone 
therapy for a pulmonary indication were identified for this study; two third from re-
gional hospitals and one third from an academic referral center for sarcoidosis. Mean % 
predicted FVC at start of prednisone treatment was 83.4 ± 20.4, and mean % predicted 
diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin 
levels) was 69.9 ± 25.0 (Table 1). Average weight was 79.2 ± 19.2 and average body mass 
index (BMI) was 26.6 ± 5.9 kg/m2; 48.1% of the patients were men and 71.1% of the 
patients had Scadding stage II sarcoidosis. Additional baseline characteristics are shown 
in Table 1. 
fVC change upon prednisone treatment
Mean initial prednisone dose was 32.6 ± 8.7 mg (Table 1). On average, prednisone was 
tapered to 10 mg/day at approximately 6 months (Figure 1 and Figure E2). Mean FVC (% 
predicted) change over time was calculated using a multilevel model that incorporated 
regression lines of all 54 individual patients (Figure E1). FVC changed significantly over 
time (P < 0.001), with an average increase of 7.4 % predicted (95% CI: 5.5 to 9.3) at 3 
months and 9.6 % predicted (95% CI: 7.2 to 12.1) at 12 months (Figure 1). At 24 months, 
an average increase of 10.8 (95% CI: 8.0 to 13.5) was observed (Figure 1), which was 
largely preserved in patients with data available at 3 and 5 years following therapy initia-
tion (Figure E1A). Interestingly, the major increase in FVC occurred within 1-3 months of 
treatment (Figure 1). 
fVC change and prednisone dose
The association between change in FVC and prednisone dose used, was determined. 
Although all correlations were weakly positive, no significant correlation was found 
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Figure 1
figure 1. FVC change after initiation of predni-
sone therapy. FVC change over time during pred-
nisone treatment. Percent predicted FVC change 
compared to baseline (absolute change; blue 
line) and the mean prednisone dose given per 
day in milligrams of patients with available data 
is shown. Statistics: Data is calculated using a 
multilevel model with FVC over time as outcome. 
Abbreviations: FVC = forced vital capacity, mg = 
milligrams. 
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Table 1. Baseline characteristics of study cohort 
Characteristics Patients n=54
Age 44 ± 13
Gender
Male 26 (48,1)
Female 28 (51,9)
Treated in
Academic center 18 (33,3)
Training hospital 36 (66,7)
Race/Ethnicity
Unknown 17 
White 23 (62,2)
Black 7 (18,9)
Hispanic 7 (18,9)
BMI in kg/m2 (n=52) 26,6 (± 5,9)
Weight in  kg (n=52) 79,2 (± 19,2)
Smoking
Unknown 8 
Never 21 (45,7)
Current 7 (15,2)
Former 18 (39,1)
Scadding stage
Unknown 9 
I 8 (17,8)
II 32 (71,1)
III 5 (11,1)
Extra pulmonary organ involvement* 
No/Yes 26/ 28
Skin 7 (13)
Eyes 14 (25,9)
Joints 15 (27,8)
Other (e.g. liver, heart, neural) 9 (16,7)
Prednisone dose at start 32,6 ± 8,7
>10 ≤20 mg 6 (11,2) 
>20 ≤30 mg 32 (59,3)
>30 ≤40 mg 12 (22,2)
>40 ≤50 mg 2 (3,7)
>50 ≤60 mg 2 (3,7)
Pulmonary function tests
% predicted FVC (n=42) 83,4 ± 20,4
% predicted DLCO (n=34) 69,9± 25,0
Categorical data is presented as No. (% of total patients with available data) and continuous data as mean 
± SD of patients with available data (No. of patients with available data is presented behind the continuous 
variable). Abbreviations: CNS: central nervous system, DLCOc: diffusing capacity of lung for carbon monox-
ide (corrected for hemoglobin levels), FVC: forced vital capacity, kg: kilograms, mg: milligrams. *As assessed 
and described by the treating physician.
Prednisone dose and FVC change in sarcoidosis
161
between FVC change and cumulative prednisone dose used in the short-term (3 (Figure 
2A), 6 (not shown) and 9 months (not shown)) and long-term (12 (Figure 2B) and 24 
months (Figure 2C)). At 12 months, the correlation became almost zero after correction 
for start FVC (correlation: -0.07, P = 0.76). Similarly, no significant correlation was found 
between the average daily prednisone dose used in the first 3 months and FVC change 
(Figure E3). 
weight change upon prednisone treatment
To gain insight in side effects occurring during prednisone treatment, we captured 
weight change over time using a multilevel model (Figure E4). Weight changed signifi-
cantly over time (P < 0.001), with an average increase of 3.3 kg (95% CI: 2.3 to 4.3) at 3 
months and 4.3 kg (95% CI: 3.0 to 5.6) at 12 months (Figure 3). After tapering of the 
prednisone dose to a mean of ≤ 5 mg/day, weight remained increased compared with 
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Figure 2
figure 2. Association between FVC and pred-
nisone dose. Correlation between percent pre-
dicted FVC change and cumulative prednisone 
dose in milligrams used in the short term at (A) 
3 months, and long-term at (B) 12 months and 
(C) 24 months. The cumulative prednisone dose 
used was calculated per individual at time of an 
available FVC around month 3, 12 and 24 fol-
lowing treatment initiation. The correlation was 
analyzed using Spearman’s rank-order correla-
tion test. The regression line with the correlation 
and P-value are shown in the plot. Abbreviations: 
FVC = forced vital capacity, % pred = percent pre-
dicted, mg = milligrams. 
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baseline with an average of 4.8 kg (95% CI: 3.3 to 6.3) at 24 months, which persisted up 
to 5 years in patients with data available (Figure 3 and Figure E2). Similar to FVC change 
(Figure 1), the largest proportion of weight gain occurred during the first 1-3 months of 
treatment (Figure 3). 
weight change and prednisone dose
We aimed to determine whether weight change depends on total prednisone dose 
used. No significant correlation was found between weight change and cumulative 
prednisone dose used in the short-term at 3 (Figure 4A), 6 (not shown) and 9 months (not 
shown). Also, no significant correlation was found between daily prednisone dose used 
and weight change in the first 3 months (Figure E5). However, an association between 
cumulative prednisone dose and weight change became apparent and significant in the 
long-term at 12 (Figure 4B) and 24 months (Figure 4C), respectively. 
Prednisone regimen analysis
In order to gain insight in clinical practices that are associated with reduced prednisone 
use, we aimed to determine the average daily prednisone dose regimen administered 
to patients that received a relatively low versus a higher cumulative dose at 12 months. 
Therefore, patients with available data on prednisone therapy at 12 months (n=39) 
(Figure E2) were divided into a low dose and a high dose group. The median cumulative 
dose given at 12 months was 4000 mg (range 1050 to 13090 mg) thus patients who had 
received less than 4000 mg prednisone were assigned to the low dose group (n=20), 
and patients who had received 4000 mg prednisone or more were assigned to the high 
dose group (n=19). 
The average start dose of prednisone was lower in the low dose treated group than 
the high dose treated group, but this did not reach statistical significance (30.3 ± 9.1 
mg versus 36.1 ± 9.8 mg; P = 0.06) (Table 2). The treatment strategy leading to a lower 
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Figure 3
figure 3. Weight change after initiation of pred-
nisone therapy. Weight change in kilograms over 
time during prednisone treatment compared 
to baseline (absolute change; blue line) and the 
mean prednisone dose given per day in milli-
grams of patients with available data. The blue 
line is calculated using a multilevel model with 
weight over time as outcome. Abbreviations: kg = 
kilograms, mg = milligrams. 
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cumulative dose prednisone at 12 months seemed mainly characterized by earlier dose 
tapering, i.e. less than 10 mg/day at 3.5 months, whereas the high cumulative dose 
group was characterized by later dose tapering i.e. less than 10 mg/day at 6.9 months 
(Figure 5). 
low versus high dose prednisone
We examined baseline and therapy-response characteristics in order to determine fac-
tors associated with a treatment strategy leading to a high or low cumulative dose. 
No significant differences were observed between the high and low dose groups 
in baseline characteristics such as race/ethnicity (P = 0.76), Scadding stage (P = 1.00), 
weight (P = 0.83) or BMI (P = 0.87) (Table 2). Furthermore, no statistical significant differ-
ence was observed in the presence of extra pulmonary organ involvement (P = 0.15), but 
the low dose treated group tended to have more skin involvement (including 2 patients 
with erythema nodosum) than the high dose treated group (20% versus 0%, P = 0.11), 
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figure 4. Association between weight change 
and prednisone dose. Correlation between 
weight change in kilograms and cumulative 
prednisone dose in milligrams used in the short 
term at (A) 3 months, and long-term at (B) 12 
months and (C) 24 months. The cumulative pred-
nisone dose used was calculated per individual 
at time of an available weight around month 3, 
12 and 24 following treatment initiation. The 
correlation was analyzed using Spearman’s rank-
order correlation test. The regression line with 
the correlation and P-value are shown in the plot. 
Abbreviations: kg = kilograms, mg = milligrams. 
164
Chapter 7
Table 2. Baseline characteristics of low versus high dose treated patients
low dose n=20 high dose  n=19 P-value
Age 46 ± 14,0 (20) 43 ± 12,5 (19) 0.54
Gender
Male 9 (45) 9 (47,4) 0.88c
Female 11 (55) 10 (52,6)
Treated in
Academic center 3 (15) 6 (31,6) 0.27f
Regional hospital 17 (85) 13 (68,4)
Race/Ethnicity
Unknown 8 5 
White 8 (66,7) 7 (50,0) 0.76f
Black 2 (16,7) 4 (28,6)
Hispanic 2 (16,7) 3 (21,4)
BMI in kg/m2 27,5 ± 5,1 (18) 27,9 ± 6,8 (19) 0.87
Weight in kg 82,1 ±17,6 (18) 83,6 ± 23,1 (19) 0.83
Smoking
Unknown 4 1 
Never 7 (43,8) 9 (50,0) 0.34f
Current 4 (25,0) 1 (5,6)
Former 5 (31,2) 8 (44,4)
Scadding stage
Unknown 1 3 
I 4 (21,1) 3 (18,8) 1.00f
II 13 (68,4) 11 (68,8)
III 2 (10,5) 2 (12,5)
Extra pulmonary organ involvement* 12 (60) 7 (36,8) 0.15c
Skin 4$ (20) 0 (0) 0.11f
Eye 4 (20) 5 (26,3) 0.72f
Joint 6 (30) 7 (36,8) 0.65c
Other 1 (5) 4$$ (21,1) 0.18f
Multiple organs 2 (10) 7 (36,8) 0.07f
Prednisone dose use at start 30,3 ± 9,1 36,1 ± 9,8 0.06
>10 ≤20 mg 5 (25) 0 (0) 0.08f
>20 ≤30 mg 9 (45) 12 (63,2)
>30 ≤40 mg 5 (25) 4 (21,1)
>40 ≤50 mg 1 (5) 1 (5,3)
>50 ≤60 mg 0 2 (10,5)
PFT, % predicted
FVC 96,5 ±20,8 (16) 70,7 ±15,7 (14) 0.001
DLCOc 76,9 ± 20,6 (13) 64,7 ± 18,2 (13) 0.12
Prednisone dose and FVC change in sarcoidosis
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while high dose treated patients seemed to have more involvement of other organs, 
such as cardiac and neurological involvement (5% versus 21.1%, P = 0.18). Also, a trend 
was observed that high dose treated patients had more often multiple organs affected 
(10% versus 36.8%, P = 0.07) (Table 2). Interestingly, the baseline percent predicted FVC 
was significantly lower in the high dose treated group (70.7 ± 15.7) than the low dose 
treated group (96.5 ± 20.8) (P = 0.001) (Table 2). When we looked into therapy-response 
characteristics, no significant differences were however observed between the two 
groups in the number of patients that experienced an exacerbation during tapering (P = 
0.66) or patients that received additional second or third line drugs (P = 0.34) (Table 3). 
DISCUSSIon
It currently remains unknown what dosing strategy for first-line prednisone treatment 
in pulmonary sarcoidosis has the best balance between effect and side effect. In this 
study, we aimed to determine treatment outcome of different prednisone regiments 
used in current clinical practice for newly treated pulmonary sarcoidosis. No strong cor-
relation was found between prednisone dose used and FVC change at different time 
points, while weight increased significantly more in patient receiving a higher cumula-
tive prednisone dose in the long-term. These data suggest that a treatment strategy 
leading to a lower cumulative dose prednisone in the long term has the potential to be 
equally effective in treating pulmonary sarcoidosis patients as a higher dose regimen, 
while reducing side-effects. 
In this study, we gained more insight in prednisone therapy-induced effects. Serial 
FVC is currently the best end-point to monitor pulmonary sarcoidosis patients’ response 
to therapy (11). We observed an increase of approximately 10% predicted FVC after 
prednisone treatment initiation. Strikingly, the major part of the FVC change seems 
to occur within the first 1-3 months of therapy, as has been described in exacerbation 
patients (12). The FVC increase observed after prednisone initiation is likely a clinical 
significant therapy effect (11), although we cannot formally discount the notion that this 
improvement is in part due to the natural history of the disease. Importantly, no clear 
Categorical data is presented as No. (%) and continuous data as mean ± SD (No. of patients with available 
data and were included in the analyses). Statistics: We tested the continuous outcomes for residuals and 
they had a normal distribution. Significance between continuous data was analyzed with an unpaired stu-
dent t-test. Categorical data was analyzed with a X2 (=c) or the Fisher (=f) exact test. P values are given for 
significant differences between the two groups. Abbreviations: NS = not significant; PFT: Pulmonary func-
tion tests. DLCOc: diffusing capacity of lung for carbon monoxide (corrected for hemoglobin levels). FVC: 
forced vital capacity, kg: kilograms, mg: milligrams. $ Two patients had erythema nodosum. $$ One patient 
had heart involvement, one had parotids involved and two patients had peripheral neurological involve-
ment. *As assessed and described by the treating physician.
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correlation was found between average daily or cumulative prednisone dose given and 
FVC change. 
Weight gain is a well-known side effect of prednisone therapy (10). In this study, we 
found a correlation between weight increase and cumulative dose used, specifically in 
the long term. A treatment strategy leading to a lower cumulative dose at 12 months 
was characterized by early dose tapering, i.e. to less than 10 mg/day at 3.5 months, while 
the strategy leading to a higher dose was characterized by prolonged use of more than 
10 mg/day up to 6.9 months. Prolonged prednisone therapy for pulmonary sarcoidosis 
at a dose of more than 10 mg a day was reported to induce significant more side-effects 
than a lower dose (13), which is now further supported by the results of this study. These 
data highlight that early dose tapering can be essential in reducing cumulative predni-
sone dose and hazardous side-effect such as weight gain. 
Taken together, our data suggest that a lower prednisone dose increases and/or 
maintains FVC similar to a higher dose, thus meeting an important therapy objective, i.e. 
preserving organ function, while avoiding side effects (6). 
Table 3. Response to therapy of low versus high dose treated patients
low dose n=20 high dose n=19 P-value
Exacerbation
No 18 (90) 16 (84,2) 0.66
Yes 2 (10) 3 (15,8)
Additional 2nd or 3th line drugs
No 19 (95) 16 (84,2) 0.34
Yes 1 (5) 3 (15,8)
Data are presented as No. (%) or mean ± SD. Categorical data was analyses with the Fisher exact test. P 
values are given for significant differences between the two groups. Abbreviations: NS = not significant; FVC 
= forced vital capacity, kg: kilograms. 
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Figure 5
figure 5. Prednisone regimen analysis. The mean 
prednisone dose given per day in milligrams 
(mg) to patient who had received a low (< 4000 
mg; n=20) or high (≥ 4000 mg; n=19) cumula-
tive dose prednisone at 12 months. Patients who 
received a low or high cumulative prednisone 
dose at 12 months were treated with more than 
10 mg/day up to 3.5 or up to 6.9 months, respec-
tively. 
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There are a number of limitations to our study. Our study included a small number 
(n=7) of black patients, thus it remains to be determined whether these patients, who 
more often suffers from a severe chronic form of sarcoidosis, responds identically to 
first-line prednisone therapy. While a number of characteristics such as radiographic 
Scadding stage and BMI were similar, baseline FVC was significantly lower in patients 
treated with a higher cumulative prednisone dose. Also these patients tended to have 
features associated with severe disease, such as multiple organ involvement more of-
ten. We did not observe a clear correlation between cumulative prednisone dose and 
FVC change; when correcting for FVC at baseline the weak non-significant association 
between cumulative prednisone dose and FVC change at 12 months (r = 0.203) was no 
longer found (r = -0.07). Furthermore, high dose treated patients did not more often 
experience an exacerbation during tapering or receive additional second or third line 
drugs than low dose treated patients. Nevertheless, the retrospective design of our 
study does not allow for firm conclusion on whether these patients may have benefit-
ted from a lower dose. Other factors may have been taken into account by the treating 
physicians when determining a treatment strategy, such as change in symptoms, DLCO, 
radiological features or extra-thoracic organ involvement (11, 14, 15). 
In conclusion, we did not find a clear association between prednisone dose and FVC 
change in newly treated pulmonary sarcoidosis patients, while weight gain positively 
correlated with cumulative prednisone dose used in the long term. These results sup-
port that prednisone therapy that is mainly aimed at maintaining and/or improving FVC 
in pulmonary sarcoidosis may be dose-reduced in current clinical practice by early dose 
tapering and highlight the need for prospective clinical trials on treatment strategies 
that carefully balance effects-side-effects.
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Supplementary Figure E1
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figure E1. Mean FVC change over time was calculated using a multilevel model that incorporated regres-
sion lines of all 54 individual patients. (A) All individual FVC observations per patient, including the calculat-
ed multilevel regression fitted values (blue) for the median patient. (B) Individual regression lines of percent 
predicted FVC change over time. Statistics: Data is calculated using a multilevel model with FVC over time 
as outcome. Abbreviations: FVC = forced vital capacity, % pred = percent predicted. 
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Supplementary Figure E2
figure E2. The mean prednisone dose given per day in milligrams of patients with available data. The total 
number of patients with available data (in red text) is shown at baseline, month 3, 6, 12, 18, 24, 30, 36, 42, 
48, 54, 60, respectively. Abbreviations: mg = milligrams. 
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Supplementary Figure E3
figure E3. Correlation between percent predicted FVC change and mean prednisone dose used per day 
in milligrams over 3 months. The correlation was analysed using Spearman’s rank-order correlation test. 
The regression line with the correlation and P-value are shown in the plot. Abbreviations: FVC = forced vital 
capacity. 
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Supplementary Figure E4
figure E4. Mean weight change over time was calculated using a multilevel model that incorporated re-
gression lines of all 54 individual patients. (A) All individual weight observations per patient, including the 
calculated multilevel regression fitted values (blue) for the median patient. (B) Individual regression lines 
of weight change over time. Statistics: Data is calculated using a multilevel model with weight over time as 
outcome. Abbreviations: kg = kilograms.
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Supplementary Figure E5
figure E5. Correlation between weight change in kilograms and mean prednisone dose used per day in 
milligrams over 3 months. The correlation was analysed using Spearman’s rank-order correlation test. The 
regression line with the correlation and P-value are shown in the plot. Abbreviations: kg = kilograms, mg = 
milligrams.
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Daily Home Spirometry to Detect Early Steroid 
Treatment Effects in Newly-Treated Pulmonary 
Sarcoidosis
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aBSTRaCT
Background: Optimization of first-line prednisone therapy for sarcoidosis is urgently 
needed, since side effects can be severe and long-term benefits are debated. Prospec-
tive data on the early response towards prednisone treatment is lacking. We initiated a 
prospective study to evaluate the early lung function response to prednisone treatment 
and tapering, using daily home spirometry.
methods: Treatment naïve sarcoidosis patients in whom prednisone therapy was about 
to be initiated for a pulmonary indication were eligible. Prednisone treatment was 
standardized for the first three months (mo) of treatment. Forced vital capacity (FVC) 
was monitored daily at home using a hand-held spirometer and in hospital at baseline, 
1-mo and 3-mo. Symptom scores were filled out weekly. FVC is shown as mean percent 
(%) predicted (± SD). 
Results: Eighteen patients performed daily home spirometry. In-hospital measure-
ments showed a significant change in FVC of 12.3 (±9.8) at month 1 (P < 0.001) and 
a smaller change between month 1 and 3 (3.8 (±6.9), P = 0.045). A similar pattern was 
observed in ACE and sIL-2R, and symptom scores (MRC, SGRQ and FAS). Interestingly, 
home-monitoring revealed that home spirometry of FVC correlated with in hospital 
measurements (Pearson correlation: 0.97 (P < 0.001)) and that already at 17 days (95% 
confidence interval (CI): 16 to 18) after prednisone initiation 90% of the total FVC in-
crease was reached, whereas a plateau in FVC improvement was already reached at 23 
days (95% CI: 20 to 28). MRC and FAS decreased significantly within 2 weeks following 
treatment initiation. 
Conclusion: These results show that in newly-treated sarcoidosis patients most of the 
prednisone effect on FVC, fatigue and dyspnea symptoms is reached within approxi-
mately 2-3 weeks. Timely and precise measurement of pulmonary function and symp-
toms using daily home spirometry can help individualize first-line prednisone therapy in 
pulmonary sarcoidosis patients, aiming at early dose tapering and side-effect reduction.
Daily home spirometry in pulmonary sarcoidosis
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InTRoDUCTIon
Sarcoidosis is characterized by granuloma formation upon an unknown cause, often 
affecting mediastinal lymph nodes and lungs (1). The immune response observed in 
sarcoidosis-affected organs is suggestive for an exaggerated immune response upon 
chronic antigenic stimulation (2). Although granulomas resolve spontaneously in the 
majority of the cases, in 30-50% of the sarcoidosis patients lung granulomas remain 
chronically present and may cause burdensome symptoms, such as dyspnea, chest pain 
and cough, that warrant therapy (3). 
Since the etiology of the disease remains unknown, sarcoidosis treatment is not cura-
tive, but characterized by immune suppression. Prednisone is the main stay of sarcoid-
osis treatment, as it is known to induce symptom relieve, improve the chest X-ray and 
increase forced vital capacity (FVC) in the short-term (4-6). However, since the long term 
benefit of prednisone therapy is debated (e.g. slowing down progression or develop-
ment of fibrosis), the treatment regimen should mainly be aimed at symptom control, 
inflammation control to prevent (further) organ damage, and improving patient’s qual-
ity of life (3, 4, 6, 7). 
The optimal treatment time and dose remain unknown (1, 6, 8), thus clinical guidelines 
include a broad range, leading to variability of doses used in clinical practice (Broos et 
al., submitted). Prolonged high dose prednisone therapy, in particular at higher doses, is 
associated with burdensome side-effects (3, 9)(Broos et al., submitted). These data high-
light that prednisone treatment optimization is warranted, and that early dose tapering 
has the potential to reduce side-effects. 
Gaining insight in the early treatment response can help determine when tapering 
could be initiated. Two retrospective studies in either exacerbation or newly-treated 
sarcoidosis patients found that the major change in FVC upon treatment occurred 
within 1 month, and remained stable up to 3-12 months during tapering (10)(Broos 
et al., submitted). An older, small, prospective study monitored (mostly newly-treated) 
patients regularly with in-hospital lung function equipment during the first 2 months of 
treatment and found a steep increase in FVC already within the first 10 to 21 days, and 
remaining stable up to 2 months (11). 
However, a prospective study monitoring patient-administered lung function on a 
daily basis also including clinical symptoms is lacking, and can help gain further insight 
in the early treatment response towards prednisone in sarcoidosis. Therefore, we have 
initiated a prospective, observational study to evaluate early FVC changes during pred-
nisone treatment and tapering in newly-treated sarcoidosis patients, using daily home 
spirometry.
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mEThoDS
Study design
This study was a multicenter, prospective and observational study in order to deter-
mine early treatment responses in newly-treated pulmonary sarcoidosis patients (Trial 
registration number in the Dutch National Trial Register (http://www.trialregister.nl/
trialreg): NTR4328 (Acronym: STEPS study). Six hospitals in the Netherlands participated, 
of which 1 academic referral center for sarcoidosis (Erasmus MC (Rotterdam)) and 5 
training-hospitals (Franciscus Gasthuis (Rotterdam), Ikazia hospital (Rotterdam), Amphia 
hospital (Breda), Haaglanden Medical Center (The Hague) and Zuyderland Medical Cen-
ter Heerlen (Heerlen)). 
Study subjects
Treatment naïve sarcoidosis patients in whom prednisone therapy was about to be 
initiated for a pulmonary indication were eligible for this study. Disease diagnosis was 
established according to criteria recognized by the joint statement of the American Tho-
racic Society (ATS), the European Respiratory Society (ERS) and the World Association of 
Sarcoidosis and Other Granulomatous Disorders (WASOG) (1). At screening for eligibility 
patients had to further meet the following criteria: an FVC of ≤ 80% predicted and/or 
FVC had declined ≥ 10% predicted (absolute decline) within the previous 12 months. Po-
tential subjects who met any of the following criteria were excluded from participation: 
previous immunosuppressive treatment for sarcoidosis (e.g. prednisone, methotrexate, 
anti-TNF); use of systemic immunosuppressive therapy within the previous 3 months 
for another disease than sarcoidosis; contra-indications for steroids; co-morbidities of 
other conditions that could influence pulmonary function, such as chronic obstructive 
pulmonary disorder (COPD), active asthma (diagnosis established according to GINA 
guidelines), pulmonary malignancies, fibrotic disease, pregnancy or morbid obesity 
(body mass index (BMI) ≥ 35 kg/m2). 
Treatment policies
Study patients were treated according to current guidelines (1, 8). Prednisone regimen 
was standardized for the first three months according to a consensus that was reached 
between all participating pulmonary physicians. Accordingly, patients were intended 
to be treated with the following prednisone regimen: 4 weeks 40 milligrams (mg)/day, 
2 weeks 30 mg/day, 2 weeks 20 mg/day, 2 weeks 15 mg/day, 2 weeks 10 mg/day. At any 
time the treating physician was allowed to deviate from this consensus regimen, if the 
clinical situation so demanded. 
Daily home spirometry in pulmonary sarcoidosis
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In-hospital monitoring
Routine in-hospital clinical monitoring with lung function and laboratory tests was 
performed at baseline, 1 and 3 months following treatment initiation. Besides these, 
patients were asked to fill out symptom- and quality of life-related questionnaires, 
including the St. George Respiratory Questionnaire (SGRQ), Short Form Health Survey 
(SF-36), King’s Sarcoidosis Questionnaire (KSQ), the Medical Research Council Dyspnea 
(MRC) scale and Fatigue Assessment Scale (FAS). Also, patients were weighted at each 
visit. European Respiratory Society standard prediction equations for pulmonary func-
tion were used in all hospitals.
home monitoring
During the first 3 months of treatment daily home monitoring of the lung function was 
performed by the patient on a calibrated hand-held spirometer that is available and 
used in regular care (Micro Diary, Carefusion). Participants were asked to undertake 3 
maneuvers each day at approximately the same time in order to enhance compliance. 
An alarm clock would remind the patient that same day if a maneuvers was late and 
therefore would possibly be forgotten. Next to lung function data, daily prednisone 
dose was automatically recorded on the home spirometer. Additionally, patients were 
asked to fill out a MRC and FAS score at the end of each treatment week.
home spirometer training
Participants were trained how to use the home spirometer for approximately 45 minutes 
at start of the study. A refreshment training was performed at the routine follow-up 
hospital visit after 4 weeks. Trainers were either respiratory physiologists or research 
nurses who were officially certified to perform lung function tests on hospital lung func-
tion equipment. A detailed training protocol was used by all trainers in participating 
hospitals to ensure and level training quality. A patient was declared to be adequately 
trained when at least 3 FVC maneuvers on the home spirometer were reproducible, of 
which the top 2 best were less than 150 ml apart. Also, the trainer had to ensure that the 
record of the FVC on the home spirometer did not deviate more than 10% of the FVC 
measured on in-hospital lung function equipment. After one week patients were con-
tacted and results of the first week were reviewed with the patient. When 3 FVC records 
on the home spirometer of the previous week were lower than 80% of the baseline FVC 
measurement on the home spirometer, while the patient did not experience an increase 
in disease symptoms, a refreshment training was considered with the participant.
Statistical analysis
Export records of daily FVC measurements on the hand-held spirometer were used for 
analyses. The written home diary was used to read out weekly MRC and FAS scores. The 
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comparison of means of continuous variables measured at different time points during 
in-hospital monitoring at baseline, month 1 and month 3 were tested with the paired 
student t test. Daily FVC and weekly MRC/FAS scores measured during home monitoring 
were used as outcome in multilevel models with patient as random factor. For analyses 
of the FVC a multilevel model was used that incorporated the change of the curvature at 
an estimated time point at which the maximum improve in lung function was reached. 
This model assumes that after a certain number of days a maximum level is reached 
(tau) and the curvature of the trajectory between start and maximum has some freedom 
(gamma)(see Supplementary Figure E1). For MRC/FAS scores we modelled linear splines 
with a knot at 4 weeks, using multilevel models. Statistical analyses and figures were 
performed/created using SPSS (version 21.0.0.1) and R software (version 3.2.2), using the 
package lme4. A P-value <0.05 was considered as statistically significant. 
Ethical requirements
The Medical Ethical Committee of the Erasmus MC approved this study, under the Dutch 
act for medical research involving human subjects (Wet Medisch Onderzoek). The local 
institution review board of all participating centers approved with registration number 
MEC-2013-244.
RESUlTS
Patients
Thirty-eight sarcoidosis patients with a pulmonary treatment indication for first-line 
prednisone therapy were screened for eligibility for this study. Eighteen patients were 
excluded due to various reasons (Figure 1), including a FVC>80% (5); contra-indication 
for prednisone (e.g. diabetes mellitus) (4); active asthma (1); morbid obesity (1); incapable 
or practical contra-indications to perform daily spirometry, including a multi-trauma, a 
recent cerebral event and a planned aortic valve replacement during study procedures 
(3); not treatment naïve (1); incapability to give informed consent due to language (1); 
and finally one patient had already started with prednisone (1) and one patient did 
not want to participate (1). In total 20 sarcoidosis patients were enrolled in this study. 
However, 1 patient chose to withdraw from the study at day one enrolment, and from 1 
patient the FVC at start of study was >10% higher than the screening FVC, suggesting a 
major spontaneous improvement before start of treatment. This leaves 18 patients that 
were home monitored and analysed for this study (Figure 1). 
The study group consisted of 11 males and 7 females. Mean age was 44 (± 11) years. 
The majority of the patients (78%) was diagnosed with Scadding stage II sarcoidosis. In 
half of the patients, sarcoidosis also affected extra thoracic organs. Patient demograph-
ics are shown in Table 1. 
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Prednisone treatment
Thirteen patients were treated according to the agreed standard prednisone regiment. 
In 2 patients the treating physician felt that prednisone could not be tapered to 10 
mg/day within 3 months due to an unsatisfactory clinical response at 4-8 weeks after 
treatment initiation, thus prednisone was kept on a higher daily doses (≥ 20 mg/day). 
One of these received additional methotrexate therapy at month 2. Another patient 
experienced retro sternal pains and nervousness after initiation of prednisone, and the 
treating physician decided on earlier tapering to 10 mg/day. One patient by accident 
took 40 mg/day for an additional two weeks instead of tapering. Finally, one patient 
chose to stop prednisone treatment and also home-spirometry after 2 months, without 
report of any adverse event or other reason. 
In-hospital monitoring
In-hospital clinical parameters, including lung function tests, laboratory tests, quality of 
life and weight, were monitored at baseline and month 1 and 3 after prednisone treat-
ment initiation. 
Lung function
In-hospital clinical monitoring showed a signifi cant FVC increase upon treatment from 
68.7 (±14.9) to 80.9 (±14.8) percent predicted at month 1 (mean change 12.3 (±9.8), P 
< 0.001) (Figure 2a). Interestingly, a smaller FVC improvement was observed between 
          Screened for eligibility
N=38
Enrolled
N=20
Excluded
N=2
Withdrawal at ﬁrst day (1)
FVC at start of treatment > 10% 
higher than screening FVC (1)
Included
N=18
Excluded 
N=18
FVC > 80% (5)
Contra-indication prednisone (4) 
Asthma (1)
Morbid obesity (1)
Incapable or practical contra-indication to perform daily spirometry 
(3)
Not treatment naïve (1)
Incapable to give informed consent (1)
Missed inclusion (1)
Did not want to participate (1)
figure 1. Flowchart of patient that were eligible for this study and that were enrolled, included or excluded. 
Abbreviations: FVC = forced vital capacity. 
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month 1 (80.9 (±14.8)) and month 3 (84.7 (±14.4)) (mean change 3.8 (± 6.9), P = 0.045) 
(n=16) (Figure 2a). 
Furthermore, in a subgroup of patients diffusing capacity of lung for carbon monoxide 
(DLCO) (corrected for hemoglobin level) was measured, and a significant increase in 
percent predicted DLCO was observed within 1 month from 59.4 (±22.5) to 71.6 (±20.6) 
(mean change 12.2 (±8.1), P < 0.001). However, DLCO decreased somewhat again be-
tween month 1 and 3 to 66.7 (±16.2) (mean change -5.0 (±8.5), P = 0.047) (n=14) (Figure 
2b). 
These data show that most of the effect on FVC is reached within 1 month of predni-
sone treatment in newly-treated sarcoidosis patients. 
Table 1. Study subject characteristics
Patient baseline characteristics Total study cohort (n=18)
Age (Mean years (SD)) 44 (11)
Sex (Male/Female) 11/7
Race (n (%))
White 9 (50)
Black 6 (33)
Asian 3 (17)
Weight (mean kg (SD)) 80,1 (17,6)
BMI (mean kg/m2 (SD)) 26,7 (6,1)
Smoking
Never 12 (67)
Former 4 (22)
Current 2 (11)
Scadding Stage at start treatment (n (%))
Stage II 14 (78)
Stage III 4 (22)
Extrathoracic involvement (Yes/No) 9/9
Extrathoracic involvement (n (%))
Skin 3 (17)
Eyes 2 (11)
Articular$ 6 (33)
Central nervous system 0 (0)
Other (e.g. liver, spleen, skeletal) 2 (11)
PFT (mean % predicted (SD))
FVC 69,4 (14,2)
DLCO 61,0 (22,6)(n=15)
Abbreviations: SD: standard deviation, kg: kilogram, PFT: pulmonary function tests. $ Self-reported articular 
involvement.  
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Serum markers
Proposed serum markers of disease activity in sarcoidosis include angiotensin-convert-
ing-enzyme (ACE) and soluble interleukin-2 receptor (sIL-2R)(12, 13). 
Since several variables could have influenced ACE levels between patients assessed 
in our study cohort (such as ACE genotypes (14) and distinct methods used within 
participating centers to determine ACE levels), merely level changes were analyzed. 
Interestingly, ACE levels decreased significantly upon treatment between baseline and 
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figure 2. In-hospital clinical monitoring of percent (%) predicted FVC (A) and DLCO (corrected for hemoglo-
bin levels) (B) values at baseline, month 1 and 3 during prednisone treatment of patients with data available 
at all three time points. Statistics: Lines represent paired results from one patient (A: n=16 and B: n=14). Sig-
nificance was determined using a two-tailed paired T-test. Abbreviations: FVC = forced vital capacity, DLCOc 
= diffusing capacity of lung for carbon monoxide (corrected for hemoglobin levels). 
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figure 3. In-hospital clinical monitoring of ACE (A) and sIL-2R (B) at start (baseline) and month 1 and 3 dur-
ing prednisone treatment of patients with data available at all three time points. Statistics: Absolute values 
are shown. Lines represent paired results from one patient (A: 18 and B: 10). Significance was determined 
using a two-tailed paired T-test. Abbreviations: ACE = angiotensin-converting-enzyme, U/L = units per liter, 
sIL-2R = soluble interleukin-2 receptor, pg/ml = pictograms per milliliter. 
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month 1 (P < 0.001), however no significant change was observed between month 1 and 
3 (P = 0.23) (n=18) (Figure 3a). 
Also sIL-2R levels decreased significantly upon treatment between baseline (17160 
(±10685)) and month 1 (5320 (±3052)) (P = 0.002), but not between month 1 (5320 
(±3052)) and 3 (5940 (±4701) (P = 0.61)(n=10) (Figure 3b). 
These data show that serum inflammatory markers decrease significantly during 
sarcoidosis prednisone treatment within 1 month, remaining stable over 3 months. 
Adverse events and weight
In total 18 different adverse events were reported. Table 2 shows adverse events that 
were reported in more than 1 patient (n=9). One patient was hospitalized during the 
study for an elective surgical operation (parathyroidectomy). No further SAE’s occurred. 
In order to further objectify an important side-effect of prednisone treatment in 
pulmonary sarcoidosis, weight was assessed during hospital visits. Average weight at 
start of treatment was 80.1 (± 17.6) kg and BMI was 26.7 (± 6.1) kg/m2 (Table 1). Paired 
analyses showed that weight increased significantly between baseline and month 1 
(mean change 2.3 (± 2.6) kg (P = 0.002)) and month 3 (mean change 5.4 (± 4.2) kg (P < 
0.001)) (n=18), respectively (Figure 4).
These data show that weight increased significantly during prednisone treatment and 
tapering. 
Symptoms and quality of life
Change in symptoms and/or quality of life during prednisone treatment is shown in 
Table 3. Importantly, MRC score significantly decreased at month 1 compared with 
baseline (P = 0.001), indicating less dyspnea. FAS score was also significantly improved 
at month 1 compared with baseline (P = 0.001), indicating less fatigue (15). Similar to 
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Figure 4
figure 4. In-hospital clinical monitoring of 
weight at baseline, month 1 and 3 during pred-
nisone treatment. Statistics: Absolute kilograms 
are shown. Lines represent paired results from 
one patient (n=18). Significance was determined 
using a two-tailed paired T-test. Abbreviations: kg 
= kilograms. 
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FVC and serum markers (Figure 2 and 3), MRC and FAS score remained stable between 
month 1 and 3 (Table 3). 
SGRQ sub- and total scores showed a similar pattern of improvement as MRC and 
FAS scores (Table 3). Total SF-36 score did not show much change, although the mental 
component summary (MCS) score was statistically significant improved at month 3 com-
Table 2. Reported adverse events
adverse event reported in > 1 patient Total patients (%)
Weight increase/Cushingoid features 3 (15,8)
Upper airway infection† 3 (15,8)
Insomnia 3 (15,8)
Chest pain 2 (10,5)
Muscle cramps 2 (10,5)
Gastrointestinal disturbance 2 (10,5)
Neuropsychiatric 2 (10,5)
Other bacterial/viral infection†† 2 (10,5)
Acne 2 (10,5)
† All three patients received antibiotics for the upper airway infection. †† One patient had a bacterial testicu-
lar infection and one patient had herpes zoster. 
Table 3. Symptoms and quality of life assessed during prednisone treatment
Symptom and/or quality of life-related 
questionnaire
Baseline
Mean (SD)(No.)
month 1
Mean (SD)(No.)
month 3 ¥
Mean (SD)(No.)
MRC 2,56(1,03)(16) 1,44(0,89)(16)* 1,50(0,89)(16)*
FAS 28,0(10,9)(17) 21,2(6,8)(17)* 21,1(7,6)(17)*
SGRQ
Symptoms 45,4(21,7)(16) 31,5(21,8)(16)* 27,5(25,9)(16)*
Activity 56,8(25,4)(16) 41,2(25,9)(16)* 39,1(27,7)(16)*
Impact 29,8(23,6)(16) 19,4(15,7)(16) 19,0(14,8)(16)*
Total 41,2(22,1)(16) 28,0(17,6)(16)* 26,6(18,9)(16)*
SF-36
PCS 38,3(7,2)(13) 39,3(7,0)(13) 36,2(6,6)(13)
MCS 33,8(6,6)(13) 36,8(7,2)(13) 39,5(8,2)(13)*
KSQ
GHS 59,8(15,1)(9) 70,5(19,0)(9)* 63,6(14,4)(9)
Lung 57,1(14,3)(8) 66,5(23,3)(8) 67,3(21,8)(8)*
Data is shown as mean (± SD) (No. of patients with available paired data over the 3 time points). * P < 0.05 
compared with baseline, using a paired sample T-test. ¥ None of the values is statistically significant at 
month 3 compared with values at month 1. Abbreviations: SD: standard deviation, No. = number, MRC: 
medical research council dyspnoea score, FAS: Fatigue Assessment Scale, SGRQ: St. George Respiratory 
Questionnaire, SF-36: Short Form Health Survey, PCS: Physical Component Score, MCS: Mental Component 
Score, KSQ: King’s Sarcoidosis Questionnaire, GHS: General Health Status. 
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pared with baseline (P = 0.04). A subgroup filled out the KSQ score (16) during the study 
after it was validated in the Netherlands (17), and this sub analyses showed that general 
health status (GHS) improved significantly within one month of treatment (P = 0.009). 
This however did not remain stable over 3 months, whereas lung specific symptoms 
recorded in this questionnaire were still significantly better at 3 months compared with 
baseline (P = 0.03) (Table 3). 
These data show that symptoms such as dyspnea (MRC/SGRQ) and fatigue (FAS) 
decreased significantly during prednisone treatment within 1 month. 
home monitoring
In the home setting, FVC and dyspnea (MRC) and fatigue (FAS) scores were monitored by 
the patient at a daily and weekly basis, respectively. 
Home spirometry
In order to determine when the maximum improve in lung function occurs, individual 
FVC changes over time were recorded on a daily basis after prednisone initiation, using 
a calibrated home-spirometer. Figure 5a shows the best daily FVC measurements on 
the home spirometer per individual patient over time in liters. Data was recalculated to 
percent predicted FVC, using the predicted values on the individual in-hospital baseline 
FVC record, and in-hospital FVC measurements at baseline, 1 month and 3 months are 
shown next to the home spirometry data in red dots (Figure 5b). Although FVC mea-
sures tended to be lower on the home spirometer than on in-hospital lung function 
equipment (~197 ml), there was a strong correlation between those two parameters 
(Pearson correlation: 0.97 (P < 0.001)). Furthermore, individual analyses of the home 
spirometer-derived results showed that the mean standard deviation of the 3 repeated 
FVC measurements within an individual patient on one day was 100 ml. These data 
imply that the home spirometer can be used as a reliable tool to measure FVC changes 
in pulmonary sarcoidosis patients on a daily basis. 
Mean FVC change over time was calculated using a multilevel model that incorporated 
regression lines of all 18 individual patients (Figure 6). Mean percent predicted FVC at 
start of treatment was 65.9 (95% CI: 60.9 to 73.4). A maximal mean increase of 10.0 (95% 
CI: 9.6 to 10.5) % predicted FVC was observed after treatment initiation. A plateau of FVC 
increase was observed at 23 days (95% CI: 20 to 28), and 90% of the total FVC increase 
was reached at day 17 (95% CI: 16 to 18). 
Weekly symptom scores
In order to get insight whether the early change in lung function correlated with 
patient-relevant outcomes (i.e. symptom relieve) short symptom scores, such as MRC 
and FAS were assessed weekly in the home-setting. Weekly symptom scores showed a 
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decreasing trend during the first month (see Supplementary Figure E2). Multilevel analy-
ses of MRC scores showed that symptoms decreased significantly with 0.3 (95% CI: 0.2 
to 0.4) MRC points per week (P < 0.001), stabilizing after 1 month. Similarly, FAS scores 
decreased significantly with 2.1 (95% CI: 1.7 to 2.5) FAS points per week (P < 0.001), 
stabilizing after 1 month. 
Together these data show that MRC and FAS scores were also already significantly 
decreased within 2 weeks of prednisone treatment in sarcoidosis patients. 
DISCUSSIon
This is the first study showing prospectively by daily home spirometry that most of the 
change in FVC and symptoms occurs within 2-3 weeks after prednisone therapy initia-
tion in a cohort of newly-treated sarcoidosis patients. 
As long term disease modifying benefits of prednisone are debated (4-6), carefully 
balancing potential beneficial effects on symptoms and quality of life with potential 
side effects in first-line treatment of pulmonary sarcoidosis is warranted (3, 4, 6, 7). 
Current guidelines differ in recommendation on the dose and duration of treatment (1, 
8), but daily home spirometry could facilitate a personalized approach to treatment for 
each patient aiming at achieving the maximum effect of lung function and symptom 
improvement with the lowest possible dose of prednisone, in order to minimize side 
effects. This study shows that daily home spirometry of the FVC is an effective tool to 
monitor sarcoidosis response to therapy (18). Moreover, multi-level analyses of daily 
home monitored FVC showed that most (90%) of the prednisone effect on FVC already 
occurred around 17 days, reaching its maximum improvement around 23 days. A signifi-
cant decrease in dyspnea (MRC) and fatigue (FAS) (15) scores was also observed within 2 
weeks of treatment. These data argue that FVC changes observed at approximately 2-3 
weeks can help physicians evaluate response to therapy in newly-treated sarcoidosis 
patients. Consequently, physicians might earlier decide on dose tapering and/or the 
need for initiation of second-line steroid-sparing therapies than is now advised on (1, 8). 
Our results are in line with other studies that have suggested that the major increase 
in FVC during prednisone treatment in sarcoidosis occurs within 1 month (10, 11)(Broos 
et al., submitted). These studies were however either performed retrospectively in 
exacerbation patients that have previously shown to be responsive to prednisone (10) 
and/or evaluated changes on in-hospital lung function equipment at determined time 
points, (possibly) missing early and individual daily changes in FVC (10, 11). This study 
is the first to perform daily home spirometry and include home monitoring of weekly 
symptom scores, evaluating early effects on dyspnea (MRC) and fatigue (FAS) (15) next 
to FVC, strengthening the accuracy of clinical evaluation in pulmonary sarcoidosis (13). 
Furthermore, results showed that inflammatory markers that have been suggested to 
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reflect disease activity in sarcoidosis, such as ACE and sIL-2R (12, 13), also decreased 
significantly within 1 month, remaining stable up to 3 months. Similarly, quality of life 
(SGRQ) scores improved clinically significantly within 1 month (19, 20). In a sub cohort 
DLCO increased within one month during prednisone therapy, but it did not remain 
fully stable during tapering. However, although DLCO measurements are likely to reflect 
earlier interstitial changes in sarcoidosis (21), reproducibility of DLCO measurements 
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Figure 5
figure 5. Daily best FVC measurements recorded on the home spirometer (Micro Diary, Care Fusion) per 
individual patient (n=18) over time (days) in liters (A) or as percentage of predicted (B). Calculations: Data 
was recalculated to percent predicted FVC, using the predicted values on the individual in-hospital baseline 
FVC record, and in-hospital FVC measurements at baseline, 1 month and 3 months were added to the home 
spirometry data in red dots (B). Abbreviations: FVC = forced vital capacity, L = liters. 
Daily home spirometry in pulmonary sarcoidosis
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is lower than FVC measurements, thus only a major change (>15%) in DLCO has been 
suggested to reliably exclude confounding by measurement variation (13).
Early dose tapering to a maintenance dose is very likely to reduce important side-
effects in pulmonary sarcoidosis. It has been found that a daily dose of lower than 10 mg 
prednisone is less likely to induce side effects and is regarded as a successful tapering 
(3, 9, 22). Furthermore, our retrospective study in newly-treated sarcoidosis patients 
showed that specifically a high cumulative dose prednisone received in the long term 
(at 12 and 24 months) significantly correlated with weight increase. Remarkably, the 
treatment regimen leading to a high cumulative dose in the long term was character-
ized by a prolonged use of more than 10 mg prednisone per day compared with the low 
dose regimen (Broos et al., submitted). 
Interestingly, questionnaires that were more focused on general health status, such 
as SF-36 and KSQ-GHS showed either no or less pronounced changes during predni-
sone treatment in our study group than scores purely including physical symptoms 
such as MRC and FAS. This could have been caused by concurrent side-effects that are 
likely to occur during prednisone treatment, counterbalancing the positive (physical) 
outcomes of prednisone treatment. Indeed, in our study a number of adverse events 
were reported that are associated with prednisone treatment, and our data also showed 
that sarcoidosis patients underwent significant weight gain within the first 3 months of 
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Figure 6
figure 6. Daily best FVC measurements recorded on the home spirometer (Micro Diary, Care Fusion) per 
individual patient over time (days) in as percentage of predicted, including regression lines of all 18 indi-
vidual patients. Calculations: Data was recalculated to percent predicted FVC, using the predicted values 
on the individual in-hospital baseline FVC record. Statistics: A multilevel model was used that incorporated 
the change of the curvature at an estimated time point when the maximum improve in lung function was 
reached. This model assumes that after a certain number of days a maximum level is reached (tau) and the 
curvature of the trajectory between start and maximum has some freedom (gamma)(see Supplementary 
Figure E1). Abbreviations: FVC = forced vital capacity.
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treatment (~ 5 kg). These data confirm that it remains relevant to continuously evaluate 
benefit-risk ratio of prednisone treatment in consultation with the individual patient (3, 
6, 7). Although prednisone seems highly effective in the short term on FVC, symptoms 
and inflammatory markers, side-effects remain a prominent problem during therapy 
and can therefore influence quality of life of sarcoidosis patients. 
A multi-level model provided evidence that most of the FVC effect in the majority 
of the newly-treated sarcoidosis patients seems to occur within 2-3 weeks, remaining 
stable up to 3 months. However, the individual home monitoring data also highlight that 
patients can respond uniquely to prednisone and suggest the need for tailored medi-
cine in sarcoidosis treatment (6, 7). For example, in a few cases FVC kept increasing or 
partly decreased again after 2-3 week or during tapering. Also, in 2 patients, prednisone 
therapy could not be tapered below 20 mg because of an unsatisfactory response and 
one of these patients received additional methotrexate during this study. Sarcoidosis is 
well known for great heterogeneity in clinical course, thus long-term follow-up of this 
study cohort may reveal differences in disease course and ultimate treatment outcome. 
Long-term follow-up of an expanded cohort should reveal whether early FVC changes 
can predict treatment outcome, and whether home spirometry can guide physicians in 
early initiation of second- and or third-line therapy to spare prednisone. In idiopathic 
pulmonary fibrosis it has been shown that change in disease course could well be de-
tected with home spirometry and was predictive for long term outcomes (23). 
Taken together, results of this study validate the use of home spirometry in first-line 
treatment of sarcoidosis patients and suggest that daily home monitoring of FVC 
changes in clinical practice has the potential to personalize sarcoidosis treatment, aim-
ing at early dose tapering and side-effect reduction. Importantly, quality of the home 
spirometry maneuvers, and therefore the reliability of home-monitored FVC measure-
ments can be influenced by training quality and patient-related factors, thus critical 
review of individual results always remain warranted before the physician includes such 
results in clinical treatment decisions. Up till now, not one clinical test has been found 
to be sufficiently accurate in assessing disease severity in pulmonary sarcoidosis (13). 
Future studies are needed to evaluate whether careful home monitoring of prednisone 
treatment (including FVC and symptom scores) and personalized dose titration (24, 25), 
will allow for a non-inferior treatment effect compared to current clinical practice, while 
increasing pulmonary sarcoidosis patients’ quality of life (6, 7). 
ConClUSIon
This study validates the use of home spirometry in first-line treatment of pulmonary 
sarcoidosis and shows that the major improvement in lung function occurs within 2-3 
weeks. Early (home) monitoring of lung function and symptoms has the potential to 
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individualize prednisone therapy, aiming at early dose tapering, side-effect reduction 
and patient-related quality of life. 
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SUPPlEmEnTaRy maTERIal
SUPPlEmEnTaRy fIgURES
F̂VC = αi + β.t
′
t′ =
{
1− ( τ−tτ )γ if t < τ
1 otherwise
where:
F̂VC fitted value of FVC estimated FVC without random error
αi random intercept estimated FVC at start for individual i
β effect of the intervention difference between start and final level
t’ transformation of time t shape of the change between start and end of the
followup
τ time at wich the level is reached non linear parameter in the regression model
t time in days
γ curvature of the change before τ γ = 1 means straight line from 0 to τ
γ = 2 means parabola from 0 to τ
figure E1. Mathematical model that was used to predict FVC change over time. A multilevel model was 
used that incorporated the change of the curvature at an estimated time point when the maximum im-
prove in lung function was reached. This model assumes that after a certain number of days a maximum 
level is reached (tau) and the curvature of the trajectory between start and maximum has some freedom 
(gamma). 
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Supplementary Figure E2
figure E2. Weekly MRC (A) and FAS (B) scores filled out in a home diary per individual patient over time 
(weeks), including regression lines of all 18 individual patients. Statistics: A multilevel model was used that 
modelled linear splines with a knot at 4 weeks. Abbreviations: MRC = Medical Research Council Dyspnea 
score, FAS = Fatigue Assessment Scale. 
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EPIlogUE
Important goals of sarcoidosis research are to identify predictors of disease course, 
biomarkers of disease activity and targets for effective (new) therapies. Insight in these 
factors can help guide sarcoidosis specialists on ‘Who, When and How’ to treat, helping 
them to fine-tune treatment strategies, thereby increasing quality of life of pulmonary 
sarcoidosis patients.
The first aim of this thesis was to (further) unravel the immune-related pathogenesis 
of sarcoidosis, so as to discover contributors to disease etiology and disease course (Part 
1). The second aim was to gain insight into the current mainstay of sarcoidosis treat-
ment, that is prednisone therapy, in order to optimize treatment strategies to reduce 
side-effects (Part 2). In this epilogue, results of both parts of the thesis are put into the 
perspective of implications for clinical practice, ending with a summary of outstanding 
questions and concluding remarks. 
gEnERal DISCUSSIon of ThE ThESIS
Implications for practice: who to treat?
Sarcoidosis affects all people over the world with different races/ethnicities, but the 
disease course varies greatly per individual patient (1). Some patients will undergo 
spontaneous resolution without any treatment, and others develop chronic, sometimes 
progressive disease with need for treatment. Consequently, an intriguing question in 
sarcoidosis research is what factors determine the difference between these patients. 
This can help identify biomarkers that predict disease course and therefore help physi-
cians decide which patient to treat and which patient not. Results of this thesis that are 
valuable in this sense are discussed below. 
Predictors of disease course: A role for Treg and Th 17-lineage cell-associated factors? 
Results of this thesis and current evidence suggest that immunological factors related 
to regulatory T cells (Tregs) and T helper (Th)17-lineage cells are attractive candidates to 
study as biomarker predicting disease course in pulmonary sarcoidosis. 
The distribution within and/or functionality (e.g. cytokine production) of Th17-lineage 
cells might be predictors of disease course. Sarcoidosis lung proportions of Th17.1 cells 
are significantly higher than Th17 cells in newly-diagnosed and progressive patients 
(this thesis). Within the limited number of patients analyzed in our study, we found 
that patients that develop chronic sarcoidosis have significantly higher proportions 
of Th17.1 cells in the lungs at time of diagnosis than patients who undergo resolution 
within 2 years (Chapter 5). Also, the ratio Th17.1/Th1 cells and (although it did not reach 
statistical significance) Th17.1/Th17 cells was increased at time of diagnosis in patients 
that develop chronic disease. Although these data merely show an association, and do 
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not proof causality, Th17.1 cells have previously been found to be pathogenic in other 
autoimmune disorders, by upregulation of pro-inflammatory cytokines and corticoste-
roid resistance (2), making it conceivable that Th17.1 cells do contribute to development 
of progressive disease. 
Recently, results of Grunewald and colleagues also suggested a role for Th17.1 cells 
in sarcoidosis disease prognosis. They however identified increased proportions of 
T-bet+RORγT+ CD4+ T cells, also co-expressing CCR6 and CXCR3 like Th17.1 cells (Chapter 
4 (3) and 5), in lungs of Löfgren patients; a subtype of acute sarcoidosis that is associated 
with a favorable disease outcome (4). In contrast to our results, observed in non-Löfgren 
patients (Chapter 5), a positive correlation was found between lung T-bet+RORγT+ CD4+ 
T-cell proportions and resolving disease in Löfgren patients. However, interestingly, 
although Löfgren lung CD4+ T cells consisted of ~65% T-bet+RORγT+ CD4+ T cells, IFN-γ 
production by Löfgren BALF cells was lower than by non-Löfgren BALF cells in vitro (4). 
Additionally, benign Th17-lineage cytokine (IL-17A and IL-10) production was higher. 
These data suggest that maybe not so much Th17.1 cell proportions, but mostly the 
distribution of cytokine production by these cells is a contributor to sarcoidosis disease 
course. It is however important to mention that Löfgren’s syndrome may constitute a 
separate disease from sarcoidosis, as suggested by a distinct clinical presentation, a 
separate genetic background (5), and in most patients, an antigen-specific immune 
response. Therefore, careful research of the predictive value of Th17.1 cells is needed in 
both disease entities, as the immune pathology may be different. 
Failure of immunosuppressive Tregs has also been suggested to contribute to ongo-
ing inflammation in sarcoidosis (Chapter 1 (6)). Decreased Treg proportions have been 
detected in broncho-alveolar lavage fluid (BALF) of patients that develop chronic active 
disease (7), suggesting that Tregs can contribute to disease course. In this thesis we did 
not find evidence for reduced Treg numbers at site of disease activity (Chapter 2 (8) 
and 3 (9)). In contrast, circulating Treg proportions were significantly enhanced at time 
of diagnosis in patients developing (active) chronic disease (Chapter 3 (9)). Together 
these data could suggest that enhanced circulating Treg proportions reflect impaired 
Treg migration towards the site of inflammation and/or failure of local Tregs to control 
Th cell inflammation, leading to ongoing IL-2 production and homeostatic Treg expan-
sion (Chapter 3 (9)). Therefore, circulating Treg proportions might serve as a biomarker 
predicting chronic disease in sarcoidosis. 
However, Treg proportions have also been described to be significantly lower in BALF 
of Löfgren patients than non-Löfgren sarcoidosis patients (10)(Chapter 1), and like in 
Th17-lineage cells, that would suggest an opposite role of these cells as contributor 
to sarcoidosis disease course. Although Löfgren syndrome is often accompanied by a 
favorable prognosis, the disease is also characterized by an acute onset of pronounced 
inflammation, reflected in noticeable fever (11). Therefore, the excessive presence of 
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Th17.1 cells and decreased Treg proportions might be more an indicator of disease ac-
tivity (see below) alongside other important determinants of disease course, such as the 
ability to adequately get rid of the putative antigen. Alternatively, as mentioned above, 
although insights in immunological responses observed in Löfgren patients might help 
shed light on sarcoidosis pathogenesis, Löfgren disease very likely evolves different than 
non-Löfgren disease (5), thus contradictory results between these patients may exist. 
It is important to notice that studies in this thesis and reported in current literature 
were not primarily aimed at evaluating Th17-lineage cell or Treg proportions/function 
as potential predictor of disease course in pulmonary sarcoidosis, and were thus not 
powered to make a firm conclusion on ‘Who’ to treat. From these data, it is however 
evident that Th17-lineage cells and Tregs are likely involved in immunological responses 
that contribute to ongoing inflammation in pulmonary sarcoidosis. Prospective studies 
should aim to clarify whether Th17-lineage cell (Chapter 5) and/or Treg (Chapter 3 (9)) 
proportions and/or function of these cells (4) (e.g. cytokine production) can predict 
disease outcome, serving as a prognostic biomarker that could indicate the need for 
treatment. Therefore, ideally, different sarcoidosis-affected organs should be studied 
paired-wise at time of diagnosis in distinct, well-defined sarcoidosis disease entities, 
including Löfgren patients and non-Löfgren patients. Furthermore, serial data during 
active, progressive, resolved and treated disease can further shed light on the role of 
these cells and related factors as determinant of sarcoidosis disease course. 
Implications for practice: when to treat?
Once determined who needs (or will need) treatment, it remains to be decided when to 
start therapy. Biomarkers that reflect disease activity can help physicians decide on the 
need to initiate treatment, but also help evaluate response to therapy. Several serologi-
cal biomarkers have been suggested to reflect disease activity in pulmonary sarcoidosis, 
including angiotensin-converting-enzyme (ACE) and soluble interleukin-2 receptor (sIL-
2R) (12, 13). These markers are however not specific for sarcoidosis activity, and serial 
testing has not proven an additional predictive value to pulmonary function testing and 
radiology (13). The benefit of a reliable peripheral blood biomarker for disease activity is 
evident, as it could assist in monitoring and detecting (subclinical) disease activity and/
or evaluate response to therapy. 
Biomarkers of disease activity: A role for the Treg/Th17 ratio? 
Results of this thesis and current literature suggest a potential role for Treg/Th17 ratio as 
candidate biomarker of disease activity in pulmonary sarcoidosis. Chapter 3 (9) shows 
that circulating Tregs are significantly increased in active pulmonary sarcoidosis patients 
at time of diagnosis. Also, enhanced circulating Th17 cells proportions were detected 
during active disease and at time of progression (3, 14-16) (Chapter 4 (3)). Although 
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both subsets increase in peripheral blood during active/progressive disease, the Treg/
Th17 ratio was found decreased (17-19), suggesting that induction of inflammatory 
cells outbalances anti-inflammatory cells. Importantly, candidate biomarkers should 
correlate with clinical parameters and response to treatment. Indeed, circulating Treg 
proportions are lower in patients at time of relapse than at time of remission and Th17 
cells vice versa (17). This study also published that the Treg/Th17 ratio associates with 
clinical parameters, such as pulmonary function and serum ACE and remission after 
treatment (17). 
Furthermore, data presented in this thesis suggest that BALF Th17.1 cells correlate 
with disease activity (Chapter 4 (3) and 5). However, to confirm this assumption, ideally, 
sarcoidosis Th17.1 BALF proportions should also be measured during inactive disease 
and/or at time of resolution. This is however not very feasible, since patients should then 
undergo a second broncho-alveolar lavage at time of disease inactivity. Furthermore, as 
mentioned above, the advantage of a peripheral blood biomarker is evident above per-
forming serial invasive techniques, such as a broncho-alveolar lavage, to detect disease 
activity. Interestingly, the epigenome is very valuable in in this sense, since it provides 
information on the developmental history, present identity and future potential of cells. 
Since lung Th17.1 cells likely derive from circulating Th17 cells that are initiated in the 
lung mediastinal lymph nodes (MLN) (Chapter 5) it is an attractive idea to examine the 
epigenomic signature of sarcoidosis circulating T cells. Hypothetically, the epigenetic 
profile of circulating Th17 cells reflects the local aberrant Th17.1 cell inflammatory re-
sponse in pulmonary sarcoidosis and can therefore potentially serve as a biomarker. 
Future studies should reveal whether epigenetic profiling of T cells can help optimize 
and personalize pulmonary sarcoidosis treatment in the future. 
In conclusion, these data highlight that there is a role for the Treg/Th17 ratio as disease 
activity marker in pulmonary sarcoidosis, however these studies should be extended, 
evaluating Treg/Th17 ratios at time of diagnosis, at time of resolution or progression 
and during treatment, correlating findings with clinical parameters. Insight could help 
further evaluate the role of the circulating Treg/Th17 ratio as candidate biomarker of 
disease activity in pulmonary sarcoidosis. Furthermore, although still in its infancy, an 
attractive line of investigation to identify new biomarkers for pulmonary sarcoidosis 
would be to examine the epigenome of circulating T cells in pulmonary sarcoidosis. 
Implications for practice: how to treat? 
The ideal therapy for pulmonary sarcoidosis would alter the natural course of the dis-
ease. This means: inducing resolution in patients that suffer (or will suffer) from chronic 
sarcoidosis. The cornerstone of current pulmonary sarcoidosis therapy, i.e. prednisone, 
does suppress symptoms and inflammation in pulmonary sarcoidosis, but does not 
seem to alter disease course in the long-term (20). Therefore, therapeutic targets that do 
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change disease course are warranted. Additionally, current prednisone therapy induces 
significant side-effects, thus treatment strategies reducing these side-effects could 
increase quality of life of patients. Results of this thesis that are valuable in this sense 
are discussed below. 
Potential new therapy (1): A role for CTLA4-Ig?
The heterogeneity of sarcoidosis suggests that determinants of disease etiology (Why 
does someone develop the disease in the first place?) in sarcoidosis are (at least partly) 
distinct from factors determining disease course (Why does the disease not resolve in 
some patients?). New therapeutic targets that have the potential to change disease 
course may be identified from looking into factors determining disease etiology or 
disease progression.
Importantly, findings in Chapter 2 (8) of this thesis argue for a key role for cytotoxic 
T lymphocyte antigen (CTLA)4 and specific CD4+ T-cell subsets (Tregs and Th17 cells) 
in sarcoidosis disease etiology. The cause of impaired CTLA4 expression in specifically 
Tregs and Th17 cells in sarcoidosis MLN remains unclear. Based on findings presented 
in Chapter 2 (8), it is not very likely that T-cell exhaustion underlies impaired CTLA4 
expression in sarcoidosis. This idea is indeed further strengthened by results in Chap-
ter 5 providing evidence for a significant decrease in programmed cell death protein 
(PD)-1 expression on specifically sarcoidosis Th17 cells, rather than an increase as would 
be expected during exhaustion. Currently, also more and more case reports emerge 
regarding sarcoidosis development or exacerbation during anti-PD1 therapy in cancer 
patients (21-24), making it more likely that global deregulation of co-inhibitory receptor 
expression might be a determinant of disease etiology, rather than aberrant expression 
of CTLA4 alone. 
Interestingly, butyrophilin-like 2 (BTNL2) also negatively regulates T-cell activation, 
independently of CTLA4 and PD-1, and a recent meta-analyses showed that a BTNL2 
polymorphism contributes to disease susceptibility in sarcoidosis (Chapter 6 (25)). Fur-
thermore, CTLA4 and BTNL2 gene mutations have also been identified in families with 
common variable immunodeficiency (CVID), including patients with granulomatous 
lung disease (26, 27). However, although it seems conceivable that genetic changes 
can (partly) drive the aberrant expression of checkpoint inhibitors that contribute to 
granuloma formation in sarcoidosis, results in Chapter 2 (8) and 3 (9) suggest that the 
genetic contribution is likely very low. Mutations in CTLA4 in patients with CVID led 
to impaired upregulation of this protein on activated Tregs (27), yet, we found that 
CTLA4 on activated Tregs is significantly upregulated compared with other Th subsets in 
sarcoidosis MLN (Chapter 2 (8)) and circulating Tregs even showed a significant increase 
in CTLA4 expression compared with their control counterpart (Chapter 3 (9)). Finally, in 
a screening experiment we did not find evidence for the presence of CTLA4 mutations 
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in 38 sarcoidosis patients (data not shown). Together, these data rather suggest that 
CTLA4 expression is differentially regulated in sarcoidosis-affected organs, for example 
by epigenetic mechanisms and/or due to the local inflammatory environment. 
For instance, expression of co-inhibitory receptors depends on the strength of T-cell 
receptor (TCR) signaling (28), which can vary between affected immunological compart-
ments. Findings in our studies do not provide evidence for decreased CD28 expression 
on Th17 cells in pulmonary sarcoidosis MLN (Chapter 2 (8) and 5). However, an impaired 
response of sarcoidosis peripheral blood (PB)- and BALF-derived T cells towards anti-
CD3 and anti-CD28 has been reported in active sarcoidosis (29). Thus, theoretically, dis-
tinct sarcoidosis T-cell subsets could have become less dependent on CD28 signaling, 
possibly due to chronic antigenic stimulation, resulting in deregulated PD-1 and CTLA4 
pathways, which is remarkably similar to findings in chronic beryllium disease (30); an 
occupational lung disease that is also characterized by granuloma formation on the 
lungs that can be indistinguishable from sarcoidosis. 
Nonetheless, consistent with previous literature and our results in Chapter 2 it is at 
least very likely that decreased CTLA4 (and possibly also PD-1) expression on specifically 
Tregs and Th17 cells in sarcoidosis MLN can cause double trouble in sarcoidosis, i.e. by 
increasing Th17 cell responses (thereby affecting the delicate Treg/Th17 balance (17-19), 
since Treg proportions remain unaffected (Chapter 2 (8))) and impairing Treg function (6) 
(see Figure 2 in Chapter 6 (25)). Therefore, future research should aim to clarify the role 
of co-inhibitory and co-stimulatory receptors on distinct T-cell subsets in sarcoidosis-
affected organs, helping to gain further insight in this likely important determinant of 
sarcoidosis disease etiology and further providing a rationale to evaluate the role of 
CTLA4-Ig (e.g. Abatacept) in the treatment of (chronic) pulmonary sarcoidosis. 
Potential new therapy (2): A role for anti-IL23p19? 
This thesis is the first to identify a role for failure of immune regulation within a Th cell 
in sarcoidosis, which is decreased CTLA4 expression on specifically Th17 cells (Chapter 2 
(8)). Interestingly, as CTLA4 expression displayed limited interpatient variability in Th17 
cells of newly-diagnosed and treatment-naïve sarcoidosis patients (Chapter 2 (8)), it is 
more likely that reduced CLTA4 expression is a contributor to disease etiology rather than 
to disease course. However, as previously highlighted, in this thesis also a significant as-
sociation was found between lung Th17.1 cells and disease prognosis (Chapter 5). It is 
thought that Th17.1 cells can derive from Th17 cells (2, 31, 32), and data in Chapter 5 
indeed argue for a role of Th17-Th17.1 cell plasticity in sarcoidosis lungs. Therefore, it is 
tempting to speculate that decreased CTLA4 expression on Th17 cells is a trigger that 
contributes to Th17 differentiation in sarcoidosis MLN (8, 14, 15)(Chapter 5), and that a 
distinct factor contributes to ongoing inflammation and possibly development of fibro-
sis in the future. Although research of this thesis did not look into factors contributing 
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to development of fibrosis in pulmonary sarcoidosis, aberrancies in Tregs and Th17 cells 
and related factors have been described to contribute to pulmonary fibrosis (33-38), 
and CCR6+-lineage cells have been found to affect synovial fibroblasts in rheumatoid 
arthritis (31), thus further investigation of these cells in patients with Scadding stage IV 
seems an attractive line of investigation. Nevertheless, based on findings in this thesis it 
is very likely that factors contributing to Th17-Th17.1 plasticity in sarcoidosis lungs are 
likely to include target candidates to inhibit ongoing chronic inflammation. 
For example, IL-23R signaling was found to be essential for conversion of Th17 cells 
towards Th17.1 cells in mice (39, 40) and two independent polymorphisms within the 
IL23R gene were associated with (chronic) sarcoidosis (41, 42). A monoclonal antibody 
that binds to the shared p40 subunit of IL-12 and IL-23 (Ustekinumab) has been evalu-
ated in chronic pulmonary sarcoidosis with the rationale to inhibit both Th1 and Th17 
cell induction (43). However, no obvious effect on forced vital capacity (FVC) change and 
secondary endpoints were detected in this trial (43), although it was argued that the 
trial design of this study may have contributed to a failure to detect a potential effect of 
Ustekinumab (44). Data of this thesis (Chapter 4 (3) and 5) show that not Th1 cells, but 
specifically Th17-lineage cells are affected in pulmonary sarcoidosis. Since Th17.1 cells 
are likely most pathogenic in sarcoidosis (Chapter 4 (3)), an antibody directed against 
solely IL-23R-signaling, i.e. anti-IL-23p19 (Tildrakizumab/Guselkumab), which was re-
cently described to be successful in psoriasis (45), may be a more attractive alternative 
for evaluation in pulmonary sarcoidosis. 
Nevertheless, future research should first aim to clarify function (e.g. T-cell receptor 
specificity and cytokine production) of Th17-lineage cells in pulmonary sarcoidosis, since 
the role of these distinct T-cell subsets in pulmonary sarcoidosis (and Lofgren’s disease) 
remain relatively under-investigated and inconclusive (as previously discussed). Identi-
fying for example T-cell receptor specificity of these cells can help evaluate whether they 
are of oligoclonal or polyclonal origin and therefore targeted at the putative antigen or 
randomly attracted, respectively. Finally, in-vitro studies should aim to evaluate the role 
of IL-23R-signaling and other factors in Th17-Th17.1 cell plasticity in chronic pulmonary 
sarcoidosis. 
Optimizing current prednisone treatment: A role for early dose tapering? 
Prednisone, the current mainstay of pulmonary sarcoidosis therapy, is immunosup-
pressive but not curative. It restores the Treg/Th17 ratio in pulmonary sarcoidosis, 
while leaving Th1 and Th2 cells unaffected (17-19), confirming an important role for a 
disruption of a delicate balance between these cells in active pulmonary sarcoidosis 
(Chapter 6) (25). As it is debated whether prolonged therapy affects the course of the 
disease or prevents complications such as developing fibrosis in the future (20), it is now 
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thought that prednisone therapy in pulmonary sarcoidosis needs to be given as long as 
the disease is active and clinical symptoms demand suppression. 
The optimal prednisone treatment strategy in newly-treated patients that controls 
symptoms and inflammation, while minimizing serious side-effects, remains unknown. 
Findings described in this thesis (Chapter 7 and 8) suggest that current treatment strate-
gies can be adjusted in order to optimize prednisone therapy, i.e. by early initiation of 
dose tapering, guided by daily home spirometry. 
Results described in Chapter 7 indicate that there is no clear correlation between 
prednisone dose given for newly-treated pulmonary sarcoidosis and FVC change, while 
cumulative prednisone did correlate with weight increase in the long term. A lower 
cumulative prednisone dose in the long term (12 months) was mainly characterized by 
early dose tapering, i.e. to below 10 milligrams (mg)/day within 3.5 months, and to a 
lesser extent by the initial starting dose. Results of a prospective, observational study 
that carefully home-monitored early treatment responses in newly-treated pulmonary 
sarcoidosis patients (Chapter 8) further showed that most (>90%) of the change in 
FVC and dyspnea symptoms already occurs within 2-3 weeks, remaining stable up to 3 
months during dose tapering. 
Together these data suggest that prednisone therapy in newly-treated pulmonary 
patients, that is predominantly focused on preserving lung function (i.e. FVC) and con-
trolling pulmonary symptoms, will likely benefit from earlier clinical evaluation, which 
could lead to earlier and personalized prednisone dose tapering, preventing side effects 
while retaining effect. 
In our retrospective study in Chapter 7 we did not find evidence that FVC response 
to a lower prednisone dose treatment strategy is influenced by characteristics of severe 
disease at start of treatment. It is tempting to speculate that patients receiving a high 
cumulative dose, often exhibiting more severely impaired lung function at the start of 
treatment, were tapered off of prednisone more slowly in pursuit of a ‘normal’ lung func-
tion. Indeed, prednisone therapy with more than 10 mg/day in pulmonary sarcoidosis 
patients might be warranted in certain cases. For example, a very low FVC at start of 
treatment can prolong time to recovery of the lung function to a level that relieves 
symptoms (Chapter 8). Ultimately, the treatment goal (e.g. prevention of organ damage, 
improvement versus ‘normalization’ of lung function, improvement of symptoms and/
or quality of life) and with that the treatment strategy will remain a topic of careful, 
individual assessment and discussion between patient and caregiver. Our data on short 
term effects and long term side effects may help in making a balanced assessment. 
Long-term follow up of our prospective trial cohort (Chapter 8) should reveal whether 
early changes in FVC can predict therapy outcome in the long-term, such as the need for 
second- and third-line treatments (46). 
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Importantly, data in Chapter 8 of this thesis validate the (daily) use of a hand-held 
spirometer to careful home monitor patients’ individual early lung function response 
to therapy in pulmonary sarcoidosis. However, ideally, in the future, an approach that 
integrates multiple home monitored features, such as pulmonary function, but also 
patient-reported outcomes, would further increase accuracy of clinical evaluation (13) 
and will help further personalize treatment of pulmonary sarcoidosis patients, both of 
new onset as well as patients suffering from chronic sarcoidosis. In order to reach such 
a goal, a study comparing effectivity and steroid-sparing potential of an internet-based 
home monitoring system that adjusts prednisone treatment daily and/or weekly (47) 
with current clinical practice of prednisone treatment for pulmonary sarcoidosis patients 
in a randomized fashion could be conceived. 
outstanding questions for future research
This thesis provided new questions for future research in pulmonary sarcoidosis, that is 
to say: 
- Can a Treg and/or Th17-lineage cell-associated factor serve as a new biomarker in 
pulmonary sarcoidosis?
- Can the epigenomic signature of circulating T cells function as new potential bio-
marker in pulmonary sarcoidosis? 
- What is the TCR specificity of Th17.1 cells in pulmonary sarcoidosis?
- What factors contribute to Th17-Th17.1 plasticity in pulmonary sarcoidosis?
- What is the role of CCR6+ Th17-lineage cells in fibrotic (Scadding stage IV) sarcoid-
osis?
- What molecular/cellular link between CCR6+ Th17-lineage cells and Tregs contributes 
to granuloma formation in pulmonary sarcoidosis?
- Can CTLA4-Ig and/or anti-IL23p19 serve as a new therapy for pulmonary sarcoidosis?
- Can frequent home monitoring be employed to optimize and personalize treatment 
of pulmonary sarcoidosis patients? 
Concluding remarks
Findings described in this thesis provide a new perspective on sarcoidosis pathogen-
esis, challenging long-held paradigms (Chapter 3 (3)) and providing novel (technical) 
approaches to further unravel this immunological complex disease (Chapter 6 (25)). The 
importance of carefully characterizing T-cell subsets (including proportions, phenotype 
and predisposition to plasticity) in distinct affected organs (lungs, mediastinal lymph 
nodes and peripheral blood) in pulmonary sarcoidosis is highlighted, and is likely part 
of the key to further understand this enigmatic disease. 
In this sense it should be noticed that research presented in this thesis has focused 
on the role of T-cell subsets in pulmonary sarcoidosis, however the importance of an-
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tigen presenting cells (macrophages, dendritic cells and B cells (48)) as being part of 
sarcoidosis etiology is acknowledged by the author (see Chapter 1 (6)). Ideally, the total 
immune profile of distinct organs in pulmonary sarcoidosis patients is characterized, 
and techniques analyzing ‘big immunological data’ in an unsupervised fashion should 
be applied (49) to determine other key role players or interactions between immune 
cells and derived factors that determine disease etiology/outcome. 
Furthermore, because of the heterogeneity of disease presentation, it is conceivable 
that the immunological profile of patients is also personally determined and that similar 
to prednisone therapy (Chapter 7 and 8), treatment with other (new) immune modulat-
ing therapies should be personalized, depending on what aberrant immunological re-
sponse is predominant. Detailed clinical characterization of patients is highly warranted 
during immunological profiling. 
Data in this thesis also point towards a striking overlap between sarcoidosis and other 
auto-immune disorders, such as rheumatic arthritis, systemic lupus erythematosus and 
psoriasis. Developments in the autoimmunity field in both immunology and clinical 
therapies should be carefully followed and validated/applied in sarcoidosis research. 
Indeed, this thesis helped to provide a rationale to evaluate the potential of certain 
existing therapies that are used/evaluated in other auto immune diseases. Although the 
search for the ideal experimental model for sarcoidosis remains ongoing, current models 
mimicking granuloma formation can at least be considered for pre-clinical evaluation of 
potential efficacy of these drugs (50). 
Finally, results of this thesis provided practical clinical suggestions that may be ap-
plied in current treatment policies. The main challenge for future research lies within in-
tegrating these basic immunological and practical findings into current clinical practice 
and therefore a tight collaboration between physicians and researchers remains most 
essential. Thus to conclude, to suffer from pulmonary sarcoidosis, It Takes Two To Tangle, 
to solve it, it will (at least) Take Two To Tango! 
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SUmmaRy of ThE ThESIS
Pulmonary sarcoidosis is an intriguingly complex immunological disorder. It is character-
ized by granuloma formation in the lung and the lung-draining mediastinal lymph nodes 
(MLN), upon chronic antigenic stimulation of unknown origin. Sarcoid granulomas can 
also affect the eyes and the skin, and in rare cases the heart, liver, central nervous system 
or bones. 
A granuloma is a conglomerate of immune cells and formation of a granuloma likely 
occurs in order to optimize interactions between antigen presenting cells and adaptive 
immune cells, such as T cells. Typically, a fibrotic rim encapsulates the granuloma, aid-
ing in preventing dissemination of the (infectious) antigen. A granuloma can arise in 
response to infectious agents such as mycobacteria and fungi, but also inorganic agents, 
such as silica and beryllium, can induce granuloma formation. Although several antigens 
have been proposed to be part of sarcoidosis etiology, not one antigen has yet been 
identified that can explain all cases of the disease. Therefore, sarcoidosis is considered a 
multisystem granulomatous disorder of unknown cause. 
The disease affects people all over the world, but the incidence/prevalence rates and 
natural course of the disease vary greatly. For example, the incidence rate of sarcoidosis 
is approximately three times higher in Afro-Americans than Caucasians. Also, granulo-
mas tend to resolve spontaneously in the majority of patients, but in approximately 30% 
of the patients, granulomas persist, which can lead to chronic, sometimes progressive 
disease with need for treatment. Afro-American women with pulmonary sarcoidosis 
have a higher chance of developing chronic disease. In contrary, clinical presentation 
with the Löfgren triad, that is lung bihilar lymphadenopathy on the lungs alongside 
uveitis and erythema nodosum or ankle arthritis, is typically associated with a good 
prognosis and occurs more often in Caucasians. 
Gaps in knowledge on sarcoidosis disease etiology and determinants of disease 
course have thus far impeded rational decisions on ‘Who, When and How’ to treat. The 
mainstay of sarcoidosis therapy remains immunosuppressive, using relatively high doses 
of systemic prednisone. However, although often effective, corticosteroid treatment can 
be accompanied by severe side effects and knowledge on optimal dosing strategies 
balancing effects and side effects, is lacking. Detailed insight in the immunological 
response occurring in pulmonary sarcoidosis patients can help find determinants of 
disease etiology and disease course, which can yield new therapeutic targets. Therefore, 
the first aim of this thesis is to further unravel the immune-related pathogenesis of pul-
monary sarcoidosis (Part 1). The second aim of this thesis is to gain insight into current 
prednisone treatment, in order to optimize treatment strategies to reduce side-effects 
and increase quality of life of pulmonary sarcoidosis patients (Part 2). 
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Part 1: Unraveling the pathogenesis of pulmonary sarcoidosis
A well-developed sarcoid granuloma consists of a tightly formed conglomerate of 
epithelioid- and multinucleated-giant cells encircled by lymphocytes, especially CD4+ 
T helper (Th) cells, but also rare CD8+ T cells and B cells. In Chapter 1 a model for 
granuloma formation in pulmonary sarcoidosis is proposed, combining careful clinical 
observations with existing evidence in literature. Available evidence suggests that an 
unknown antigen in pulmonary sarcoidosis activates interstitial dendritic cells (DCs) 
and alveolar macrophages (AMs). This process is possibly initiated by toll-like receptor-2 
(TLR-2) ligands in pulmonary sarcoidosis, such as Mycobacterium tuberculosis-derived 
ESAT-6 or mKatG proteins. Following stimulation, DCs migrate towards MLN where 
they initiate differentiation and expansion of Th1 and Th17 cells. Simultaneously, TLR-2 
stimulation of AMs initiates a cascade of cytokine and chemokine production in the 
lungs, including production of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), C-C 
motif chemokine ligand 2 (CCL2), CCL20 and C-X-C motif chemokine ligand 10 (CXCL10). 
This process leads to cellular aggregation, formation of multinucleated giant cells, and 
attraction of important building blocks of the sarcoid granuloma, namely Th1/Th17 
cells, monocytes and regulatory T cells (Tregs).
Granuloma formation in pulmonary sarcoidosis is widely considered as an exagger-
ated Th1/Th17 immune response upon exposure to an unknown antigen. However, 
mechanisms contributing to this exaggerated response in pulmonary sarcoidosis pa-
tients remain largely obscure. Key players in a disease are often identified by mouse 
models that lack or overexpress a specific protein or cell type of interest. Development 
of a universally accepted mouse model for sarcoidosis has proven difficult, hampering 
research efforts employing this strategy. Interestingly, in Chapter 2 we describe how 
emerging clinical observations in human cancer treatment shed new light on key play-
ers in sarcoidosis pathogenesis and helped identify a key role for Tregs and Th17 cells in 
pulmonary sarcoidosis. 
As presented in Chapter 2, more and more case reports describe occurrence of sar-
coidosis or sarcoid-like disease during “re-boosting” of the immune system in cancer 
patients using anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) agents. CTLA4 is an 
important suppressor of T-cell mediated immune responses, thus this phenomenon 
provided a rationale to look into CTLA4 expression in sarcoidosis-derived T cells. Intrigu-
ingly, we found that specifically Tregs and Th17 cells in sarcoidosis MLN showed aberrant 
expression of this important immune suppressive protein. A model is proposed whereby 
this phenomenon can cause double trouble in sarcoidosis, i.e. by increasing Th17 cell 
responses (thereby affecting the delicate Treg/Th17 balance, since Treg proportions 
remained unaffected) and impairing Treg function. 
Failure of immune regulation by Tregs has long been suggested to contribute to on-
going inflammatory responses in pulmonary sarcoidosis. However, factors contributing 
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to this phenomenon remained largely unknown and conflicting data was published re-
garding their proportions in various affected organs. In Chapter 3 we aimed to system-
atically investigate the role of Tregs in pulmonary sarcoidosis by analyzing their propor-
tions, phenotype, survival and apoptotic susceptibility. We confirmed that circulating 
sarcoidosis-derived Tregs have an impaired immune suppressive function, and clarified 
that no evidence was found for a numeral deficit, neither locally nor systemically. Rather, 
circulating Treg proportions were significantly increased in sarcoidosis patients, specifi-
cally in patients developing chronic disease. Also, no evidence was found for decreased 
expression of important immunosuppressive proteins, such as FoxP3, CD25 or CTLA4 on 
circulating Tregs. However, importantly, circulating sarcoidosis Tregs were found to be 
highly apoptotic, likely contributing to an impaired function of these cells in pulmonary 
sarcoidosis. 
Whereas Th17 cells were previously found to be increased in patient lungs, sarcoidosis 
was still largely thought to be a Th1 mediated disease, because the total proportions 
of interleukin (IL)-17-producing cells remained very low. However, our findings in 
Chapter 2 suggested a key role for Th17 cells in pulmonary sarcoidosis and concomi-
tantly it became clear in the T-cell field that stringent classification of T cells based on 
cytokine production may not be correct. Certain T-cell subsets, such as Th17 cells, are 
found to be more prone to plasticity and can adopt cytokine production capabilities 
of other T-cell subsets. We previously identified increased proportions of IL-17A/IFN-γ-
double-producing memory Th cells in a small sarcoidosis patient cohort and therefore 
hypothesized that the role of Th17 cells in pulmonary sarcoidosis may be greater than 
anticipated. Th17 cells perhaps play an important role in the disease pathogenesis by 
mimicking Th1 cytokine (IFN-γ) production. So called Th17.1 cells are known for this 
ability in other disease states. In Chapter 4 we aimed to identify the origin of IFN-γ-
producing cells in pulmonary sarcoidosis. And indeed, we found that not Th1 cells, but 
specifically Th17-derived IFN-γ-producing cells (Th17.1 cells) are increased in sarcoidosis 
and responsible for the exaggerated IFN-γ production in sarcoidosis lungs, challenging 
long-held paradigms in the sarcoidosis field. 
Primary Th cell activation and subset differentiation occurs in lung draining MLN. Above 
mentioned IFN-γ-producing Th17.1 cells can derive from Th17 cells under influence of 
a specific cytokine milieu. Therefore, we hypothesized that in pulmonary sarcoidosis 
Th17 cells are primarily induced in the MLN and that the granulomatous environment 
in the lungs induces plasticity towards Th17.1 cells. In Chapter 5 we challenged this 
hypothesis and aimed to gain more insight in the induction of Th17.1 cells in sarcoidosis 
by looking into proportions and phenotypic characteristics of CCR6+ Th17-lineage cells 
in sarcoidosis and control MLN, and sarcoidosis lungs. The results of this study suggest a 
model whereby Th17 cells are induced in sarcoidosis lymph nodes, and show plasticity 
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towards pathogenic Th17.1 cells in sarcoidosis lungs, where they are particularly critical 
for development of chronic disease. 
Finally, in Chapter 6 recent insights in sarcoidosis T-cell immunology are reviewed. 
Based on new findings in Tregs, Th17.1 cells and checkpoint inhibitors we propose that 
it is very likely that a disruption of the delicate balance between helper and regulatory 
cells contributes to the exaggerated Th cell response in pulmonary sarcoidosis. Data 
presented in Part 1 of this thesis provide a new perspective on sarcoidosis pathogenesis 
and consequently on therapeutic targets. 
Part 2: optimization of prednisone treatment in pulmonary sarcoidosis
Prednisone therapy in pulmonary sarcoidosis is only indicated in certain cases, such 
as during development of a dangerous health situation or when there is a significant 
decrease in the patient’s quality of life. Unfortunately, the optimal dose and duration of 
prednisone treatment remains uncertain, thus current guidelines include a broad range, 
which could result in low dose-treated patients versus high dose-treated patients, 
depending on the physician’s practice, which might lead to unmet therapeutic goals or 
unnecessary side effects. 
Identifying the optimal treatment strategy that preserves organ function and relieves 
symptoms, but simultaneously minimizes side-effects, may increase quality of life of 
newly-treated pulmonary sarcoidosis patients. Therefore, in order to gain insight in what 
dosing strategy has the best balance between effect and side-effects, in Chapter 7 we 
aimed to describe forced vital capacity (FVC) (effect) and weight (side-effect) changes 
during different prednisone doses used in daily practice for treatment naïve pulmonary 
sarcoidosis patients. Using a retrospective, multicenter set-up, this study indeed showed 
clinical variation in prednisone treatment, but did not find evidence for a strong asso-
ciation between prednisone dose used and FVC change in newly treated sarcoidosis 
patients in the short (3-9 months) and long (12-24 months) term. However, weight 
gain positively correlated with cumulative prednisone dose used in the long term. The 
strategy leading to a lower dose at 12 months was characterized by early dose tapering, 
i.e. less than 10 mg/day at 3.5 months. Importantly, we did not find evidence that FVC 
response to a lower prednisone dose treatment strategy is affected by characteristics 
of more severe disease at start of treatment. These results suggest that prednisone 
therapy, aimed at maintaining/improving FVC in pulmonary sarcoidosis can often be 
reduced in clinical practice and highlight the need for prospective trials that carefully 
monitor treatment efficacy of a lower dose treatment regimen, characterized by early 
dose taping, in newly treated sarcoidosis patients. 
Results presented in Chapter 7 and available evidence suggested that early dose ta-
pering is likely to reduce side-effects in prednisone therapy for pulmonary sarcoidosis. 
It was previously suggested that prednisone effect on FVC occurs quickly within one 
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month. However, a prospective study monitoring individual lung function changes on 
a daily basis in newly-treated sarcoidosis patients to identify effect optimum, and also 
including clinical symptoms, is lacking. Therefore, in Chapter 8 results are presented of 
a prospective, observational study, evaluating early FVC and symptom changes during 
prednisone treatment and tapering in newly-treated sarcoidosis patients, using daily 
home spirometry. Results of this study showed that most of the improvement in lung 
function and symptoms occur within 2-3 weeks during first-line prednisone treatment. 
Importantly, these results suggest that frequent (home) monitoring of lung function 
and symptoms has the potential to individualize prednisone therapy, aiming at early 
dose tapering, side-effect reduction and increasing patient-related quality of life. 
Several results of this thesis may be of value for clinical practice and are highlighted 
in the Epilogue. From this thesis it is evident that Th17-lineage cells and Tregs are 
likely involved in immunological responses that contribute to ongoing inflammation in 
pulmonary sarcoidosis, thus prospective studies evaluating Treg and Th17-lineage cell-
associated factors as predictor of disease course or disease activity are expected to have 
implications for clinical practice in the future. Intriguingly, results of this thesis provide 
a rationale to evaluate the potential of both novel and existing therapies in pulmonary 
sarcoidosis, such as CTLA4-Ig (e.g. abatacept) or anti-IL-23p19 (e.g. tildrakizumab/
guselkumab). And finally, results of this thesis provided practical clinical suggestions 
that could be applied in current prednisone treatment policies. The main challenge for 
future research lies within integrating these basic immunological and practical findings 
into current clinical practice and therefore a tight collaboration between physicians and 
researchers remains most essential. Thus to conclude, to suffer from pulmonary sarcoid-
osis, It Takes Two To Tangle, to solve it, it will (at least) Take Two To Tango! 
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SamEnVaTTIng Van hET PRoEfSChRIfT
Pulmonale sarcoïdose is een intrigerend complexe immunologische aandoening. De 
ziekte wordt gekarakteriseerd door granuloom vorming in de longen en in de long-
drainerende mediastinale lymfeklieren. De granulomen ontstaan door chronische 
antigeen-gemedieerde stimulatie van het immuunsysteem. De oorzaak hiervan is echter 
onbekend. Granulomen kunnen bij sarcoïdose ook worden aangetroffen in de ogen, de 
huid en in zeldzame gevallen ook in het hart, de lever, het centrale zenuwstelsel en in 
de botten. 
Een granuloom is een opeenhoping van afweercellen en ontstaat zeer waarschijnlijk 
om de interactie tussen antigeen presenterende cellen (APC) en cellen van de verwor-
ven afweer, zoals T-cellen, te optimaliseren. Vaak wordt een granuloom omgeven door 
een fibrotische rand om verspreiding van een (infectieus) antigeen te voorkomen. Een 
antigeen is een molecuul dat in staat is een reactie van de afweer op te wekken. Een 
granuloom kan ontstaan als reactie op chronische stimulatie van de afweer door een 
infectieus agens, zoals een tuberculose bacterie of schimmel. Echter, ook anorganische 
stoffen, zoals siliciumdioxide en beryllium, kunnen granulomen induceren. Ondanks dat 
er enkele antigenen zijn gesuggereerd als oorzaak van sarcoïdose, is er niet één gevon-
den die alle gevallen van de ziekte kan verklaren. Daarom wordt sarcoïdose gedefinieerd 
als een granulomateuze, multisysteem ziekte van onbekende oorzaak. 
Sarcoïdose komt voor bij mensen over de hele wereld, maar de klinische presenta-
tie en het ziektebeloop variëren enorm tussen verschillende populaties. Zo komt de 
ziekte ongeveer drie keer vaker voor bij mensen van Afro-Amerikaanse afkomst dan bij 
mensen van Kaukasische afkomst. Bij de meerderheid van de mensen verdwijnen de 
granulomen spontaan, maar bij ongeveer 30% van de patiënten blijven de granulomen 
chronisch aanwezig. Dit kan leiden tot blijvende, soms progressieve klachten met nood-
zaak tot therapie. Het is niet goed te voorspellen wie chronisch ziek zal worden, maar 
het is bijvoorbeeld wel bekend dat Afro-Amerikaanse vrouwen hier een grotere kans op 
hebben. Daartegenover staat dat een klinische presentatie met het Löfgren syndroom 
bijna altijd gepaard gaat met een snel herstel. Het syndroom wordt gekenmerkt door 
een trias van problemen bij klinische presentatie, namelijk: bihilaire lymfadenopathie, 
uveitis en erythema nodosum en/of enkel artritis. Het Löfgren syndroom komt vaker 
voor bij mensen van het Kaukasische ras. 
Aangezien we nog weinig weten over de ziekte etiologie en voorspellers van het 
ziektebeloop, blijft het nog onzeker wie, wanneer en hoe we exact moeten behandelen. 
De huidige behandeling voor pulmonale sarcoïdose is slechts immunosuppressief, niet 
curatief, waarbij in de eerste instantie aanzienlijke hoeveelheden prednison worden 
voorgeschreven. Ook al is prednison behandeling vaak effectief in sarcoïdose; het leidt 
helaas ook tot het ontstaan van vervelende bijwerkingen. Goede kennis over de opti-
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male behandelstrategie, waarbij het therapie effect van prednison in balans is met de 
bijwerkingen, mist.
Inzicht in de immunologische respons die optreedt bij pulmonale sarcoïdose draagt 
bij aan het vinden van factoren die een aandeel hebben in het ontstaan van de ziekte 
én factoren die het beloop van de ziekte beïnvloeden. Dit kan nieuwe aangrijpingspun-
ten onthullen voor effectievere therapieën. Om deze reden was het primaire doel van 
dit proefschrift om de immuun-gerelateerde pathogenese van pulmonale sarcoïdose 
verder te ontrafelen (Deel 1). Het tweede doel was om inzicht te krijgen in de huidige 
prednison behandeling, ter optimalisatie van hedendaagse behandelstrategieën om 
daarmee bijwerkingen te minimaliseren en de kwaliteit van leven van patiënten te 
verbeteren (Deel 2). 
Deel 1: het ontrafelen van de pathogenese van pulmonale sarcoïdose
Een granuloom in sarcoïdose is een opeenhoping van epithelioide histiocyten en meer-
kernige reuscellen, die worden omringd door lymfocyten, met name CD4+ T-helper (Th) 
cellen, maar ook in mindere mate CD8+ T cellen en B cellen. In hoofdstuk 1 presenteren 
wij een model voor granuloomvorming in pulmonale sarcoïdose door klinische observa-
ties te combineren met bestaande literatuur over granuloomvorming. Bestaande infor-
matie suggereert dat een onbekend antigeen de interstitiële dendritische cellen (DCs) 
en alveolaire macrofagen (AMs) activeert. Dit proces wordt waarschijnlijk gemedieerd 
door Toll-like receptor-2 (TLR-2) agonisten, zoals bijvoorbeeld de van Mycobacterium 
tuberculosis-afkomstige eiwitten ESAT-6 of mKatG. Na stimulatie migreren interstitiële 
DCs naar de mediastinale lymfeklieren, alwaar ze differentiatie en expansie van Th1 
en Th17 cellen initiëren. Tegelijkertijd leidt TLR-2-gemedieerde stimulatie van AMs tot 
de initiatie van een cascade aan cytokine- en chemokine productie in de longen. Eerst 
wordt de productie van tumor necrosis factor-α (TNF-α) door AMs geïnitieerd, waarna 
de productie van interferon-γ (IFN-γ), C-C-motief chemokine ligand 2 (CCL2), CCL20 en 
C-X-C-motief chemokine ligand 10 (CXCL10) volgen. Dit proces leidt tot cellulaire aggre-
gatie, formatie van meerkernige reuscellen en chemoattractie van belangrijke bouwste-
nen van het granuloom. Zo worden onder andere monocyten, pro-inflammatoire Th1/
Th17 cellen en immunosuppressieve regulatoire T-cellen (Tregs) aangetrokken.
Het wordt gedacht dat granuloomvorming in pulmonale sarcoïdose ontstaat door 
een (chronische) overmatige Th1/Th17 immuunrespons na expositie aan een onbekend 
antigeen (Hoofdstuk 1). Echter, de mechanismen die leiden tot het ontstaan van deze 
overmatige respons blijven grotendeels obscuur. Vaak worden met behulp van een 
muismodel factoren ontdekt die sterk bijdragen aan het ontstaan van een ziekte, bij-
voorbeeld doordat een specifiek eiwit of een celtype niet of juist overmatig kan worden 
aanmaakt. Ontwikkeling van een universeel geaccepteerd muismodel voor sarcoïdose 
is moeizaam gebleken, waardoor bovengenoemde aanpak wordt belemmerd. Echter, 
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in hoofdstuk 2 beschrijven wij hoe klinische observaties in kankerbehandeling nieuwe 
inzichten geven in de pathogenese van sarcoïdose en een belangrijke rol identificeert 
voor Tregs en Th17 cellen.
Zoals wordt gepresenteerd in Hoofdstuk 2 worden er meer en meer casussen beschre-
ven over het ontstaan van sarcoïdose of sarcoïde-achtige reacties tijdens het boosten 
van het immuunsysteem in kankerpatiënten met anti-cytotoxic T-lymfocyte antigen 4 
(CTLA4). CTLA4 is een sterke onderdrukker van de T-cel-gemedieerde immuunrespons, 
dus dit fenomeen leverde een rationale om naar CTLA4 expressie in sarcoïdose T-cellen 
te kijken. Intrigerend genoeg vonden wij dat specifiek Tregs en Th17 cellen in sarcoï-
dose mediastinale lymfeklieren een verminderde expressie hebben van dit belangrijke 
immunosuppressieve eiwit. In dit hoofdstuk wordt een model voorgesteld waarbij dit 
fenomeen kan leiden tot een dubbel probleem (‘double trouble’) in pulmonale sarcoï-
dose, namelijk door het versterken van de Th17 cel respons (daarbij wordt de delicate 
Treg/Th17 balans ontwricht, aangezien de Treg proporties onveranderd bleven) en het 
verminderen van de immunosuppressieve Treg functie. 
Een verminderde suppressieve Treg functie is eerder beschreven in pulmonale sarcoï-
dose en het is ook gesuggereerd dat dit kan bijdragen aan het ontstaan van chronische 
inflammatie. Echter, factoren die bijdragen aan deze verminderde Treg functie blijven 
onbekend. Ook is er nog veel tegenstrijdige data over Treg aantallen in verschillende 
aangedane organen. In hoofdstuk 3 analyseren wij systematisch de rol van Tregs in pul-
monale sarcoïdose, door te kijken naar proporties, het fenotype, de overleving en apop-
totische gevoeligheid. We bevestigen dat circulerende Tregs in pulmonale sarcoïdose 
een verminderde immunosuppressieve werking hebben, maar vinden geen aanwijzing 
voor een tekort in aantallen, zowel in het bloed als lokaal in de longen. In tegendeel, 
het aantal circulerende Tregs was juist verhoogd op het moment van diagnose, en met 
name bij patiënten die binnen twee jaar chronische, progressieve ziekte ontwikkelen. 
Ook vonden wij geen aanwijzingen voor een verminderde expressie van immunosup-
pressieve eiwitten, zoals FoxP3, CD25 en CTLA4, in of op de circulerende Tregs. Echter, 
circulerende Tregs in pulmonale sarcoïdose vertoonden wel een verhoogde expressie 
van CD95, een verhoogde apoptotische gevoeligheid en verminderde overleving in 
vergelijking met gezonde controles. Dit laatste fenomeen draagt zeer waarschijnlijk bij 
aan een verminderde immunosuppressieve functie van circulerend Tregs in pulmonale 
sarcoïdose.
De aanwezigheid van Th17 cellen is eerder beschreven in pulmonale sarcoïdose, 
echter de ziekte wordt nog voornamelijk beschouwd als een Th1-gemedieerde ziekte 
aangezien de aantallen interleukine (IL)-17-producerende cellen erg laag ligt. Echter, 
onze bevindingen in Hoofdstuk 2 suggereerden toch een belangrijke rol voor Th17 
cellen in pulmonale sarcoïdose. Tegelijkertijd werd het in het T-cel veld bekend dat 
classificatie van T-cellen puur op basis van cytokineproductie alleen niet correct blijkt. 
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Sommige T-cellen, zoals Th17 cellen, kunnen plasticiteit vertonen en kunnen cytokines 
produceren die oorspronkelijk door andere T-cel lijnen worden geproduceerd. Eerder 
hebben wij al de aanwezigheid van IL-17A/IFN-γ-dubbel-producerende cellen aange-
toond in de longen van een klein sarcoïdose cohort en daarom stelden wij de hypothese 
dat de rol van Th17 cellen in pulmonale sarcoïdose mogelijk veel groter is dan eerder 
geanticipeerd. Mogelijk spelen Th17 cellen een grotere rol dan we denken door de pro-
ductie van IFN-γ, waarmee ze Th1 cellen nabootsen. Zogenoemde Th17.1 cellen staan 
hier bekend om en zijn eerder aangetroffen in andere immuun-gemedieerde ziektes, 
zoals reumatoïde artritis. In hoofdstuk 4 hadden we daarom als doel om de oorsprong 
van IFN-γ-producerende cellen vast te stellen. Wij vonden inderdaad dat niet Th1 cellen, 
maar specifiek Th17-afkomstige IFN-γ-producerende (Th17.1) cellen verhoogd zijn in 
sarcoïdose en verantwoordelijk zijn voor de eerder geobserveerde verhoging van IFN-γ 
in sarcoïdose longen. Dit inzicht resulteert in een ware paradigma verandering in het 
sarcoïdose veld. 
Primaire T-cel activatie en differentiatie gebeurt in long-drainerende mediastinale 
lymfeklieren, terwijl bovengenoemde IFN-γ-producerende Th17.1 cellen elders kunnen 
ontstaan uit Th17 cellen onder invloed van een specifiek cytokine milieu. Om deze reden 
hadden wij als hypothese dat in pulmonale sarcoïdose, Th17 cellen primair worden 
geïnduceerd in de mediastinale lymfeklieren en dat de granulomateuze omgeving in 
de longen plasticiteit van Th17 cellen induceert richting Th17.1 cellen. In hoofdstuk 
5 onderzochten wij deze hypothese en stelden als doel om meer inzicht te krijgen in 
de inductie van Th17.1 cellen in sarcoïdose door naar de proporties en het fenotype te 
kijken van CCR6+ Th17-afkomstige cellen in sarcoïdose en controle mediastinale lymfe-
klieren en in sarcoïdose longen. Resultaten van deze studie tonen aan dat Th17 cellen 
in pulmonale sarcoïdose worden geactiveerd in de mediastinale lymfeklieren en sug-
gereren sterk dat de granulomateuze omgeving van de longen plasticiteit induceert 
naar pathogene Th17.1 cellen, alwaar deze cellen kunnen bijdragen aan het ontstaan 
van chronische ziekte. 
Tot slot vatten wij in hoofdstuk 6 recente bevindingen over de immunologische T-cel 
respons in pulmonale sarcoïdose samen. Gebaseerd op nieuwe bevindingen in Tregs, 
Th17.1 cellen en co-stimulatoire en co-inhibitoire moleculen stellen wij een model voor 
waarbij een ontregelde balans tussen helper en regulatoire cellen zeer waarschijnlijk bij-
draagt aan de overmatige immuunrespons in pulmonale sarcoïdose. Data gepresenteerd 
in dit eerste deel van het proefschrift bieden een nieuw perspectief op de pathogenese 
van pulmonale sarcoïdose en daardoor op aangrijpingspunten voor nieuwe therapieën. 
Deel 2: optimalisatie van prednison therapie in pulmonale sarcoïdose
Prednison is de eerste keus voor de behandeling van pulmonale sarcoïdose. Prednison 
therapie is alleen geïndiceerd in bepaalde gevallen, zoals wanneer er orgaanschade op-
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treedt of wanneer er een significante daling is in de kwaliteit van leven van een patiënt. 
Helaas is de optimale dosis en duur van de behandeling niet bekend, dus huidige 
richtlijnen handhaven ruime adviezen waardoor patiënten op verschillende manieren 
kunnen worden behandeld, vaak afhankelijk van de voorkeur van de behandelend arts. 
Mogelijk leidt dit tot suboptimale resultaten of juist onnodige bijwerkingen.
Het vaststellen van de optimale behandelstrategie die orgaanfunctie behoudt en 
symptomen reduceert, maar tegelijkertijd de bijwerkingen minimaliseert, kan de kwa-
liteit van leven van sarcoïdose patiënten verhogen. Om meer inzicht te krijgen in de 
balans tussen effect en bijwerkingen van huidige behandelstrategieën hebben wij in 
hoofdstuk 7 als doel gesteld om de geforceerde expiratoire vitale capaciteits- (FVC) 
(effect) en gewichts- (bijwerking) veranderingen te beschrijven die plaatsvinden in de 
huidige praktijk na het initiëren van prednison therapie in nieuw behandelde pulmo-
nale sarcoïdose patiënten. Middels een retrospectieve, multicenter opzet hebben wij 
ontdekt dat de huidige klinische praktijk van prednison behandeling inderdaad varieert, 
echter dat er geen sterke correlatie is tussen de prednison dosis die werd gebruikt en de 
FVC-verandering die optrad. Echter, de toename in gewicht correleerde significant met 
de cumulatieve prednison dosis die was gebruikt op de lange termijn (12-24 maanden). 
Behandelstrategieën die leidden tot een lage cumulatieve prednison dosis op de lange 
termijn werden met name gekarakteriseerd door het snel afbouwen van de predni-
son dosis, namelijk naar minder dan 10 mg/dag binnen 3,5 maand. We vonden geen 
aanwijzingen dat de FVC-respons op therapie werd beïnvloed door karakteristieken 
van ernstigere ziekte tijdens start van de behandeling. Deze resultaten suggereren dat 
prednison therapie in pulmonale sarcoïdose, gericht op het behouden en/of verbeteren 
van de FVC, kan worden gereduceerd in de huidige klinische praktijk. Deze retrospec-
tieve studie verschaft ook een rationale om een prospectieve studie op te zetten waarbij 
nieuw behandelde sarcoïdose patiënten eerder worden afgebouwd van de prednison, 
gegeven dat zij nauwlettend worden gevolgd. 
Resultaten van Hoofdstuk 7 en bestaande publicaties suggereren dat het snel afbou-
wen van prednison zeer waarschijnlijk leidt tot het verminderen van bijwerkingen in 
pulmonale sarcoïdose. Het is eerder gesuggereerd dat het effect van prednison op de 
FVC al optreedt binnen een maand. Echter, een prospectieve studie die individuele long-
functie veranderingen dagelijks vastlegt om het daadwerkelijke effect optimum vast te 
stellen mist nog. In hoofdstuk 8 worden resultaten gepresenteerd van een prospec-
tieve, observationele studie die vroege veranderingen in FVC en symptomen vastlegt 
tijdens prednison behandeling voor pulmonale sarcoïdose, middels thuis spirometrie. 
Resultaten van deze studie tonen aan dat het grootste deel van het behandel effect op 
longfunctie en symptomen al optreedt binnen 2-3 weken. Resultaten van deze studie 
suggereren verder dat dagelijkse thuismonitoring van de longfunctie en symptomen de 
potentie heeft om prednison behandeling van sarcoïdose patiënten te individualiseren. 
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Frequente monitoring is dan gericht op het snel afbouwen van de prednison dat de 
potentie heeft om bijwerkingen te verminderen en daarmee de kwaliteit van leven van 
pulmonale sarcoïdose patiënten verbetert. 
Verschillende resultaten van dit proefschrift zijn waardevol voor de klinische praktijk en 
deze worden besproken in de Epiloog. Door de studies beschreven in dit proefschrift 
is het duidelijk geworden dat CCR6+ (van Th17-afkomstige) cellen en Tregs betrokken 
zijn bij de immunologische respons die leidt tot overmatige inflammatie in pulmo-
nale sarcoïdose. Naar verwachting zullen prospectieve studies, die evalueren of Treg- en 
Th17(.1) cel-geassocieerde factoren kunnen fungeren als betrouwbare biomarker, 
invloed hebben op de toekomstige klinische praktijk. Verder verschaffen resultaten 
van dit proefschrift een rationale om de potentie van reeds bestaande (CTLA4-Ig, zoals 
abatacept) en nieuwe (anti-IL-23p19, zoals tildrakizumab/guselkumab) therapieën te 
evalueren in pulmonale sarcoïdose. Als laatste geeft dit proefschrift suggesties om de 
huidige prednison behandeling aan te passen. Een grote uitdaging blijft natuurlijk om 
deze basale en klinische onderzoeksgebieden te integreren in studies die toepasbaar 
blijken in de klinische praktijk. Een nauwe samenwerking tussen experimentele weten-
schappers en artsen blijft daarvoor essentieel. Kortom, om sarcoïdose te krijgen, It Takes 
Two to Tangle, om sarcoïdose op te lossen, It Takes (at least) Two to Tango! 
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Dankwoord
Ik kijk terug op een succesvol promotietraject. En als er iets is wat mij alleen maar duide-
lijker is geworden, dan is dat hoe belangrijk het is dat er chemie bestaat tussen mensen 
om samen succes te behalen. In dit dankwoord wil ik graag stilstaan bij alle mensen die 
hebben bijgedragen aan het tot stand komen van dit proefschrift. 
Zo geschiedde het… 
Mijn carrière had zomaar eens heel anders kunnen lopen als ik niet door twee oud Fran-
ciscus Gasthuis collega’s (Louise Urlings en Joris Veltman, dank!) mee was genomen naar 
de regionale refereeravond van de longartsen. Ik werd voorgesteld aan prof. Hoogsteden 
en later sloot dr. Wijsenbeek zich achter mij aan tijdens het opscheppen van het buffet. 
Ik weet niet precies meer hoe het ging, maar gedurende dit ‘wat slechts één minuut kan 
hebben geduurd’-moment zijn mijn gedachten over promoveren veranderd van: ‘dat is 
niet voor mij weggelegd’ tot ‘hmmm… misschien wel uitdagend’. Dr. Wijsenbeek kon me 
wel even voorstellen aan iemand die er meer over wist, en ik had nog niet een hap door 
mijn keel of plots stond dr. Van den Blink voor mijn neus. Enkele minuten laten bevond 
ik mij in een naar mijn idee niet zo succesvol sollicitatiegesprek, waarin ik eruit flapte 
dat promoveren me wel wat leek, maar dan ‘zéééker weten niet op het lab, want dat 
lijkt me zo taai’ (Oeps!). Van het een kwam het ander en een maand later startte ik mijn 
fundamentele onderzoekstraject naar de immuunrespons bij pulmonale sarcoïdose! 
Ik ben erg dankbaar dat deze fijne promotieplek op mijn pad is gekomen, want de 
afgelopen 5 jaar is een hele bijzondere tijd geweest waarin ik de kans heb gekregen om 
mezelf, zonder afleiding, volledig te verdiepen en ontplooien tot elk niveau dat ik zelf 
maar wilde bereiken. Ik heb ontdekt dat ik goed functioneer in een omgeving waarin 
men mij de vrijheid geeft om mijn eigen lat te leggen, hardop te brainstormen, waarin 
men hier nog enthousiaster overheen gaat, en waarin ik af en toe de noodzakelijke 
schouderklopjes krijg. Gelukkig was ik met mijn promotieteam met mijn neus in de 
boter gevallen. 
mijn promotieteam 
Bernt, jij was de eerste van deze kliek die over de tijd is ontstaan. Ik weet niet eens zo 
goed waar ik moet beginnen als ik terugdenk aan hoe vaak ik tijdens mijn promotie heb 
gedacht hoe blij ik met je ben als copromotor. Bij de uitspraak ‘Instruction does much, 
but encouragement does everything’ (Johann Wolfgang von Goethe), moest ik direct aan 
jou denken. Uitspraken als ‘Niets is ernstig, alles is oplosbaar’ (nadat we een ellenlange 
revisie brief hadden gekregen van de METC), ‘No Guts, No Glory’ (nadat ik twijfel of dit 
alles het wel waard is), en ‘Het wordt utterly briljant’ hebben mij enorm op de been 
gehouden tijdens mijn promotietraject. Ook staat mij nog een moment helder voor de 
geest waarop ik gedeprimeerd achter het FACS-apparaat zat rond 18:00 uur. Dat was 
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de eerste keer dat ik echt in de stress raakte van hoe ik dit alles ooit voor elkaar moest 
krijgen, waardoor ik verlamde en geen idee had waar ik moest beginnen. Bizar genoeg 
liep jij spontaan het lab op, kwam naast me zitten en zonder dat ik erom vroeg kreeg 
ik een top 3 prioriteiten voor de komende tijd voorgeschoteld. Perfect! Ik heb jou nooit 
betrapt op een gedemotiveerd moment en over de tijd heb je me altijd op het juiste 
moment een schouderklopje gegeven. Ik heb ervaren dat de juiste chemie tussen ons 
aanwezig was waardoor brainstormsessies tot in den treure door konden gaan en waar-
door er tijd genoeg was om de juiste ideeën te laten ontstaan. Jij daagde mij uit met een 
op het oog lijkend simpele vraag, waar ik dan mee aan de slag ging en waar prachtige 
resultaten uit voort zijn gekomen! Je maakte er tijdens congressen een sport van om mij 
aan belangrijke mensen voor te stellen, tot aan ernstig gênante momenten toe, maar 
tot op heden ben ik je hier nog zo dankbaar voor. Bernt, voor mij ben je een hele fijne 
goeroe geweest en ik hoop in de toekomst nog veel met je te mogen sparren!
Rudi, jij was de 2e persoon die aansloot bij mijn promotieteam. Ik twijfelde in de eerste 
instantie of ik wel zou voldoen aan de eisen van een basaal onderzoeker op jouw lab. Vrij 
snel is dit gevoel echter weggegaan. De achtergrond van de PhD student maakt jou niet 
uit, als je maar blijk geeft van enthousiasme voor de wetenschap, doorzettingsvermo-
gen en hard werken! Jouw hart voor onderzoek doen en het begeleiden van studenten 
werd mij heel duidelijk toen ik mijn eerste abstract moest insturen voor een congres 
in Freiburg. Tot in de late uurtjes heb jij met mij de laatste details veranderd voor een 
abstract van 200 woorden. Elk detail bleef belangrijk, ook al kostte dit je wat meer tijd. 
Blijkbaar kon jij je ook nog goed inleven in hoe belangrijk zo’n eerste abstract is voor een 
startende PhD student. Jouw inbreng bij het tot stand komen van dit proefschrift is zo 
belangrijk geweest. Jij wist altijd de vinger op de zere plek te leggen, kritische vragen te 
stellen en, als het nodig was, enorme verheldering te geven. Dit heeft geholpen bij het 
goed op papier krijgen van onze uitgebreide hoeveelheid resultaten. Zoveel dank voor 
je oneindige enthousiasme de afgelopen jaren. Voor mij ben je een voorbeeld figuur als 
hoogleraar en ik vond het een eer om met je te mogen samenwerken! 
Mirjam, toen brak het moment aan dat er een vrouw werd toegevoegd aan mijn pro-
motieteam! Ik vond dit een enorm leuk moment: bij het ontstaan van de I&R-groep kwam 
er een stukje professionaliteit in de voortgang van mijn PhD traject. Er vielen meerdere 
PhD’s onder de verantwoordelijkheid van jou en Bernt waardoor  een soort brainstorm 
club ontstond waarin we veel verschillende technieken en nieuw ontdekte cellen kon-
den bekijken in meerdere inflammatoire longaandoeningen. Ik kan me nog herinneren 
dat jij in het begin een beetje moest wennen als ik jou (voor de grap) ‘baas’ noemde. 
Voor mij ben je echter heel natuurlijk in het proces gestapt en ik heb veel ontzag voor 
hoe toegankelijk, geduldig en vrolijk jij bent als begeleider. Ook ben ik je erg dankbaar 
voor jouw enorm praktische oplossingen en de nuchterheid daarin. Als het niet lukt, 
dan lukt het niet, maar dan kwam jij altijd wel met een inventieve manier om het dan 
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alsnog mee te kunnen nemen. Denk hierbij aan de enorm grote FACS-kleuringen die we 
hebben samengesteld om die bizar zeldzame cellen aan te tonen! Over de tijd is er een 
hele fijne vertrouwensband ontstaan tussen ons en ik ben dan ook maar al te blij dat ik 
de kans heb om nog met jou door te gaan in onderzoek. Ik kijk uit naar de toekomst!  
mijn extended promotieteam
Naast mijn officiële promotieteam, heb ik nog een extented promotieteam gehad.
Menno, dude!, hoe had ik dit promotietraject overleefd zonder jou?! Als ik terugdenk 
aan de eerste keer dat ik jou ontmoette dan had ik dit denk ik niet voor ogen gehad. 
Marthe stelde me aan je voor tijdens de lunch toen ik een dagje kwam kijken op het lab. 
Je schoof naast me en zei: ‘Zo… jij gaat dus aan het sarcoïdose project werken? Succes 
ermee…Weet je zeker dat je de onderzoekswereld in wilt?’ Je had me toen al voorbereid 
op jouw scepticisme. Voor mij bleek dit heel fijn. Ik houd ervan om goed werk af te leve-
ren, en jij ook: voor niets gaat de zon op. Jij stelde mij kritische vragen en dan kwamen 
we er samen uit. Ik geloof dat ik vrij snel jouw vertrouwen had gewonnen en sindsdien 
ben je tot in de late uurtjes en vrije dagen loyaal geweest aan het sarcoïdose project. 
Nu nog steeds… Dankzij jou had ik elke dag een team gevoel als we weer begonnen 
aan de grote compartiment experimenten of tot in den treure de Treg assays moesten 
inzetten. Ik weet zeker dat dit traject veel zwaarder was geweest zonder jouw steun 
en plezierige aanwezigheid. In de flowkast hebben we samen kunnen lachen en huilen 
en op werk niveau hebben we naar mijn mening soms aan één blik genoeg. Ik voel me 
enorm vereerd dat jij me wil bijstaan tijdens mijn verdediging. 
Prof. Hoogsteden, ik realiseer me maar al te goed wat een ruimte u voor mij heeft ge-
creëerd om mijzelf te kunnen ontwikkelen tijdens dit promotietraject. Ik ben erg dank-
baar voor alle mogelijkheden die ik heb gekregen om mijn werk te kunnen presenteren 
op nationale en internationale congressen. Tevens heeft u tot het einde nog vertrouwen 
naar mij laten blijken door me te ondersteunen bij mijn plan om een research fellowship 
in Amerika te doen. Onder andere de kans om met zoveel verschillende nationaliteiten 
te kunnen brainstormen en samenwerken heeft mij doen realiseren hoe bijzonder ik 
onderzoek doen vind. Erg veel dank hiervoor.
Marlies, zoals al eerder beschreven, heb ik onder andere aan jou te danken dat ik 
in dit fantastische promotietraject terecht ben gekomen! Ik heb enorm genoten van 
jouw enthousiasme voor onderzoek doen en jouw netwerkkwaliteiten op congressen. 
Het was altijd enorm ontspannen om ’s avonds een biertje met jou en Bernt te kunnen 
drinken na een intense congresdag. Bedankt voor je eerlijkheid, nuchterheid en eeuwig 
handige tips over carrière keuzes. 
Linda, mijn eerste en enige student! Wat hebben wij onwijs veel gelachen. We heb-
ben ons samen door een retrospectieve studie geworsteld waarover we tot op de dag 
van vandaag nog steeds een beetje ‘tangled’ zijn. Wat mij in ieder geval heel duidelijk is 
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geworden is dat jij een doorzetter bent, want over de jaren heen ben je je altijd blijven 
inzetten om dit verhaal echt op papier te krijgen. Het kwam erop neer dat we dan onder 
het genot van een biertje, koffietje of taartje ons weer lachend blind zaten te staren 
op ons stuk. Een mooie bijkomstigheid hiervan is dat we elkaar over de jaren heen zijn 
blijven zien en op de hoogte zijn gebleven van elkaars ontwikkelingen: voornamelijk 
onze prachtige reizen in het buitenland! Voor mij blijft het WASOG-congres in Turkije 
een van de momenten waarop we elkaar beter hebben leren kennen en waarop ik me 
realiseerde dat ik ook maar beter geen 2e student kon gaan begeleiden, want die zou 
toch niet voldoen aan de lat die jij had gelegd! Zet hem op als ANIOS-gynaecologie, en 
we borrelen snel weer over het retroSTEPS stuk en de ‘T3 die geen string heeft’. 
De promotiecommissie
Mijn dank gaat ook uit naar Dr. E. Lubberts, Prof. Dr. J.C. Grutters en Prof. Dr. B.N.M. 
Lambrecht voor het kritisch lezen van het manuscript en het zitting nemen in de pro-
motiecommissie.   
onderzoek deelnemers
Resultaten uit dit proefschrift zijn tot stand gekomen uit verschillende multicenter 
studies waar veel verschillende mensen bij betrokken zijn geweest. 
Allereerst grote dank aan alle sarcoïdose patiënten die deel hebben genomen aan de 
sarcoïdose studie, GRANULOMA-trial, SARTREG-studie en STEPS-studie. De voortgang 
van sarcoïdose onderzoek staat of valt bij deze belangeloze deelname. Ook veel dank 
aan mensen die bloed of BAL hebben gedoneerd voor onze studies als controle weefsel. 
Verder wil ik Bregje ten Berge, Marthe Paats, Bob von Barthold en hun promotieteams 
bedanken voor hun inzet bij het verzamelen van sarcoïdose en controle weefsel waar-
door mijn onderzoekstraject snel op gang kon komen.
Het opzetten van multicenter studies vraagt om veel organisatie, wat ik niet in mijn 
eentje had kunnen uitvoeren of bedenken. Annemarie, met jou werk ik al sinds het begin 
van mijn promotietraject, en ik ben enorm onder de indruk van het bedrijf dat jij in de 
tussentijd hebt opgezet om research op onze afdeling soepel te laten verlopen. Ik heb 
veel met je gelachen en ben jou en de andere research dames erg dankbaar voor de on-
dersteuning die jullie nog steeds geven bij het includeren en vervolgen van sarcoïdose 
studie patiënten. Marjolein, jij hebt veel werk van mij overgenomen het afgelopen jaar 
om de SARTREG en STEPS-studie door te kunnen laten lopen. Bedankt voor je punctu-
aliteit en inzet hiervoor. Monique en Linda, bedankt voor jullie vergaande hulp en inzet 
bij het opzetten van de STEPS-studie en het protocolleren van het thuis-monitoren met 
spirometers. Frans en Hadassa, bedankt voor het opvangen van onverwachte inclusies 
en vragen uit andere klinieken! En ook dank aan Karin Lammering voor het ondersteu-
nen van de STEPS-studie op de longfunctie afdeling. 
Acknowledgments
245
Mirjam van Manen, dank voor je gezelligheid op congressen en je hulp bij het verwer-
ken van vragenlijsten. Femke, dank voor je ondersteuning bij de STEPS-studie database. 
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Summary of PhD training and teaching
Name PhD student: C.E. (Caroline) Broos
Erasmus MC Department: Pulmonary Medicine
Research School: Molecular Medicine
PhD period: 2012-2016
Promotor: Prof.dr. R.W. Hendriks
Supervisor: Dr.ing. M. Kool and Dr. B. van den Blink 
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Interstitial lung disease (ILD) winter course, Davos
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Endnote workshop
NVVI Lunteren symposium: ‘APC’s revisited’
Basic introduction course on SPSS 
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Course on Molecular Diagnostics VII 
BROK course
Workshop on Photoshop & Illustrator 
Workshop on Indesign CS5 
Interstitial lung disease (ILD) winter course, Davos (for assistance)
Open Clinica Training 
NVVI Lunteren symposium: ‘Mucosal Immunology; crossing borders’ 
Basic Human Genetics course: Genetics for Dummies 
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BROK-course (re-registration)
2012
2012
2012
2012
2012
2012
2012
2012
2012
2012
2012
2013
2013
2014
2015
2015
2016
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0,3
3,0
0,3
0,5
0,8
0,15
1,0
2,0
0,3
0,15
1,0
0,3
0,5
0,5
0,3
0,15
(Inter)national scientific presentations and conferences
16th Molecular Medicine day, Rotterdam (poster)
Longdagen, Utrecht (poster)
Chronic inflammatory disorders of the lung symposium, Freiburg (poster)
Symposium Sarcoidose & IPF, Rotterdam (presentation)
NRS Young Investigator Meeting, Amsterdam (poster)
NVVI Winter School, Noordwijkerhout (poster)
Longdagen, Utrecht (poster)
ATS International Conference, Philadelphia (poster discussion)
WASOG International Meeting, Paris (poster)
NRS Young Investigator Meeting, Amsterdam (poster discussion)
NVVI, Winter School, Noordwijkerhout (poster)
18th Molecular Medicine day, Rotterdam (poster)
Longdagen, Utrecht (poster)
ATS International Conference, San Diego (poster discussion)
13th International Meeting on Dendritic Cells, Tours (poster)
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2012
2012
2013
2013
2013
2013
2013
2014
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2014
2014
2014
2014
2015
2015
2016
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0,3 
1,0
0,5
0,3
0,8
0,5
1,5
0,5
0,3
0,5
0,3
0,5
1,5
1,0
1,5
0,5
1,5
1,0
1,0
2. Teaching
Winter course, Research Master Infection & Immunity, Erasmus University, Rotterdam. 
Lecture: “Unraveling the pathogenesis of sarcoidosis”
2014-2015 0,5
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Supervising Master’s theses L.H.C. Poell, Erasmus University, Rotterdam. 2014 3,0
Journal Club tutor for first year medical students, Erasmus University, Rotterdam. 2013-2014 1,0
Symposium sarcoidosis and IPF for medical doctors, Erasmus MC, Rotterdam. Lecture: 
“The T cell in sarcoidosis” 
2012 0,3
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Abstract Scholarship Award, ATS, Philadelphia (sponsored by the Foundation of 
Sarcoidosis Research (FSR))
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NRS Young Investigator Travel Grant for WASOG-BAL, Kasadasi
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Fundamenteel immunologisch onderzoek heeft mij enorm doen realiseren en waarde-
ren hoe bijzonder ons immuunsysteem is. Immunologische cellen zijn zo goed op elkaar 
afgestemd dat het ons lichaam erg vaak lukt om aanvallen van buitenaf adequaat af 
te weren. Toch weten micro-organismen of ontregelde cellen soms te ontsnappen aan 
deze scherp afgestelde patrouille van cellen, waardoor we infecties of kanker krijgen. 
Anderzijds lijkt ons afweersysteem soms zo overmatige enthousiast dat we juist tegen-
overgestelde ziektes ontwikkelen, zoals allergieën of auto-immuunziektes. Onderzoek 
doen naar de pathogenese van sarcoïdose heeft mijn kennis over de immunologie op 
de proef gesteld. Er blijkt in de sarcoïdose wereld nog een levendige discussie gaande 
over de vraag of het immuunsysteem overmatig of juist middelmatig reageert. Deze 
vraagstelling, die soms opspeelt tijdens congressen, daagt je enorm uit om af en toe los 
te komen van je eigen theorieën en weer terug te gaan naar de basis… 
Het granuloom is bij uitstek de basis van sarcoïdose en dit granuloom fascineert me. 
Zonder de aanwezigheid van granulomen, bestaat sarcoïdose niet. Oorspronkelijk wordt 
er gedacht dat granulomen ontstaan door chronische stimulatie van het immuunsys-
teem, en meestal is dat doordat het ons lichaam niet lukt om (schadelijke) stoffen of 
bacteriën op te ruimen. Denk hierbij aan wat er gebeurt bij tuberculose of berylliose. In 
sarcoïdose granulomen zijn tot op heden nog geen stofjes gevonden die alle casussen 
kunnen verklaren. Dit laatste suggereert dat het sarcoïdose immuunsysteem overmatige 
reageert en wat waarschijnlijk niet echt nodig is. Dit wordt bevestigd door het feit dat 
sarcoïdose patiënten niet ernstig ziek worden als zij behandeld worden met prednison. 
In tegendeel: prednison is de huidige eerste keus voor de behandeling van de ziekte. 
Echter, prednison en andere therapieën lossen het probleem op de lange termijn niet 
op… Dus wat is hier gaande? Is granuloomvorming in sarcoïdose een uiting van het 
immuunsysteem dat in de basis niet adequaat is en daarom overschakelt op een van 
oorsprong oud afweersysteem om (gevaarlijke) aanvallen op afstand te houden? Of is 
het een uiting van een combinatie van fouten in specifieke cellen, waardoor specifiek 
overmatige stimulatie van het immuunsysteem ontstaat, zoals sommige resultaten uit 
dit proefschrift doen vermoeden? Al met al zijn we nog stappen verwijderd van het 
echte antwoord. Wat ik in ieder geval heb geleerd van sarcoïdose onderzoek is dat je 
moet uitkijken met aannames doen die al langer bestaan. Om verder te komen moet je 
jezelf telkens blijven uitdagen om weer even vanuit een andere hoek te durven kijken. 
Daarbij is het heel belangrijk om goed te blijven kijken naar wat je ziet: zowel in de 
kliniek als naar de basis, het granuloom…
De voorkant is ontstaan doordat ik mijn schoonvader, Olphaert den Otter, beeldend 
kunstenaar, microscopie plaatjes liet zien van sarcoïdose granulomen. Het duurde 
niet lang voordat hij met zijn talent voor gedetailleerd observeren, een verband legde 
met gemarmerd papier. Papier marmeren is een kunstmethode die oorspronkelijk is 
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ontstaan in Azië en waarbij de vormen op papier ontstaan door verdunde olieverf op 
een substantie te leggen waar het niet mee mengt en waardoor het niet mengt met an-
dere verfkleuren. Met behulp van verschillende tools kunnen lijnen en figuren worden 
getrokken. Als de vormen naar wens zijn wordt het papier op de kop op de substantie 
gehouden, et voilà! Gemarmerd papier werd vroeger ook vaak gebruikt om boeken te 
kaften. Toen Olphaert mij voorbeelden hiervan liet zien, was ik meteen verkocht. Er gaat 
een wereld van verschillende soorten granulomen voor je open! En laten we eerlijk zijn: 
deze wirwar ontstaat toch eigenlijk vooral door Two substanties die Tanglen… 
Ik wil hiermee mijn dank uiten aan Olphaert die mij enorm heeft geholpen om tot 
een voorkant van mijn proefschrift te komen waar ik erg content mee ben. Tevens wil ik 
mijn dank uitspreken aan Jonna Cohen (boekrestaurator): zij heeft mij geholpen bij het 
vinden van het juiste gemarmerde papier. Ook gaat mijn dank uit naar Marijn de Jong 
(fotograaf ): hij heeft mij geholpen om dit papier goed digitaal te krijgen. Het gemar-
merde papier komt van Michel Duval (Paris) en de voorkant is ontworpen door grafisch 
ontwerper Erwin Timmerman van Optima Grafische Communicatie. Mijn grote dank!
Sarcoidosis is an intriguingly complex immunological dis-
order. It is characterized by the formation of non-necro-
tizing granulomas that are most commonly found in the 
mediastinal lymph nodes and lungs of patients. Gaps in 
knowledge on sarcoidosis disease etiology and determi-
nants of disease course have thus far impeded rational 
decisions on ‘Who, When and How’ to treat. The main-
stay of sarcoidosis therapy remains immunosuppressive, 
using relatively high doses of systemic prednisone. How-
ever, although often effective, corticosteroid treatment 
can be accompanied by severe side effects. Detailed in-
sight in the immunological response occurring in pulmo-
nary sarcoidosis patients can help ﬁ nd determinants of 
disease etiology and disease course, which can yield new 
therapeutic targets. Therefore, the ﬁ rst aim of this thesis 
is to further unravel the immune-related pathogenesis of 
pulmonary sarcoidosis. The second aim is to gain insight 
into current prednisone treatment, in order to optimize 
treatment strategies to reduce side effects and increase 
quality of life of pulmonary sarcoidosis patients. 
Findings described in this thesis provide a new perspec-
tive on sarcoidosis pathogenesis, challenging long-held 
paradigms and exploring novel approaches to further un-
ravel this immunological complex disease. Furthermore, 
a rationale is provided to evaluate the potential of certain 
existing therapies that are currently used in other auto-
immune diseases for pulmonary sarcoidosis treatment. 
Finally, results of this thesis lay a strong foundation for fu-
ture studies that can help individualize sarcoidosis treat-
ment and thereby increase pulmonary sarcoidosis-related 
quality of care and patient-related quality of life. 
Caroline Elizabeth Broos
